

AD _____

Award Number: DAMD17-00-1-0124

TITLE: Molecular Disruption of Breast Tumor Angiogenesis

PRINCIPAL INVESTIGATOR: Paul J. Higgins, Ph.D.

CONTRACTING ORGANIZATION: Albany Medical College
Albany, New York 12208-3412

REPORT DATE: July 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2004	3. REPORT TYPE AND DATES COVERED Final (15 Jun 00 - 14 Jun 04)	
4. TITLE AND SUBTITLE Molecular Disruption of Breast Tumor Angiogenesis			5. FUNDING NUMBERS DAMD17-00-1-0124	
6. AUTHOR(S) Paul J. Higgins, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Albany Medical College Albany, New York 12208-3412 E-Mail: higginp@mail.amc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates. All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Endothelial cells must express plasminogen activator inhibitor type-1 (PAI-1) in order to undergo an angiogenic switch during tumor progression. The PAI-1 gene, therefore, has emerged as an important candidate target for gene therapy of human breast cancer. During the period of this grant, we carried out studies to confirm that targeted ablation of PAI-1 gene expression resulted in a marked attenuation of endothelial cell migration as well as an inability to form and maintain capillary network structures on Matrigel-coated surfaces. Addition of PAI-1 protein or transfection of PAI-1 expression vectors rescued the migratory phenotype. Confirmatory results were obtained with human microvessel endothelial cells. Breast cancer-derived factors (TGF- β , EGF) were found to be important contributors of continued PAI-1 expression and long-term maintenance of capillary structures. PAI-1 synthesis and/or protease inhibitory activity, even in mature tubular networks, was required for a invasive growth and a stabilized angiogenic response. The work carried out under this award support the "balanced proteolysis" concept of angiogenesis, identified critical molecular mechanisms underlying the angiogenic response and support our hypothesis that the PAI-1 gene is an accessible anti-angiogenic target.				
14. SUBJECT TERMS Angiogenesis, gene therapy, plasminogen activator inhibitor-1				15. NUMBER OF PAGES 64
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	13
Reportable Outcomes.....	15
Conclusions.....	18
References.....	19
Appendices.....	20

INTRODUCTION

Continued growth of a malignant tumor beyond a certain critical size is dependent on the development of a network of feeder blood vessels (1,2). This "angiogenic switch" is highly-dependent on the temporally-regulated and focalized activity of several extracellular proteases and protease inhibitors involving members of both the plasmin-based and metalloproteinase cascades (3,4). *In vitro* analysis of the requirements for the formation of endothelial tubular networks in various culture model systems implicated both urokinase plasminogen activator (uPA) and its fast-acting type-1 inhibitor (PAI-1) as necessary to achieve complete angiogenesis, consistent with the "balanced proteolysis" concept of endothelial cell migration (5-7). Recent data in mice genetically-engineered to be deficient in expression of genes that encode specific elements of the plasmin activation system has confirmed, in fact, the critical importance of PAI-1 synthesis in tumor-induced angiogenesis (5-7). Indeed, the absence of host PAI-1 completely inhibited local invasion and vascularization of transplanted malignant tumors in PAI-1 null mice (5,6). This inability to mount an angiogenic response, moreover, prevented invasive growth by a highly aggressive and metastatic tumor type (5,6).

Breast tumors with elevated PAI-1 levels are particularly fast-growing carcinomas with a well-developed angiogenic network, a significant incidence of metastatic spread, early recurrence and poor prognosis (8, reviewed in 9). PAI-1 as a determinant in aggressive growth behavior is specifically important in the progression of mammary carcinoma. Most recently, PAI-1 has been shown to be markedly promigratory for invasive breast cancer cells, an effect attenuated by direct inhibition of PAI-1 function (10). Targeted knockout/reconstitution studies, moreover, identified PAI-1 as essential for, and an efficient modulator of, the neovascularization process. Recent findings, in fact, support a multifunctional role for PAI-1 in angiogenesis (e.g., this uPA inhibitor regulates stromal barrier proteolysis, facilitates endothelial cell migration by focalized exposure of cryptic matrix-binding sites, stabilizes nascent vessel structure and controls cell-to-matrix adhesion/de-adhesion). Analyses of systems that model specific stages in angiogenesis have disclosed that PAI-1 can exert potent pro- and anti-angiogenic effects depending on the context and the concentration (as well as specific activity) of this SERPIN (serine protease inhibitor) in the tissue microenvironment. These data highlight the potential relevance of PAI-1 modulation as a means to treat human breast cancer and complement our own work on genetic targeting of PAI-1 mRNA transcripts with subsequent attenuation of cellular motile traits (11-13).

The goals of this investigation were to determine, for the first time, the level of endothelial cell PAI-1 expression necessary for development and maintenance of the angiogenic phenotype in a 3-D culture model of breast tumor-stromal-endothelial cell interactions that mimics the *in vivo* disease state. Gene therapy approaches using antisense vector constructs as well as homologous recombination methods previously developed in this laboratory were utilized to directly disrupt PAI-1 gene expression in cultured endothelial cells. The consequences of this targeted disruption on the ability of endothelial cells to form branching angiogenic networks in response to co-culture with human breast cancer cells or identified breast cancer-derived factors was evaluated. This study constitutes the first comprehensive assessment of PAI-1 genetic therapy as an approach to inhibit growth of human breast cancers by targeting a gene essential for the angiogenic process. We also took this opportunity to assess mechanisms of PAI-1 gene expression control under culture conditions that closely mimic the optimal angiogenic response *in vivo*.

BODY

The work carried out during the period of this grant focused on three specific aims:

Task 1. To quantify the consequences of PAI-1 down-regulation (by antisense targeting) on the angiogenic response and the effects of vector-driven PAI-1 synthesis on human breast tumor-induced angiogenesis in endothelial cells (including PAI-1-null cells, a clone in which the endogenous PAI-1 gene was disrupted by molecular targeting). This phase of the work was necessary to determine the threshold level of PAI-1 expression required for cultured endothelial cells to undergo a switch to an angiogenic phenotype and involved the following:

- a. development of a panel of endogenous PAI-1-null endothelial cells which synthesize differing levels of exogenous (vector-driven) PAI-1 mRNA and protein upon transfection with a constitutively active (CMV promoter-based) PAI-1 expression construct. This panel complements cells in which PAI-1 synthesis was disrupted using antisense expression vectors.
- b. correlate levels of PAI-1 expression for each transfectant PAI-1-null-derived endothelial cell line with the extent of the angiogenic response (i.e., ability to form branched tubular networks and migrate over planar surfaces) induced by co-culture with human breast tumor cells and/or tumor-derived angiogenic stimuli (i.e., secreted growth factors).

Task 2. To determine the consequences of molecular genetic down-regulation of endogenous PAI-1 gene expression on the ability of endothelial cells to form branching angiogenic networks upon co-culture with human breast carcinoma cells as well as to migrate through matrix barriers in response to tumor-derived angiogenic stimuli. This is necessary to assess the extent to which endogenous PAI-1 gene expression is susceptible to genetic manipulation and the window of down-regulation required to achieve a defined and quantifiable therapeutic result (i.e., a reduction in, or loss of, the angiogenic response). The mechanism of PAI-1 gene regulation was also addressed using culture conditions and identified growth factors that predispose to development of an optimal angiogenic response.

Task 3. To evaluate the therapeutic usefulness of endothelial cell-specific targeting of anti-angiogenic expression vector constructs in the human breast carcinoma-stimulated co-culture model of induced angiogenesis.

Experimental findings.

Endothelial cell migration and capillary sprouting requires proteolysis. Studies in mice deficient in elements in the plasmin activation cascade confirmed the importance of uPA, PAI-1 and plasmin in cell migration (13). Excessive protease activity as typically evident in chronic wounds, however, prevents the coordinated assembly of endothelial cells into capillary structures highlighting the requirement for an appropriate proteolytic "balance" in tubular network formation. Genetic studies *in vivo*, moreover, have implicated PAI-1 as an important regulator of this balance. These data have been reviewed in our recent publication (13) (**appended**). Indeed, orienting experiments confirmed that PAI-1 is expressed specifically in angiogenic "cords" and

migrating endothelial cells (**Figure 1**).




Figure 1. Identification of PAI-1-expressing endothelial cells in outgrowth culture. Human saphenous vein endothelial cells migrate into a fibrin gel within 2 weeks after placement of vein “rings” into a fibrin matrix (left panel). The original ring is at the upper right. Cells that migrate out of the vein segment express PAI-1 (upper right panel). Substitution of pre-immune rabbit serum in place of PAI-1 antibodies resulted in loss of immunoreactivity (Control, lower right panel). Unlike the obvious expression of PAI-1 by endothelial elements locomoting through the fibrin gel, the residual endothelium in the explant was PAI-1-negative.

Once it was established that PAI-1 synthesis was part of the angiogenic program, we created functional PAI-1 “knockout” cells using T2 cells as the parental strain by transfection of a PAI-1 antisense expression vector (10,11) to assess the role of this serine protease inhibitor in the angiogenic process. While wild-type T2 cells formed tubular networks when placed in culture over a Matrigel substrate and expressed high levels of PAI-1 mRNA, antisense vector-transfectants did not exhibit an angiogenic response (**Figure 2**). Northern blot analysis confirmed that the T2/IAP antisense cell line did not express PAI-1 transcripts (**Figure 2**) and that the down-regulation of expression achieved was, at the protein level, specific for PAI-1 (**Figure 3**). A similar approach was used to create the PAI-1 functionally-null cell line 4HH (12). While wild-type T2 cells were capable of forming extensively branched capillary networks in a complex 3-D gel consisting of a 3:1 mixture of Vitrogen-Matrigel, 4HH cells were incapable of lattice formation and effectively degraded the gel scaffold (**Figure 3**).

Since these data provided proof of principle (i.e., that inhibition of PAI-1 ablated *in vitro* angiogenesis), we derived a stable PAI-1-null T2 cell line by molecularly-disrupting the endogenous gene with a targeting vector. The resulting cell line (T2-null) similarly failed to form branched angiogenic networks *in vitro*. T2-null cells were subsequently transfected with the PAI-1 sense expression vector Rc/CMVPAI (8,9) and four neomycin (G418)-resistant cell lines were derived that varied in the level of vector-driven PAI-1 transcript expression and migratory ability (**Table 1**). Unlike T2 cells (or the related 4HH cell line) where PAI-1 expression is ablated by antisense PAI-1 (9), antisense *c-fos* (10) constructs or by targeted gene disruption and which are poorly motile and non-angiogenic (**Table 1**), vector-mediated PAI-1 “rescue” restored (to varying extents) cellular motile ability. The data presented in **Figures 2 and 3** as well as in **Table 1** implicate PAI-1 as an important element in the cellular motile process. To further evaluate the role of PAI-1 in various endothelial cell functions (i.e., matrix adhesion, motility, tubulogenesis), two endothelial cell lines (T2-WT, HMEC-1) were used in experiments to: (a) specifically attenuate

PAI-1 synthesis by transfection with the Rc/CMVIAP vector (as above), followed by attempts to “rescue” endothelial function by addition of exogenous active PAI-1 protein, or (b) inhibit PAI-1 activity with a neutralizing antibody. Genetically-targeted PAI-1 down-regulation with the antisense approach effectively inhibited T2 cell migration (**as in Table 1**) and this motile deficit could be rescued by addition of active PAI-1 protein; a similar rescue was evident in the PAI-1-




Figure 2. Capillary formation on Matrigel requires migration. T2 cells were stably transfected with the “empty” Rc/CMV vector (V) or vector bearing a full-length PAI-1 cDNA insert in antisense configuration (IAP) (as in Figure 2). Northern analysis indicated that control T2 cells or T2/V cells expressed abundant PAI-1 transcripts (left panel) and formed well-developed highly-branched tubular structures with luminal spaces within 48 hours after plating onto hydrated Matrigel-coated surfaces (middle panel). T2/IAP transfectants, in contrast, had significantly reduced PAI-1 mRNA levels (left panel) and failed migrate and coalesce into a defined capillary network. T2/IAP cells remained either as single cells (without any evidence of an associated migratory track) or formed small multicellular aggregates (right panel).




Figure 3. Targeted down-regulation of PAI-1 synthesis inhibits *in vitro* tubulogenesis. Construction of Rc/CMV plasmid vectors that drive expression of a full-length PAI-1 cDNA insert, cloned in sense (PAI) and antisense (IAP) orientations, under control of a CMV promoter (left panel). The black fill-in region corresponds to the PAI-1 cDNA insert. EC-1 parental cells were transfected with the Rc/CMVIAP vector and stable clones derived. To assess the success of Rc/CMVIAP driven down-regulation of PAI-1 synthesis and matrix accumulation, saponin-extracts of ³⁵S-methionine-labeled cells were separated by gel electrophoresis and proteins visualized by fluorography (middle panel). One derivative (4HH) did not express detectable PAI-1 protein nor accumulate PAI-1 in the matrix (middle panel). Cells transfected with Rc/CMV vector without insert expressed levels of PAI-1 similar to that of EC-1 controls. Wild-type T2 cells (top right panel) formed highly-branched and anastomizing capillary networks when suspended in a complex support matrix consisting of a 3:1 mixture of Vitrogen-Matrigel. Many of these tubular processes had clearly evident lumens. Extensive sprout formation was evident at the tips of T2 branches, moreover, indicative of both invasive and differentiated compartments. PAI-1^{-/-} 4HH cells (bottom right panel), in contrast, failed to construct stable tubular structures and extensively degraded the gel matrix.

Table 1. Effect of PAI-1 expression targeting and vector “rescue” on cell motility using a quantifiable assay of planar locomotion^a

Cell Line	Method of PAI-1 Expression Regulation	Relative Motility ^b
T2	None (wild-type)	100
T2/IAP	Rc/CMVIAP transfection	40 ± 8
T2-null	Targeted disruption vector	37 ± 5
T2-nullR1	Rc/CMVPAI	56 ± 4
T2-nullR2	Rc/CMVPAI	78 ± 9
T2-nullR3	Rc/CMVPAI	93 ± 7
T2-nullR4	Rc/CMVPAI	49 ± 3

^a Wounds were created by pushing the narrow end of a sterile P1000 plastic pipette tip (Continental Laboratory Products, San Diego, CA) through the monolayer. Cultures were incubated in the existing media for times indicated in the text. Wound closure was assessed by time-lapse photomicroscopy and injury repair rates calculated, as a function of time, from measurements made utilizing an inverted microscope fitted with a calibrated ocular grid.

^b Relative motility = distance migrated in 24 hours compared to wild-type T2 cells.

functionally-null 4HH cell line (**Figure 4**). Use of PAI-1 neutralizing antibodies similarly attenuated T2 cell locomotion and also promoted substrate detachment of both T2 and HMEC-1 cells. PAI-1 activity was required for endothelial tubulogenesis on Matrigel surfaces as addition of neutralizing antibodies blocked cellular coalescence into tubular networks. This effect is consistent with the block in tubulogenesis attained by Rc/CMVIAP transfection (**Figures 2 and 3**)




Figure 4. Effect of targeted PAI-1 ablation on migration of EC-1 cells and the PAI-1 functionally-null, EC-1-derived, 4HH cell line (**top panel**). The deficient motility typical of 4HH cells reflected a failure to synthesize *de novo* PAI-1 protein, as a consequence of constitutive expression of PAI-1 antisense transcripts, compared to parental EC-1 or Rc/CMV empty vector-transfected EC-1 controls (**insert in top panel**). Wound closure in 4HH cultures increased significantly following addition of active PAI-1 (1 µg/ml) (**bottom panel**). PAI-1-augmented motility was effectively ablated by co-incubation of PAI-1 with neutralizing PAI-1 antibodies prior to addition to wounded 4HH monolayers. Data plotted is the mean ± s.d. of 15 individual measurements on duplicate cell cultures.

but, more specifically, implicate PAI-1 activity as required for tube formation. Importantly, the integrity of capillary networks formed by both WT-T2 and HMEC-1 endothelial cells was disrupted by addition of neutralizing PAI-1 antibodies suggesting that continued PAI-1 synthesis, even in "mature" tubes, was required for network stability. Indeed, recent findings (14) support a model whereby continued PAI-1 synthesis by "mature" tubular networks is required to prevent plasmin-dependent capillary regression and our results are confirmatory of this suggestion. These data are reviewed in the appended paper by Kutz and Higgins (2004). Collectively, these data indicate that PAI-1 expression is an essential and targetable aspect of a successful angiogenic response *in vitro*. The results presented in this Final Report, therefore, support our hypothesis that therapies directed at perturbation of PAI-1 synthesis or function in developing as well as mature angiogenic network structures may have significant benefit in the management of human breast tumors.

While T2 cells formed tubular structures in Matrigel culture, these networks were generally unstable and regressed after 2-3 days. The long-term (i.e., > 1 week) maintenance of the angiogenic response (complete with gel invasion, sprout formation from the lateral surface of the tubular structures, formation of complex branching patterns in 3-D orientation and, most importantly, maintenance of capillary network integrity) required co-culture with MDA-MB-231 human breast cells (as monolayers under the Matrigel overlays). A similar effect could be achieved (albeit with varying efficiency) using MDA-MB-231 conditioned medium in place of cells in the Matrigel culture. More importantly, the collagen-induced reorganization of endothelial cell cultures into "pre-capillary" structures (i.e., the earliest recognizable tubular response) was evident not only in T2 cells but also in primary rat aortic, bovine microvessel, human microvessel, and human umbilical endothelial cells and was similarly augmented by conditioned medium from human breast cancer cells. A variety of approaches (neutralizing antibodies to cytokines, pharmacologic inhibitors of signal transduction pathways) were used to identify the "active" angiogenic component elaborated by the human breast cancer cells. TGF- β 1 was found to be essential to long-term maintenance of the tubular structures in both T2 and HMEC-1 cells since addition of neutralizing antibodies to MDA-MB-231 conditioned medium before addition to Matrigel cultures attenuated network stability and promoted tubular regression. More importantly, use of the EGF receptor inhibitor AG1478 also significantly reduced network stability suggesting that TGF- β 1 and EGF ligands cooperate to maintain the long-term integrity of angiogenic networks that form in response to stimuli produced by human breast cancer cells. Since our data indicate that PAI-1 was a critical element in angiogenesis, it was important to determine if TGF- β 1 actually induced EGF receptor activation (i.e., phosphorylation) and whether receptor activation was required for TGF- β 1-induced PAI-1 expression. Indeed, TGF- β 1 effectively stimulated EGF receptor activation (**Figure 5**) and pharmacologic inhibition of this receptor completely blocked PAI-1 gene expression (**Figure 6**) as well as growth factor-induced cell migration (**Figure 7**). We are currently evaluating whether this same requirement governs the angiogenic response in primary endothelial cells.

We had established that cell migration (i.e., one essential aspect of the angiogenic switch) was a sufficient stimulus to activate PAI-1 expression in previously quiescent monolayers and that induced expression required binding of the bHLH-LZ transcription factor USF-1 to an E box motif in the PAI-1 promoter (these data are detailed in the three appended papers: Providence et al, 2002; Qi and Higgins, 2003; Allen et al, 2004). Most recently, culture of endothelial cells under optimal angiogenic conditions (i.e., in Matrigel using medium supplemented with FBS and TGF- β 1), resulting in long-term maintenance of the formed capillary network, was determined to require




Figure 5. Activation of the EGFR by TGF- β 1. Immunocytochemistry using antibodies specific for the activated form of the EGFR (clone 74) confirmed a relatively low level of receptor activation in quiescent (Q) cells (A). Exposure to individual growth factors (EGF, TGF- β 1) resulted in a significant increase in fluorescence intensity and perinuclear EGFR accumulation (indicative of increased receptor internalization). The fraction of TGF- β 1-treated cells that exhibited increased EGFR internalization (i.e., "activated" EGFR) was approximately comparable to that of EGF-stimulated cells; this induction was inhibited by AG1478 pretreatment (B). Data plotted (B) represent the mean \pm s.d. of triplicate experiments. Western analysis of EGFR activation (by immunoreactivity with clone 74 antibodies) indicated that phosphorylation of the 170 kDa EGFR in TGF- β 1-stimulated cultures was AG1478-sensitive (B). AG = AG1478 (2.5 μ M); T = TGF- β 1.




Figure 6. EGF- and TGF- β 1-induced PAI-1 protein expression is attenuated by pretreatment with the EGFR inhibitor AG1478. Following serum-deprivation, near-confluent quiescent R22 cell cultures were exposed to increasing concentrations of AG1478 (as indicated) for 30 minutes prior to a 6-hour incubation with either EGF (10 ng/ml) or TGF- β 1 (1 ng/ml). Cell extracts were separated by electrophoresis and PAI-1 protein levels assessed by western blotting. As expected, AG1478 effectively suppressed EGF-induced PAI-1 expression (A). TGF- β 1-stimulated PAI-1 expression was similarly sensitive to AG1478 pretreatment (with complete ablation of PAI-1 induction at AG1478 concentrations >1 μ M), suggesting the involvement of EGFR signaling in TGF- β 1-mediated PAI-1 synthesis (B). Histogram (C) represents the summary (mean \pm s.d.) of triplicate experiments normalized to cellular ERK2 levels. AG = AG1478 (numbers indicate concentration in μ M); T = TGF- β 1.




Figure 7. TGF-β1-stimulated cell motility is attenuated by pretreatment with AG1478. Pretreatment with the EGFR inhibitor AG1478 reduced scrape-stimulated cell migration to that approximating basal motility. Histogram represents mean±s.d. of triplicate experiments. AG = AG1478.




Figure 8. Dominant-negative USF-1 (USF-1A) attenuates TGF-β1-induced PAI-1 protein expression and barrier invasion. USF-1 was confirmed to be an endogenous PAI-1 promoter PE2 region DNA-binding factor by chromatin immunoprecipitation using antibodies to USF-1 (A). Controls included addition of sonicated cellular DNA but without immunoprecipitation (input DNA), addition of PAI-1p806-Luc DNA as a control template for PCR (template DNA) and PCR reaction mixtures with H₂O in place of DNA (-DNA). L = sizing ladder. To evaluate the effects of molecular genetic interference with USF function, RK cells were untransfected or transfected with CMV-driven WT USF-1 or CMV-driven dominant-negative USF-1A. Whole cell lysates from quiescent cultures or cells stimulated with 20% FBS or 1 ng/ml TGF-β1 were collected, separated on 9% SDS-PAGE, proteins transferred, and blots probed with anti-rat PAI-1 antibody (B). Transfers were reprobed with antibodies to ERK1/2 to assess protein loading. Invasion of RK cells expressing either WT (USF-1) or dominant-negative (USF-1A) expression constructs was compared ± TGF-β1 (C). Data in (C) specifically represent TGF-β1-induced fold-invasion of Matrigel-coated barriers (i.e., TGF-β1-associated invasion/untreated controls); histogram represents mean±standard error from 8 migration evaluations. Approximately 60% of the cells used in invasion assays were anti-HA positive (i.e., 60% transfection efficiency). Only 5% of cells that invaded the Matrigel barrier, in contrast, stained positively with the HA antibody indicating that the majority of USF-1A-expressing cells were non-invasive.

continued PAI-1 synthesis (Kutz and Higgins, in preparation) likely to prevent tubular regression (14). Such PAI-1 expression was both USF-1-dependent and inhibited by exposure to AG1478. Most importantly, and a critical aspect of the work directed to Task 2, we demonstrated that targeted down-regulation of TGF- β 1-induced PAI-1 expression using a dominant-negative USF-1A construct effectively attenuated matrix barrier invasion in response to TGF- β 1 (**Figure 8**). We are presently evaluating the ability of both dominant-negative USF-1A and PAI-1 antisense expression vectors to similarly inhibit TGF- β 1-induced barrier invasion by transfected primary




Figure 9. Schematic illustration of factors that regulate PAI-1 expression and function in response to TGF- β 1 stimulation. TGF- β 1 initiates a kinase cascade, at least partly as a function of EGFR activation (either through release of appropriate ligands or direct receptor transactivation), that involves participation of MEK and ERK1/2. Pharmacologic intervention, use of dominant-negative constructs and kinase assays suggest that pp60^{c-src} is upstream of MEK and ERK1/2 in this model. Activated ERKs are thought to target nuclear bHLH-LZ transcription factors including members of the USF family that, once phosphorylated, bind as dimers to E box (5'-CACGTG-3') motifs in the PAI-1 promoter. E box site occupancy relieves PAI-1 transcriptional repression characteristic of the quiescent state. Expression attenuation and inhibition of PAI-1 synthesis can be achieved by transfection of DN-USF-1 or PAI-1 antisense (CMVIAP) expression vectors. Addition of PAI-1 neutralizing antibodies, in turn, effectively modulates PAI-1-dependent, uPA- and/or plasmin-mediated, matrix remodeling as well as cellular motility.

endothelial cells of human and rodent origin. Collectively, the work carried out during the tenure of this grant have led us to construct an overall model of PAI-1 gene expression control by breast cancer-derived promigratory growth factors such as TGF- β 1 that involves an EGF inductive loop (Figure 9). These data are consistent with known molecular events associated with tumor progression in the breast and other organ sites (Figure 10).




Figure 10. Molecular events associated with breast tumor progression. In experimental models of breast cancer, *Ha-ras* activation results in the emergence of initiated epithelial cells that ultimately progress (through loss of cell cycle control elements) to benign lesions. Elevated autocrine/paracrine expression of TGF- β 1, and/or amplification of the epidermal growth factor receptor, is frequently associated with progression to an aggressive, high-level PAI-1 synthesizing, metastatic phenotype.

Experiments were initiated to evaluate if replacement of the CMV promoter element in the current PAI-1 antisense Rc/CMVIAP construct with endothelial cell-specific transcriptional control elements (derived from the *flt-1* and *VE-cadherin* promoters) conferred endothelial-specific PAI-1 gene control. Primers were designed to amplify regions of both the *flt-1* and *VE-cadherin* promoter regions for substitution cloning into Rc/CMVIAP. One initial *VE-cadherin*-IAP candidate clone was selected for transfection into both endothelial (HMEC-1) an non-endothelial (HaCaT) cells. Preliminary findings suggest that a *VE-cadherin*-driven IAP construct was expressed at high levels in HMEC-1 cells but not (or at least at very low levels relatively) HaCaT transfectants. We plan to continue these studies with one goal being to submit a new USAMRMC research grant utilizing these preliminary data as supporting evidence that endothelial-specific targeting of antisense PAI-1 transcripts will have therapeutic application.

KEY RESEARCH ACCOMPLISHMENTS

The key accomplishments achieved during the grant period are as follows:

1. Confirmed that targeted ablation of endothelial cell PAI-1 gene expression, using antisense expression vectors (Rc/CMVIAP) resulted in marked inhibition of cell motility and an inability to form angiogenic networks on Matrigel-coated surfaces.

2. Developed transfection techniques to introduce sense PAI-1 expression vectors (Rc/CMVPAI) into endothelial cells in which the PAI-1 gene was disrupted by homologous recombination (T2-null) to assess the effects of expression "rescue" on cell motility.
3. Created 4 such rescued cell lines (T2-nullR1-4); each line exhibited unique patterns of locomotion in the monolayer denudation injury model of induced cell motility that was statistically different (Student's t-test) from the rate of migration characteristic of the parental T2-null cells.
4. Addition of recombinant PAI-1 to cultures of T2 endothelial cells with genetically-attenuated PAI-1 levels restored their migratory rate to approximate that of wild-type cells. Similar positive effects on the migration of the PAI-1 functionally-null 4HH cell line was achieved by exogenous PAI-1 supplementation. This approach to motility assessments confirmed that PAI-1 is a critical element in the cellular migratory program. These findings support the likelihood that the overall experimental strategy to target PAI-1 expression in tumor angiogenesis will result in the design of genetic approaches that will have a defined therapeutic applicability.
5. Confirmatory results were obtained in the human microvessel endothelial cell line HMEC-1 which validates findings in the well-characterized T2 and 4HH cell systems in the context of human endothelial cells and tubulogenic differentiation.
6. Importantly, the integrity of capillary networks formed by both WT-T2 and HMEC-1 endothelial cells was disrupted by addition of neutralizing PAI-1 antibodies suggesting that continued PAI-1 synthesis, even in "mature" tubes, was required for network stability. Collectively, these data indicate that PAI-1 expression is an essential and targetable aspect of a successful angiogenic response in vitro.
7. TGF- β 1 and EGF ligands were determined to be important breast cancer-derived factors that contributed to the long-term maintenance of formed angiogenic networks, induced PAI-1 gene expression and cell migratory ability.
1. Down-regulation of TGF- β 1-induced PAI-1 expression using a dominant-negative USF-1A construct effectively attenuated growth factor-stimulated matrix barrier invasion confirming our hypothesis that the PAI-1 transcriptional control network represents a potential therapeutic target for breast cancer treatment.
2. We have created a model that integrates our findings within the general context of human breast cancer progression that details molecular events which contribute to PAI-1 over-expression resulting in matrix remodeling, induced cell invasivity, and angiogenic capillary stabilization. Collectively, these effects foster breast tumor progression and metastatic spread.
3. Studies were initiated, and are presently ongoing, to develop vectors designed for endothelial cell-specific expression of potentially therapeutically-useful constructs

(dominant-negative USF-1A; antisense PAI-1 sequences) identified during the course of this study. Current strategy involves use of endothelial-specific gene promoters (flt-1, VE-cadherin) to drive expression of cloned inserts.

REPORTABLE OUTCOMES

1. The following manuscripts have been published or are in press and cite support from grant DAMD17-00-1-0124.

Kutz, S.M., Hordines, J., McKeown-Longo, P.J., and Higgins, P.J. (2001) TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. Journal of Cell Science 114:3905-3914.

Samarakoon, R. and Higgins, P.J. (2002) MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type-1 gene expression upon drug-induced disruption of the microfilament and microtubule networks. Journal of Cell Science 115:3093-3103.

Providence, K.M., White, L.A., Tang, J., Gonclaves, J., Staiano-Coico, L., and Higgins, P.J. (2002). Epithelial monolayer wounding stimulates binding of USF-1 to an E box motif in the plasminogen activator inhibitor type-1 gene. Journal of Cell Science 115:3767-3777.

Samarakoon, R. and Higgins, P.J. (2002) pp60^{c-src} integrates cytoskeletal dynamics, MAP kinase activation and PAI-1 gene regulation. In: Recent Research Developments in Biochemistry 3:157-167.

Samarakoon, R. and Higgins, P.J. (2003) pp60^{c-src} mediates ERK activation/nuclear localization and PAI-1 gene expression in response to cellular deformation. Journal of Cellular Physiology 195:411-420.

Qi, L. and Higgins, P.J. (2003) Use of chromatin immunoprecipitation to identify E box-binding transcription factors in the promoter of the growth state-regulated human PAI-1 gene. Recent Research Developments in Molecular Biology 1:1-12.

Providence, K.M., Staiano-Coico, L., and Higgins, P.J. (2003) A quantifiable *in vitro* model to assess the effects of PAI-1 gene targeting on epithelial cell motility. In: Wound Healing: Methods and Protocols (DiPietra, L., Editor), Methods in Molecular Medicine 78:293-303.

Providence, K.P and Higgins, P.J. (2004) PAI-1 expression is required epithelial cell migration in two distinct phases of *in vitro* wound repair. Journal of Cellular Physiology 200:297-308.

Kutz, S.M. and Higgins, P.J. (2004) Plasminogen activator inhibitor type-1 expression

targeting: new therapeutic approaches to regulate tumor growth and angiogenesis. Recent Research Developments in Cell Science 1:1-10.

Allen, R.R., Qi, L. and Higgins, P.J. (2004) Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes. Journal of Cellular Physiology (accepted for publication).

2. Abstracts published during funding of this grant.

Higgins, P.J. (2000) PAI-1 gene expression in breast carcinoma cells: implications for cellular migratory activity. Proceedings of the Department of Defense Breast Cancer Research Meeting, I, 85.

Higgins, P.J. (2000) Antisense targeting of PAI-1 expression inhibits TGF- β 1-induced migration in premalignant epidermal epithelial cells. "New Molecular Targets for Cancer Therapy" Conference Proceedings.

Kutz, S.M. and Higgins, P.J. (2001) TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. *Molecular Biology of the Cell* 12, 281a.

Samarakoon, R. and Higgins, P.J. (2001) Cytoskeletal controls on PAI-1 gene regulation. *Molecular Biology of the Cell* 12, 353a-354a.

Higgins, P.J. and Tang, J. (2002) PAI-1 promoter-driven PAI-1-GFP expression vectors for direct assessment of transcriptional activity in individual cells *in vivo*. Proceedings of the American Association for Cancer Research Special Conference on "Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications *In Vivo*", p. A-8.

Higgins, P.J. (2002) PAI-1 is an important regulator of substrate adhesion and migration in human breast carcinoma cells. Proceedings of the Department of Defense Breast Cancer Research Meeting, P26-14.

Higgins, P.J. (2002) PAI-1 expression is required for endothelial cell migration and *in vitro* angiogenesis. Proceedings of the Department of Defense Breast Cancer Research Meeting, P26-15.

Higgins, P.J. (2002) PAI-1 promoter-driven PAI-1-GFP expression vectors: tools for assessment of transcriptional activity and cellular invasive traits. Proceedings of the XXXth Meeting of the International Society for Oncodevelopmental Biology and Medicine "Translational Cancer Research".

Higgins, P.J. (2002) PAI-1 promoter-driven PAI-1/GFP expression vectors: probes for PAI-1 transcriptional activity and induced angiogenesis. Proceedings of the First Annual Meeting of the Society for Molecular Imaging.

Allen, R.R. and Higgins, P.J. (2002) Transcriptional regulation of type 1 plasminogen activator inhibitor (PAI-1) by transforming growth factor β (TGF β) in human epithelial cells. Proceedings of the American Association for Cancer Research Special Conference on "Proteases, Extracellular Matrix, and Cancer", A43.

Higgins, P.J. (2002) PAI-1 promoter-driven PAI-1-GFP expression vectors for *in vivo* assessment of transcriptional activity in individual cells. Proceedings of the Second Biennial Meeting "Molecular Targets for Cancer Therapy, p13.

Higgins, P.J. (2003) pp60^{c-src}/MEK activation are required for TGF- β 1-stimulated PAI-1 gene transcription in microvessel endothelial cells. Proceedings of the American Association for Cancer Research Conference on the TGF- β Superfamily: Roles in the Pathogenesis of Cancer and Other Diseases, 2281.

Higgins, P.J. (2003) PAI-1 transcript targeting disrupts angiogenesis: Relevance to Breast Cancer Therapy. Proceedings of the 8th Multidisciplinary Symposium on Breast Disease, P11.

Higgins, P.J. (2003) PAI-1 gene expression is required for TGF- β 1-stimulated stromal invasion by epidermal keratinocytes and angiogenic endothelial cells. Abstracts of the AACR Special Conference in Cancer Research "Mouse Models of Cancer", A40.

Higgins, P.J. (2003) pp60^{c-src} and a USF-1-binding E box element are required for TGF- β 1-stimulated PAI-1 gene transcription during growth factor-induced cellular plasticity. Proceedings of the American Association for Cancer Research 44, p968.

Higgins, P.J. (2003) Disruption of PAI-1 gene expression inhibits endothelial cell migration and *in vitro* angiogenesis. Proceedings of the Joint Cancer Conference of the Florida Universities.

Higgins, P.J. (2003) Direct real-time analysis of PAI-1 transcriptional activation and induced migration in individual cells using PAI-1-GFP reporter constructs regulated by PAI-1-specific promoter elements. Abstracts of the Second Annual Meeting of the Society for Molecular Imaging, 228.

Allen, R.R. and Higgins, P.J. (2003) Transcriptional regulation of PAI-1 by TGF- β 1 in human epithelial cells. Proceedings of the American Association for Cancer Research Workshop "Pathobiology in Cancer".

Qi, L. and Higgins, P.J. (2004) Regulation of PAI-1 gene expression during cell cycle progression. Proceedings of the Sixth Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association, "Advances in Cancer Research: Molecular and Cellular Biology, Genomics and Proteomics, Targeted Therapeutics, Novel Clinical Trials, Molecular and Genetic Epidemiology/Prevention", A28.

Higgins, P.J. (2004) Transforming growth factor- β 1-induced plasminogen activator inhibitor type-1 transcription requires pp60^{c-src}/mitogen-activated protein kinase activity and utilizes a

proximal promoter E box motif. Proceedings of the Institute Pasteur Euroconference, "Cancer: New Insights in Molecular Diagnosis and Therapy".

Higgins, P.J. (2004) pp60^{c-src}, MEK-ERK and EGFR signaling are required for TGF- β 1-induced transcription of the epithelial-to-mesenchymal transition (EMT)-associated PAI-1 gene. Proceedings of the Third Biennial Meeting: Molecular Targets for Cancer Therapy.

3. A new Idea proposal entitled "Inducible Anti-Angiogenic Gene Therapy" was funded by the DOD Breast Cancer Program.
4. Vectors have been created (Rc/CMVPAI, Rc/CMVIAP, USF-1A, endothelial-specific PAI-1 antisense) that can be distributed to DOD investigators involved in angiogenesis research.
5. Several cell lines have been developed on the T2 genetic background that will be made available to DOD investigators interested in angiogenesis and breast cancer research. The T2 line is particularly adaptable for basic studies into the mechanisms underlying the tubulogenic process as well as for drug discovery anti-angiogenic investigations (pharmacologic and genetic based). T2 was originally isolated from a mass culture of normal rat kidney cells and determined to have an "epitheloid" phenotype. These cells form branching tubulogenic networks in Matrigel culture, organize into pre-capillary-like formations in collagen I, have VEGF receptors, use VEGF as a mitogen, have von Willebrand-like inclusions and, when transformed, form tumors with a hemangiosarcoma-like pathology. T2 cells, therefore, appear to be a primitive immortalized microvessel endothelial-like cell type. Since it is specifically the microvasculature that contributes to the tumor-dependent angiogenic response, these cells represent a unique resource well-adapted for studies on tubular differentiation and angiogenesis.

CONCLUSIONS

Several important conclusions were derived as a result of work completed during the period covered by this report.

- PAI-1 expression is required for optimal endothelial cell migration *in vitro*.
- Endothelial cell motile deficits, produced as a consequence of PAI-1 expression targeting, can be restored to approximately wild-type levels by addition of exogenous "active" PAI-1 protein.
- Confirmatory results were obtained in the human microvessel endothelial cell line HMEC-1 which validates findings in the well-characterized T2 and 4HH cell systems in the context of human endothelial cells and tubulogenic differentiation.

- The integrity of capillary networks formed by both WT-T2 and HMEC-1 endothelial cells was disrupted by addition of neutralizing PAI-1 antibodies suggesting that continued PAI-1 synthesis, even in “mature” tubes, was required for network stability.
- Stimulation of angiogenesis observed clinically during the progression of human breast cancer is likely due to PAI-1 transcription induced in response to particular growth factors (i.e., TGF- β and EGF family members) elaborated by the tumor cells.
- Down-regulation of TGF- β 1-induced PAI-1 expression using a dominant-negative USF-1A construct effectively attenuated growth factor-stimulated matrix barrier invasion confirming our hypothesis that the PAI-1 transcriptional control network represents a potential and accessible therapeutic target for breast cancer treatment.
- It appears possible to develop vectors designed for endothelial cell-specific expression of potentially therapeutically-useful constructs (dominant-negative USF-1A; antisense PAI-1 sequences) identified during the course of this study. Although it is appreciated that important confirmatory studies will have to be carried out in primary microvessel endothelial cells, this finding will facilitate the creation of endothelial-targeted genetic therapies important for Phase I clinical trials.
- These data are inconsistent with the emerging realization that “balanced proteolysis”, in general, is an essential aspect of a successful angiogenic response and that PAI-1, in particular, is a major regulator of tumor-dependent angiogenesis.
- It is possible to design targeted genetic therapies to manipulate expression of an important pro-angiogenic gene (PAI-1) under defined *in vitro* conditions.

REFERENCES

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. (1995). *Nat. Med.* 1: 27-31.
2. Carmeliet, P. and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. *Nature* 407: 249-257.
3. Pepper, M.S., Belin, D., Montesano, R., Orci, L., Vassalli, J.D. (1990). Transforming growth factor-beta1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells *in vitro*. *J. Cell Biol.* 111: 743-755.
4. Lambert, V., Munaut, C., Noel, A., Frankenhe, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M.P., Foidart, J.M. (2001). Influence of plasminogen activator inhibitor type1 on choroidal neovascularization. *FASEB J* 115: 1021-1027.
5. Bajou, K., Noel, A., Gerard, R.D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N.E., Carmeliet, P., Collen, D., Foidart, J.M. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. *Nature Med* 4: 923-928.
6. Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V., Praus, M., Lund, L.R., Frandsen, t.C., Brunner, N., Dano, K., Fusenig, N.E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.M., Noel, A. (2001). The plasminogen activator inhibitor

- PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for anti-angiogenic strategies. *J Cell Biol* 152: 777-784.
7. McMahon, G.A., Petitsclerc, E., Stetansson, S., Smith, E., Wong, M.K.K., Westrick, R.J., Ginsburg, D., Brooks, P.C., and Lawrence, D.A. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. *J. Biol. Chem.* 276: 33964-33968.
 8. Fox, S.B., Taylor, M., Grondahl-Hansen, J., Kakolyris, S., Gatter-Harris, A.L. (2001). Plasminogen activator inhibitor-1 as a measure of vascular remodeling in breast cancer. *J. Pathol.* 195: 236-243.
 9. Look, M.P., et al. (2002). Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. *J. Natl. Cancer Inst.* 94: 116-128.
 10. Chazaud, B., Ricoux, R., Christov, C., Plonquet, A., Gherardi, R.K., and Barlovatz-Meimon, G. (2002). Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. *Am. J. Path.* 160: 237-246.
 11. Higgins, P.J., Ryan, M.P., and Jelley, D.M. (1997). P52^{PAI-1} gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphologic response. *Biochem. J.* 321: 431-437.
 12. Providence, K.M., Kutz, S.M., Staiano-Coico, L., and Higgins, P.J. (2000). PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. *J. Cell. Physiol.* 182: 269-280.
 13. Kutz, S.M. and Higgins, P.J. (2004) Plasminogen activator inhibitor type-1 expression targeting: new therapeutic approaches to regulate tumor growth and angiogenesis. *Recent Res. Devel. Cell Sci.* 1: 1-10.
 14. Davis, G.E., Allen, K.A.P., Salazar, R. and Maxwell, S.A. (2001) Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. *J. Cell Sci.* 114, 917-930.

APPENDED INFORMATION

Publications not previously submitted and now appended.

Kutz, S.M., Hordines, J., McKeown-Longo, P.J. and Higgins, P.J. (2001) TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. *J. Cell Sci.* 114, 3905-3914.

Providence, K.M., White, L.A., Tang, J., Gonclaves, J., Staiano-Coico, L., and Higgins, P.J. (2002) Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. *J. Cell Sci.* 115, 3767-3777.

Qi, L. and Higgins, P.J. (2003) Use of chromatin immunoprecipitation to identify E box-binding transcription factors in the promoter of the growth state-regulated human PAI-1 gene. *Recent Res. Devel. Mol. Biol.* 1, 1-12.

Allen, R.R., Qi, L. and Higgins, P.J. (2004) Upstream stimulatory factor regulates E

box-dependent PAI-1 transcription in human epidermal keratinocytes. J. Cell. Physiol. (accepted for publication).

Kutz, S.M. and Higgins, P.J. (2004) Plasminogen activator inhibitor type-1 expression targeting: new therapeutic approaches to regulate tumor growth and angiogenesis. Recent Res. Devel. Cell Sci. 1, 1-10.

List of personnel receiving support from this grant.

Paul J. Higgins, Ph.D., Principal Investigator

Stacie M. Kutz, Ph.D., Research Associate (effort was expended but no salary was requested as Dr. Kutz derives her salary from Center operating funds).

Rohan Samarakoon, Ph.D., Postdoctoral fellow (growth factor studies, EGF receptor evaluation, analysis of cooperation between TGF- β 1 and EGF in PAI-1 expression).

Jianzhong Tang, M.S., Senior Research Assistant (responsible for cell culture, expression vector construction, preparation of transfectant cell lines).

Kirwin M. Providence, M.S., Research Assistant (cell culture, development of motility assays).

Stephen P. Higgins, B.A., Research Technician (microscopy technician, isolation of primary cell cultures, 2-D and 3-D motility/invasion assays).

Principal Investigator contact information.

Dr. Paul J. Higgins

Professor and Director

Center for Cell Biology & Cancer Research

Albany Medical College

47 New Scotland Avenue

Albany, New York 12208

Tel: 518-262-5168

Fax: 518-262-5669

e-mail: higginp@mail.amc.edu

TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion

Stacie M. Kutz, John Hordines, Paula J. McKeown-Longo and Paul J. Higgins*

Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York 12208, USA

*Author for correspondence (e-mail: higginsp@mail.amc.edu)

Accepted 16 July 2001

Journal of Cell Science 114, 3905-3914 (2001) © The Company of Biologists Ltd

SUMMARY

The type-1 inhibitor of plasminogen activator (PAI-1) is an important physiological regulator of extracellular matrix (ECM) homeostasis and cell motility. Various growth factors mediate temporal changes in the expression and/or focalization of PAI-1 and its protease target PAs, thereby influencing cell migration by barrier proteolysis and/or ECM adhesion modulation. TGF- β 1, in particular, is an effective inducer of matrix deposition/turnover, cell locomotion and PAI-1 expression. Therefore, the relationship between motility and PAI-1 induction was assessed in TGF- β 1-sensitive T2 renal epithelial cells. PAI-1 synthesis and its matrix deposition in response to TGF- β 1 correlated with a significant increase in cell motility. PAI-1 expression was an important aspect in cellular movement as PAI-1-deficient cells had significantly impaired basal locomotion and were unresponsive to TGF- β 1. However, the induced migratory response to this growth factor was complex. TGF- β 1 concentrations of 1-2 ng/ml were significantly promigratory, whereas lower levels (0.2-0.6 ng/ml) were ineffective and final concentrations \geq 5 ng/ml inhibited T2 cell motility. This same growth factor range progressively increased PAI-1 transcript levels in T2 cells consistent with a bifunctional role for PAI-1 in cell migration. TGF- β 1 induced PAI-1 mRNA transcripts in quiescent T2 cells via an immediate-early response mechanism. Full TGF- β 1-stimulated expression required tyrosine kinase activity and involved MAPK/ERK kinase (MEK). MEK appeared to be a major mediator of TGF- β 1-dependent PAI-1 expression and T2 cell motility since PD98059 effectively attenuated both TGF- β 1-induced ERK1/2 activation and PAI-1 transcription as well as basal

and growth factor-stimulated planar migration. Since MEK activation in response to growth factors is adhesion-dependent, it was important to determine whether cellular adhesive state influenced TGF- β 1-mediated PAI-1 expression in the T2 cell system. Cells maintained in suspension culture (i.e., over agarose underlays) in growth factor-free medium or treated with TGF- β 1 in suspension expressed relatively low levels of PAI-1 transcripts compared with the significant induction of PAI-1 mRNA evident in T2 cells upon stimulation with TGF- β 1 during adhesion to a fibronectin-coated substrate. Attachment to fibronectin alone (i.e., in the absence of added growth factor) was sufficient to initiate PAI-1 transcription, albeit at levels considerably lower than that induced by the combination of cell adhesion in the presence of TGF- β 1. T2 cells allowed to attach to vitronectin-coated surfaces also expressed PAI-1 transcripts but to a significantly reduced extent relative to cells adherent to fibronectin. Moreover, newly vitronectin-attached cells did not exhibit a PAI-1 inductive response to TGF- β 1, at least during the short 2 hour period of combined treatment. PAI-1 mRNA synthesis in response to substrate attachment, like TGF- β 1-mediated induction in adherent cultures, also required MEK activity as fibronectin-stimulated PAI-1 expression was effectively attenuated by the MEK inhibitor PD98059. These data indicate that cellular adhesive state modulates TGF- β 1 signaling to particular target genes (i.e., PAI-1) and that MEK is a critical mediator of the PAI-1⁺/promigratory phenotype switch induced by TGF- β 1 in T2 cells.

Key words: PAI-1, Gene expression, Signal transduction, TGF- β 1

INTRODUCTION

Genetic analysis and adaptation of physiologically-relevant in vitro models of wound repair have clarified basic mechanisms involved in the tissue response to injury (Garlick and Taichman, 1994; Romer et al., 1996; Creemers et al., 2000; Providence et al., 2000). Fundamental to this process is the conversion of normally sedentary cells to an actively migrating, invasive phenotype (Martin, 1997). However, stimulated cell movement and locomotion through the provisional extracellular matrix (ECM) requires cycles of adhesion-deadhesion and precise control of the pericellular proteolytic environment (Yamada and Clark, 1996; Greenwood and

Murphy-Ullrich, 1998; Xie et al., 1998; Pilcher et al., 1999). Efficient wound re-epithelialization involves several protease systems with repair outcome highly dependent on the generation of plasmin by urokinase plasminogen activator (uPA). uPA activity is regulated, in turn, by its fast-acting type-1 inhibitor (PAI-1) (Andreasen et al., 1997; Lund et al., 1999; Zhou et al., 2000; Legrand et al., 2001). This cascade directly influences the overall injury site proteolytic balance and is a critical determinant in wound resolution (Mazzei et al., 1997; Wysocki et al., 1999) as well as directed cell movement (Pepper et al., 1987; Pepper et al., 1992; Okedon et al., 1992; Providence et al., 2000).

Injury-induced cell motility is orchestrated by various

autocrine/paracrine-acting growth factors (Martin, 1997). Most prominent are members of the transforming growth factor- β (TGF- β), fibroblast growth factor (FGF), and epidermal growth factor (EGF) families (Boland et al., 1996; Sato and Rifkin, 1988; Song et al., 2000; Ellis et al., 2001; Goke et al., 2001). TGF- β 1 and activin A, in particular, integrate the complex processes of tissue repair and cell migration (Zambruno et al., 1995; Munz et al., 1999) largely through control of genes that encode matrix components (fibronectin, type I collagen), regulators of ECM homeostasis (e.g., uPA, PAI-1) and the cellular adhesive apparatus (e.g., PAI-1, integrin subunits) (Cajot et al., 1989; Cajot et al., 1990; Wrana et al., 1991; Munz et al., 1999; Lai et al., 2000; Providence et al., 2000). Therefore, growth factor-initiated changes in the expression, focalization and/or relative activity of uPA/PAI-1 may stimulate or inhibit cell migration via ECM barrier proteolysis or by altering cellular adhesive interactions with the ECM (Stefansson and Lawrence, 1996; Mignatti and Rifkin, 2000). Variances in PAI-1 synthesis (Providence et al., 2000) and/or site-localization (Kutz et al., 1997) would specifically impact on cellular migration by affecting uPA activity as well as uPAR/vitronectin- or integrin/vitronectin-dependent cell attachment (Ciambone and McKeown-Longo, 1990; Deng et al., 1996; Chapman, 1997; Stefansson and Lawrence, 1996; Loskutoff et al., 1999).

Since TGF- β 1 stimulates cell motility (Kutz et al., 2001), PAI-1 induction (Boehm et al., 1999) in response to TGF- β 1 is probably critical to the motile process and the acquisition of epithelial cell 'plasticity' (Akiyoshi et al., 2001; Zavadil et al., 2001). This was confirmed in the present study using the PAI-1-deficient 4HH cell line (Providence et al., 2000) in a quantitative model of induced cell locomotion. Therefore, it was important to define mechanisms involved in TGF- β 1-dependent PAI-1 gene expression. PAI-1 transcription in TGF- β 1-responsive T2 epithelial cells used an immediate-early, tyrosine kinase-mediated, signaling pathway. Moreover, PAI-1 induction and basal as well as TGF- β 1-stimulated T2 cell locomotion was MEK-dependent. The involvement of MEK in TGF- β 1-initiated PAI-1 expression and the adhesion-dependency of MEK activation (Renshaw et al., 1997) suggested that substrate attachment may influence TGF- β 1-induced PAI-1 gene regulation. TGF- β 1, in fact, poorly induced PAI-1 transcription in cells maintained in suspension culture but significantly increased PAI-1 expression during attachment to fibronectin-coated surfaces. Cellular adherence to fibronectin alone (i.e., in the absence of TGF- β 1), and to a lesser extent vitronectin, also stimulated PAI-1 mRNA synthesis indicating that adhesive state can modulate TGF- β 1 signaling to particular target genes (i.e., PAI-1).

MATERIALS AND METHODS

Cell culture

T2 and EC-1 renal epithelial cells and the PAI-1-deficient 4HH line (Providence et al., 2000) were cultured in DMEM containing 10% fetal bovine serum (FBS) and antibiotics. Cells were washed twice with Hanks' balanced salt solution (HBSS; 1.3 mM CaCl_2 , 5 mM KCl , 0.3 mM KH_2PO_4 , 0.5 mM $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 0.4 mM $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.14 mM NaCl , 4 mM NaHCO_3 , 0.3 mM Na_2HPO_4 , 5.6 mM glucose) then incubated in serum-free DMEM for 3 days to initiate a quiescent state (Kutz et al., 1997). Cells were either maintained in quiescence

medium or stimulated by the direct addition of FBS or TGF- β 1 (to final concentrations of 20% and 0.2–10.0 ng/ml, respectively). Puromycin (100 $\mu\text{g/ml}$), actinomycin D (5 $\mu\text{g/ml}$), genistein (100 μM), PD98059 (5–50 nM) or wortmannin (50 nM) were added 30 minutes prior to stimulation with FBS or TGF- β 1. For culture under non-adherent conditions, quiescent T2 cells were harvested by trypsinization, washed with soybean trypsin inhibitor, and plated on 1% agarose underlays in serum-free DMEM for 4 hours (Ryan et al., 1996). Agarose-suspended cells were maintained (for an additional 2 hours) under non-adherent conditions (in the presence or absence of TGF- β 1) or seeded onto fibronectin-, vitronectin- or bovine serum albumin (BSA)-coated 100 mm plastic dishes (coating concentration 10 μg protein/ml) and allowed to re-attach for 2–6 hours (in the presence or absence of TGF- β 1) prior to RNA isolation. Directional migration assays used methods developed previously (Providence et al., 2000). Three-day post-confluent T2 cell cultures were washed twice with HBSS and incubated for 3 days in serum-free DMEM. Monolayers were maintained under serum-free or TGF- β 1-serum-supplemented conditions prior to scrape-wounding using the small end of a 1000 μl pipette tip. Initial wound size was determined for each culture dish and extent of injury closure assessed 24 hours later with an inverted microscope fitted with a calibrated ocular grid.

Northern blot analysis

Total cellular RNA was isolated and denatured at 55°C for 15 minutes in 1 \times MOPS, 6.5% formaldehyde and 50% formamide prior to electrophoresis on agarose/formaldehyde gels (1.2% agarose, 1.1% formaldehyde, 1 \times MOPS, 50 mM sodium acetate, 1 mM EDTA, pH 8.0). RNA was transferred to Nytran membranes by capillary action in 10 \times SSC (3M NaCl , 0.3 M Na citrate, pH 7.0), UV crosslinked and incubated for 2 hours at 42°C in 50% formamide, 5 \times Denhardt's solution, 1% SDS, 100 $\mu\text{g/ml}$ sheared/heat-denatured salmon sperm DNA (ssDNA) and 5 \times SSC. RNA blots were hybridized with ^{32}P -labeled cDNA probes for PAI-1 and A-50 (Ryan and Higgins, 1993) for 24 hours at 42°C in 50% formamide, 2.5 \times Denhardt's solution, 1% SDS, 100 $\mu\text{g/ml}$ ssDNA, 5 \times SSC and 10% dextran sulfate. Membranes were washed 3 times in 0.1 \times SSC/0.1% SDS for 15 minutes each at 42°C followed by 3 washes at 55°C prior to exposure to film.

Microscopy

Cells were washed twice with $\text{Ca}^{2+}/\text{Mg}^{2+}$ free phosphate-buffered saline (PBS-CMF; 2.7 mM KCl , 1.2 mM KH_2PO_4 , 0.14 M NaCl , 8.1 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$) and fixed in 10% formalin/PBS-CMF for 10 minutes. Following permeabilization with cold 0.5% Triton X-100/PBS-CMF (for PAI-1 immunolocalization) or 1% NP-40/PBS-CMF (for phalloidin-actin binding) for 10 minutes at 4°C, cells were washed 3 times (5 minutes each) with PBS-CMF then overlaid with rabbit antibodies to PAI-1 (Kutz et al., 1997) in BSA (3 mg/ml)/PBS-CMF. After three PBS-CMF washes, cells were incubated with fluorescein-conjugated goat anti-rabbit IgG (1:20 in BSA/PBS-CMF) for 30 minutes at 37°C, washed, and coverslips mounted with 100 mM *n*-propylgalate in 50% glycerol/PBS-CMF. Rhodamine-phalloidin was used to visualize actin microfilament structures (Ryan and Higgins, 1993).

MAP kinase assays

Cells were extracted for 30 minutes in cold lysis buffer (0.5% deoxycholate, 50 mM Hepes [pH 7.5], 1% Triton X-100, 1% NP-40, 150 mM NaCl , 50 mM NaF , 1 mM Na -orthovanadate, 0.1% aprotinin, 4 $\mu\text{g/ml}$ pepstatin A, 10 $\mu\text{g/ml}$ leupeptin, 1 mM PMSF) and lysates clarified by centrifugation at 14,000 *g* for 15 minutes at 4°C. For immunoprecipitation, aliquots containing 500 μg protein were incubated with 2 μg ERK1/2 antibody for 2 hours with gentle rocking. Protein A/G Plus-agarose (30 μl) was added for 2 hours, immune complexes collected by centrifugation, washed twice with lysis buffer and twice with 100 mM NaCl in 50 mM Hepes (pH 8.0) and then




Fig. 1. PAI-1 deposition in T2 cells after stimulation with serum or TGF- β 1. Quiescent (Q) cell cultures were stimulated by addition of FBS or TGF- β 1 (to final concentrations of 20% and 1 ng/ml, respectively). After 4 hours, cells were fixed and processed (see Materials and Methods) for visualization of microfilament organization (Actin) and PAI-1 immunolocalization (PAI-1).

incubated at 37°C for 15 minutes in kinase reaction buffer (10 μ Ci 32 P-ATP, 50 μ M ATP, 20 mM Hepes (pH 8.0), 10 mM MgCl₂, 1 mM DTT, 1 mM benzamidine, 0.3 mg/ml myelin basic protein (MBP)). Electrophoresis buffer (50 mM Tris (pH 6.0), 10% glycerol, 1% SDS, 1% β -mercaptoethanol) was added, samples boiled for 10 minutes and 15 μ l aliquots separated on SDS/15% polyacrylamide gels. Proteins were transferred to nitrocellulose in 25 mM Tris, 190 mM glycine, 20% methanol and membranes exposed to film for visualization of phosphorylated MBP. Western blotting for ERK2 and total MBP detection by Ponceau S staining were used to confirm equivalent loading per lane. For detection of phosphorylated ERK1/2, membranes were washed for 10 minutes in 0.05% Triton X-100/PBS-CMF followed by 2 hours in wash solution containing 3% milk. Phospho-ERK monoclonal antibody (1:1000) was added for an overnight incubation in blocking solution at room temperature. Following 3 washes for 20 minutes, horseradish peroxidase (HRP)-labeled anti-mouse secondary antibody (1:3000 in blocking solution) was added and incubated for an additional 1 hour. Membranes were washed 5 times for 10 minutes each in wash solution, incubated with ECL substrate solution (Amersham, Piscataway, NJ) for 2 minutes with gentle rocking and exposed to film. Membranes were stripped for 90 minutes at room temperature using the Western Stripper Kit (Bioworld, Dublin, Ohio), neutralized then incubated in a ERK1/2 primary antibody mixture (each diluted 1:3000 in blocking solution) followed by HRP-anti-rabbit secondary antibody and ECL reagent as described above.

RESULTS

TGF- β 1 stimulation of PAI-1 expression and directional motility is MEK-dependent

PAI-1 synthesis and accumulation in the ventral undersurface region in response to TGF- β 1 (Fig. 1) correlated with a significant increase in T2 cell motility (relative to the basal rate of movement in the scrape-wound assay) approximating that of serum-stimulated cells (Fig. 2). This rather dramatic effect of TGF- β 1 on cell migration and cytoarchitecture is consistent with involvement of TGF- β 1 target genes (e.g., PAI-1) in cellular 'plasticity' and invasive behavior (Zavadil et al., 2001). Antibodies to PAI-1, in fact, inhibit cell attachment (Higgins et al., 1991), promote substrate detachment (Rheinwald et al., 1987) and attenuate cell activation (Kutz et al., 1997).

Furthermore, recent findings have highlighted the functional linkage between induced PAI-1 synthesis and cellular motility (Mignatti and Rifkin, 2000; Providence et al., 2000; Kutz et al., 2001). To directly assess the role of PAI-1 in growth factor-stimulated cell locomotion, TGF- β 1-dependent wound closure was compared in EC-1 and 4HH cells. 4HH is a derivative of EC-1 in which PAI-1 synthesis is specifically ablated by stable constitutive expression of PAI-1 antisense transcripts under




Fig. 2. Stimulation of cell motility by serum or TGF- β 1. Confluent cultures of T2 cells were incubated in serum-free DMEM for 3 days prior to scrape-wounding. Cells were maintained in the FBS-free medium to assess basal migration (A). The percent (%) wound closure was determined 24 hours later. Data plotted are the means \pm s.d. of 20 individual measurements made on each of triplicate cultures for each treatment condition. Asterisks indicate a statistically significant difference (Student's *t*-test, $P > 0.01$) in cell migration for TGF- β 1- and FBS-supplemented cultures compared with basal (FBS-free) motility. The effect of targeted PAI-1 ablation on basal (-TGF- β 1) as well as TGF- β 1-induced (+TGF- β 1) cell locomotion was assessed in EC-1 and 4HH cell cultures by evaluation of the extent (%) of wound closure in the absence and presence of growth factor (1 ng/ml) (B). Data plotted are the means \pm s.d. of 15 individual measurements on duplicate cultures/treatment group. Asterisk indicates a statistically significant difference ($P < 0.01$) between motility under growth factor-free and supplemented conditions for EC-1 cells. By contrast, 4HH cells were unresponsive to TGF- β 1 in this assay.




Fig. 3. Metabolic requirements for TGF- β 1-induced PAI-1 expression. To assess pathways underlying induced PAI-1 expression, quiescent (Q) T2 cells were stimulated with serum (20%) or TGF- β 1 (1 ng/ml) for 2 hours, in the presence or absence of a 30 minute pretreatment with the indicated inhibitors, prior to RNA isolation (A). Northern blots were hybridized with 32 P-labeled cDNA probes for PAI-1 and A-50 simultaneously. The inability of puromycin to attenuate either serum or TGF- β 1-induced PAI-1 transcripts and the sensitivity of expression to actinomycin D indicated that PAI-1 induction by both stimuli was an immediate-early (i.e., primary) response. TGF- β 1-induced PAI-1 expression in T2 cells is MEK-dependent (B). Quiescent (Q) T2 cells were stimulated with TGF- β 1 (1 ng/ml) for 2 hours in the absence or presence of a 30 minute pretreatment with PD98059 (50 nM) prior to isolation of RNA. Northern blots were hybridized with 32 P-labeled cDNA probes to PAI-1 and A-50.

control of a strong CMV promoter (Higgins et al., 1997). These cells do not produce detectable PAI-1 protein under growth factor-supplemented culture conditions (Providence et al., 2000), thus, providing a tool to assess the relationship between PAI-1 expression and cell motility. The 4HH basal migration rate (i.e., locomotion in serum/growth factor-free medium) was $\leq 30\%$ that of parental controls. Moreover, relative to EC-1 cells in which wound closure is significantly enhanced by TGF- β 1, 4HH cells were unresponsive and failed to increase substantially their rate of movement in TGF- β 1-supplemented medium (Fig. 2).

Since PAI-1 appears to be a critical element in cellular migration, it was important to clarify pathways by which TGF- β 1 influenced PAI-1 gene expression and the motile phenotype.




Fig. 4. Coupled ERK immunoprecipitation/MBP kinase assay for assessment of TGF- β 1-induced ERK activation. ERK1/2 were immunoprecipitated from lysates of quiescent (Q), FBS- and TGF- β 1-stimulated T2 cells. Exposure of quiescent cells to FBS (20%) was for 15 minutes and stimulation with TGF- β 1 (1 ng/ml) was for 30, 60 and 90 minutes prior to cell disruption and ERK1/2 immunoprecipitation. MBP phosphorylation reaction products (MBP-P) were separated by gel electrophoresis; equivalent loading of MBP and ERK per lane was confirmed by Ponceau S staining (not shown) and ERK2 western blotting, respectively (A). In contrast to the relatively rapid rate of ERK activation by serum (15 minutes), TGF- β 1-induced changes in ERK activity were not evident until 60 minutes after growth factor addition (A), remained elevated for approximately 2 hours and then rapidly declined (B). Coupled ERK immunoprecipitation/MBP phosphorylation (MBP-P) assays (C) confirmed that ERK activation in TGF- β 1-stimulated T2 cells is sensitive to the same pharmacologic inhibitors that attenuate growth factor-induced PAI-1 expression. The more pathway restrictive inhibitor herbimycin A (250 nM) (Fukazawa et al., 1994) attenuated MBP phosphorylation but not to the same extent as genistein or PD98059.

TGF- β 1-mediated PAI-1 transcription, similar to induction by serum, was an immediate-early response (i.e., resistant to protein synthesis inhibitors) and significantly reduced by prior exposure to genistein (Fig. 3). The MEK-specific compound PD98059 effectively attenuated (at the 5–20 nM range) (Fig. 3A) and completely ablated (at 50 nM) (Fig. 3B) TGF- β 1-induced PAI-1 expression. In agreement with previous studies (Hartsough and Mulder, 1995; Yonekura et al., 1999), and the PD98059-sensitivity of PAI-1 induction (Fig. 3), addition of TGF- β 1 to quiescent T2 cells stimulated ERK1/2 activity. However, the time course of ERK activation by TGF- β 1 (as assessed by the ability of ERK1/2 to phosphorylate the target substrate MBP in a linked immunoprecipitation-in vitro kinase assay), was delayed (by approximately 60 minutes) compared with the rapid induction (within 15 minutes) typical of serum-treated cells (Fig. 4). Similarly, increases in phospho-ERK1/2 levels (sixfold those of unstimulated cells) were not evident until 1 hour after addition of TGF- β 1 to quiescent cultures (not shown). Consistent with




Fig. 5. The MEK inhibitor PD98059 attenuates both basal and TGF- β 1-stimulated T2 cell migration. Initial experiments were designed to determine the optimal concentration of TGF- β 1 on wound-induced motility (A). After scrape-injury, TGF- β 1 was added (in the concentrations indicated) and extent of migration determined 24 hours later. Data plotted is % increase in wound closure relative to non-supplemented (FBS-free) cultures. Asterisks indicate those concentrations for which motility was significantly different from basal migration (Student's *t*-test, $P > 0.0005$). To assess the requirement for MEK activity in stimulated cell movement, monolayer scrape wound-closure assays were carried out in TGF- β 1-supplemented (concentration range 0, 1, 2 and 5 ng/ml) serum-free medium in the presence (P) or absence of PD98059 (50 μ M) (B). TGF- β 1 at 1 and 2 ng/ml significantly increased T2 cell directional motility (Student's *t*-test, $P > 0.001$; asterisks) relative to basal motility (0 ng). In this series of experiments, cells exposed to 5 ng/ml of the growth factor actually had a decreased rate of locomotion relative to unsupplemented controls. At each concentration of TGF- β 1, PD98059 effectively reduced wound closure; there was no significant difference in the % closure rate among any of the treatment groups in the presence of PD98059.

the metabolic requirements for PAI-1 expression in response to TGF- β 1 (Fig. 3), genistein as well as PD98059 effectively blocked TGF- β 1-mediated ERK1/2 activation in coupled immunoprecipitation/MBP-phosphorylation assays (Fig. 4).

Although MEK was an important intermediate in TGF- β 1-dependent PAI-1 transcription, the role of this signaling pathway in TGF- β 1-stimulated T2 cell motility was unclear (Kutz et al., 2001). Since the migration-promoting effects of TGF- β 1 are often concentration, as well as context-dependent,




Fig. 6. TGF- β 1 concentration-dependent increase in relative PAI-1 mRNA transcripts. Quiescent T2 cells (Q) were stimulated with TGF- β 1 at the indicated concentrations and RNA isolated 2 hours later. Northern blots (insert for example) were scanned and the average PAI-1 transcript abundance, normalized to A-50 signal, calculated for 2 separate experiments.

it was necessary to define the optimal level of growth factor required to maximally stimulate directional T2 cell locomotion. Dose-assessments indicated that the migratory response to TGF- β 1 was complex. Motility rates in cultures supplemented with low (0.2-0.6 ng/ml) as well as high (5 ng/ml) TGF- β 1 concentrations were not significantly different from control values compared with the obvious promigratory effect associated with exposure to 1 and 2 ng/ml (Fig. 5A). TGF- β 1 levels >5 μ g/ml actually inhibited wound-induced T2 cell locomotion (when used alone or in the presence of serum) (not shown). PAI-1 transcripts progressively increased over the same growth factor concentration range (0.5-5.0 ng/ml) (Fig. 6). Collectively, these data are consistent with the suggestion that PAI-1 is a bifunctional regulator of cellular motility with positive effects likely restricted to a relatively narrow expression level 'window' (Mignatti and Rifkin, 2000). Using the determined optimal TGF- β 1 concentration (1-2 ng/ml), as well as a subeffective 5 ng/ml dose, MEK activity appeared to be important to both TGF- β 1-stimulated PAI-1 gene expression and planar motility, as PD98059 effectively attenuated both responses (Fig. 3; Fig. 5B).

Adhesive controls on TGF- β 1-induced PAI-1 expression in T2 cells

PD98059 blockade implicated MEK as a critical intermediate in the TGF- β 1-initiated pathway of PAI-1 gene expression (Fig. 3). Growth factor- and integrin-activated signaling pathways are interdependent, often converging on the MAPK cascade (Zhu and Assoian, 1995; Lin et al., 1997; Roovers et al., 1999), and MEK activation in response to growth factors requires substrate adhesion (Renshaw et al., 1997). Therefore, experiments were designed to assess whether cellular adhesive state modulated TGF- β 1-induced PAI-1 expression. Quiescent T2 cells were trypsinized and plated over agarose underlays in serum-/TGF- β 1-free DMEM where they remained in suspension as single cells. After 3 hours, agarose-cultured cells




Fig. 7. Optimum response of the PAI-1 gene to TGF- β 1 stimulation in T2 cells requires substrate adhesion. TGF- β 1-induced PAI-1 transcripts requires adhesion (to a fibronectin (FN) substrate) since cells cultured in suspension (agarose, Ag) or stimulated with TGF- β 1 (1 ng/ml) in suspension (Ag+TGF- β 1) did not express PAI-1 mRNA (A). Cells plated onto FN from suspension culture (Ag→FN) did produce low levels of PAI-1 transcripts, whereas plating onto FN in the presence of TGF- β 1 (Ag→FN+TGF- β 1) yielded optimal induction. PAI-1 induction as a consequence of FN attachment alone was also attenuated by addition of PD98059 during the 2 hour period of adhesion suggesting that MEK activity was also required for adhesion-dependent expression under growth factor-free conditions (B).

were maintained in non-supplemented medium, stimulated with TGF- β 1 (1 ng/ml) in suspension, transferred to fibronectin-coated dishes in serum-/TGF- β 1-free medium, or stimulated with TGF- β 1 during adhesion to fibronectin (all treatments were for 2 hours). Cells in agarose culture under supplement-free conditions or treated with TGF- β 1 in suspension expressed relatively low levels of PAI-1 mRNA compared with the robust expression evident upon stimulation with TGF- β 1 during attachment to fibronectin (Fig. 7A). Adhesion to fibronectin matrices alone, in the absence of added TGF- β 1, was sufficient to initiate modest PAI-1 transcription (Fig. 7A,B). This adhesion-dependent induction reflected a similarly conservative increase (i.e. threefold) in phospho-ERK1/2 levels (not shown) and, like TGF- β 1-mediated expression in normally anchored cells (Fig. 3), also required MEK activity as it was effectively inhibited by PD98059 (Fig. 7B). To further assess if this adhesion-related PAI-1 induction (in either TGF- β 1-stimulated or unstimulated cells) was dependent on the nature of the 'matrix' encountered, T2 cells were plated onto dishes coated with 10 μ g/ml fibronectin, vitronectin or BSA. TGF- β 1 did not induce PAI-1 under non-adherent conditions (i.e., culture on BSA-coated surfaces). Attachment to fibronectin for 4 hours (in the absence of TGF- β 1) was an effective inducer of PAI-1 transcripts (by three to fivefold) relative to adhesion to vitronectin (Fig. 8). Moreover, preliminary kinetic determinations indicated that PAI-1 mRNA levels increased as a function of time of attachment suggesting that subsequent cell spreading may be a factor in expression control. This was not unique to T2 cells as a similar response was evident in human dermal fibroblasts and microvessel endothelial cells (data not shown). However, no difference in either the attachment and/or spreading of T2 cells plated on fibronectin- compared with vitronectin-coated surfaces was evident within the same time (Fig. 9). More importantly, TGF- β 1 significantly enhanced PAI-1 expression only in T2 cells




Fig. 8. Matrix-type dependency of basal and TGF- β 1-induced PAI-1 expression. Quiescent (Q) T2 cells were trypsinized and replated on plastic dishes coated with BSA, fibronectin (FN) or vitronectin (VN) in the presence or absence of TGF- β 1 (1 ng/ml) for a 2 hour period. While both FN and VN induced PAI-1 mRNA transcripts, the amplitude of induction was significantly greater on FN-coated surfaces; TGF- β 1 stimulated expression only on T2 cells adhering to FN.

during attachment to fibronectin (Fig. 8). PAI-1 mRNA levels in cells seeded on vitronectin in the presence of TGF- β 1 were not different from that expressed during adhesion to vitronectin alone.

DISCUSSION

Several important aspects of *in vivo* injury repair (i.e. regional uPA/PAI-1 expression, spatial/temporal distinctions between motile and proliferative phenotypes) (Reidy et al., 1995; Romer et al., 1991; Romer et al., 1994) are recapitulated during cell migration into the denuded areas of a scrape-injured monolayer (Pepper et al., 1987; Pepper et al., 1992; Garlick and Taichman, 1994; Zahm et al., 1997; Providence et al., 2000). PAI-1 is rapidly synthesized by cells immediately adjacent to experimentally-created wounds (Pepper et al., 1992; Pawar et al., 1995; Providence et al., 2000). PAI-1 synthesis and deposition into cellular migration tracks are characteristics of a mobile cohort (Seebacher et al., 1992; Pepper et al., 1992) and an essential component of the migratory program (Providence et al., 2000; Kutz et al., 2001). The *in situ* distribution of this protein is consistent with a function in cell locomotion. De novo synthesized PAI-1 protein accumulates in the cellular undersurface region, probably in a complex with matrix vitronectin (Seiffert et al., 1994; Lawrence et al., 1997) although it appears that PAI-1 may also associate with fibronectin and/or laminin deposits in migration tracks (Seebacher et al., 1992). Therefore, this SERPIN is well-positioned to modulate integrin-ECM or uPA/uPAR-ECM interactions as well as ECM barrier proteolysis. *In vitro* studies suggest that PAI-1 may dissociate bound vitronectin from the uPAR, detaching cells that use this receptor as a vitronectin anchor (Deng et al., 1996; Kjoller et al., 1997; Loskutov et al., 1999). Alternatively, PAI-1 may directly inhibit α v integrin-mediated attachment to vitronectin by blocking accessibility to the RGD sequence located proximal to the uPAR binding site (Stefansson and Lawrence, 1996; Loskutov et al., 1999), although this inhibition is subject to spatial-temporal constraints (Germer et al., 1998). Furthermore, uPAR-associated uPA/PAI-1 complexes are internalized by endocytosis, which promotes uPA receptor recycling (Andreasen et al., 1997) and thereby




Fig. 9. Relative spreading of T2 cells on fibronectin and vitronectin. Suspended T2 cells were seeded in serum-free medium to dishes previously coated with fibronectin or vitronectin (10 μ g/ml). After 4 hours, random fields were photographed (representative examples shown) and the percent spread cells (i.e. non-refractive) calculated. Data plotted are the means \pm s.d. for assessments on three separate dishes/substrate. There was no difference in either T2 cell attachment or spreading on fibronectin or vitronectin.

vitronectin-dependent cell movement. However, transgenic approaches have suggested that PAI-1 promotes vitronectin-independent angiogenesis specifically by inhibition of plasmin proteolysis, thus preserving an appropriate matrix scaffold or providing required neovessel stability (Bajou et al., 2001). Although *in vivo* compensatory mechanisms may partly explain this discrepancy between animal and culture models, motility controls clearly vary and depend on the level of expression of participating elements, the nature of the provisional 'matrix' encountered, the context of the system studied and the growth factor environment.

TGF- β 1 exerts concentration-dependent effects on cellular locomotion in 3D culture systems (Gajdusek et al., 1993) as

well as in the more spatially restricted planar model of denudation injury (this study) (Gajdusek et al., 1993; Zicha et al., 1999). Wound repair analysis of the PAI-1-deficient 4HH cell line, in which PAI-1 synthesis is specifically ablated by antisense targeting (Higgins et al., 1997; Providence et al., 2000), supports the contention that PAI-1 is an important component in the motile program in this model. Since TGF- β 1 stimulates PAI-1 synthesis and PAI-1 impacts directly on cell motility (this study) (Deng et al., 1999; Providence et al., 2000), it was important to assess TGF- β 1-dependent controls on PAI-1 expression as well as on cellular migration. TGF- β 1 initiates PAI-1 transcription in quiescent T2 cells via an immediate-early response, tyrosine kinase-dependent pathway that involves MEK, an upstream activator of ERK1/2. However, unlike the typical rapid ERK phosphorylation associated with serum-stimulation (i.e., within 15 minutes), TGF- β 1-mediated ERK activation (as assessed by phosphorylation of the target substrate MBP) was delayed by 30-60 minutes. The MEK dependency for PAI-1 expression and TGF- β 1-stimulated as well as basal migration in T2 cells suggests that these events are related. Although MEK blockade probably interferes with cell movement at several levels (Klemke et al., 1997; Rikitake et al., 2000), genetic targeting approaches confirmed that both basal and TGF- β 1-stimulated cell migration (over a 24-36 hour period) requires PAI-1 expression (Providence et al., 2000; Kutz et al., 2001). Clearly, MEK inhibition may not affect basal locomotion in all cell types (Nguyen et al., 1998) but results may depend on the specific system studied. For example, in the monolayer denudation model (unlike random motility assays), 'basal' migration is most probably growth factor-mediated. Indeed, monolayer wounding in various cell types, in and of itself, is a sufficient stimulus to initiate autocrine growth factor expression (e.g., TGF- β 1, basic FGF, heparin-binding EGF) (Sato and Rifkin, 1988) and activate MAP kinases (Dieckgraefe et al., 1997). Moreover, growth factor synthesis and ERK phosphorylation/nuclear translocation occurs specifically in cells adjacent to the injury site (Dieckgraefe et al., 1997; Song et al., 2000; Ellis et al., 2001) similar to the distribution of locomoting PAI-1-expressing cells (Providence et al., 2000).

Matrix attachment, perhaps as part of the motile response, also stimulates PAI-1 expression. This has particular physiologic relevance. Although the present data suggest that not all matrices have equivalent inductive capability, during the process of wound healing cells 'switch' their integrin complement to accommodate the composition of the provisional ECM (Yamada et al., 1996). In certain instances, TGF- β 1 directly mediates changes in integrin availability and, therefore, cellular adhesive traits (Collo and Pepper, 1999; Dalton et al., 1999; Lai et al., 2000). Engagement of particular integrins (i.e. α v β 3, α 3 β 1) by immobilized antibodies or ligands has been implicated in PAI-1 gene control (Ghosh et al., 2000; Khatib et al., 2001). The α 3 β 1 ligands laminin-5 and collagen I, when presented immobilized on beads, were also effective inducers of uPA synthesis (Ghosh et al., 2000). Similar to data reported in this study with regard to adhesive controls on PAI-1 expression, β 1 integrin aggregation-induced uPA synthesis was also MEK-dependent as PD98059 inhibited ERK activation and uPA expression. Perhaps not coincidentally, both uPA and PAI-1 are induced by

pharmacologic disorganization of the actin-based microfilament system as is ERK activation (Higgins et al., 1992; Irigoyen et al., 1997). Since integrin ligation/clustering and cell adhesion result in various levels of cytoskeletal reorganization and recruitment of signaling intermediates (Zhu and Assoian, 1995; Lin et al., 1997; Miyamoto et al., 1998; Renshaw et al., 1997), the control of specific protease/protease inhibitors may be a common event in 'outside-in' signaling initiated by adhesive state and integrin engagement. Several matrices (i.e., fibronectin vs vitronectin) clearly differ in relative capacity to induce PAI-1 expression in T2 cells allowed to adhere under growth factor-free conditions. Most novel, however, is the observation that only certain matrix attachments synergize with TGF- β 1 to achieve maximal PAI-1 expression. Whether matrix-type variations in the amplitude and duration of ERK signaling underlies this differential response in T2 epithelial cells is currently under study. Nevertheless, the present findings indicate that adhesive influences also modulate TGF- β 1 signaling to target genes (i.e. PAI-1).

This work was supported by grants from the NIH (GM57242, GM07033, CA69612) and the Department of the Army (DAMD17-98-1-8015, DAMD17-00-1-0124).

REFERENCES

- Akiyoshi, S., Ishii, M., Nemoto, N., Kawabata, M., Aburatani, H. and Miyazano, K. (2001). Targets of transcriptional regulation by transforming growth factor- β : Expression profile analysis using oligonucleotide arrays. *Jpn. J. Cancer Res.* **92**, 252-268.
- Andreasen, P. A., Kjoller, L., Christensen, L. and Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. *Int. J. Cancer* **72**, 1-22.
- Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K. et al. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. *J. Cell Biol.* **152**, 777-784.
- Boehm, J. R., Kutz, S. M., Sage, E. H., Staiano-Coico, L. and Higgins, P. J. (1999). Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor- β 1. *J. Cell. Physiol.* **181**, 96-106.
- Boland, S., Boisvieux-Ulrich, E., Houcine, O., Baeza-Squiban, A., Pouchet, M., Schoevaert, D. and Marano, F. (1996). TGF β 1 promotes actin cytoskeleton reorganization and migratory phenotype in epithelial tracheal cells in primary culture. *J. Cell Sci.* **109**, 2207-2219.
- Cajot, J. F., Schleuning, W. D., Medcalf, R. L., Bamat, J., Testuz, J., Liebermann, L. and Sordat, B. (1989). Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. *J. Cell Biol.* **109**, 915-925.
- Cajot, J. F., Bamat, J., Bergonzelli, G. E., Kruithof, E. K., Medcalf, R. L., Testuz, J. and Sordat, B. (1990). Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. *Proc. Natl. Acad. Sci. USA* **87**, 6939-6943.
- Chapman, H. A. (1997). Plasminogen activators, integrins, the coordinate regulation of cell adhesion and migration. *Curr. Opin. Cell Biol.* **9**, 714-724.
- Ciambone, G. J. and McKeown-Longo, P. J. (1990). Plasminogen activator inhibitor type 1 stabilizes vitronectin-dependent adhesions in HT-1080 cells. *J. Cell Biol.* **111**, 2183-2195.
- Collo, G. and Pepper, M. S. (1999). Endothelial cell integrin α 5 β 1 expression is modulated by cytokines and during migration *in vitro*. *J. Cell Sci.* **112**, 569-578.
- Creemers, E., Cleutjens, J., Smits, J., Heymans, S., Moons, L., Collen, D., Daemen, M. and Carmeliet, P. (2000). Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. *Am. J. Pathol.* **156**, 1865-1873.
- Dalton, S. L., Scharf, E., Davey, G. and Assoian, R. K. (1999). Transforming growth factor- β overrides the adhesion requirement for surface expression of α 5 β 1 integrin in normal rat kidney fibroblasts. A necessary effect for induction of anchorage-independent growth. *J. Biol. Chem.* **274**, 30139-30145.
- Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. and Loskutoff, D. J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? *J. Cell Biol.* **134**, 1563-1571.
- Dieckgraefe, B. K., Weems, D. M., Santoro, S. A. and Alpers, D. H. (1997). ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. *Biochem. Biophys. Res. Comm.* **233**, 389-394.
- Ellis, P. D., Hadfield, K. M., Pascall, J. C. and Brown, K. D. (2001). Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogen-activated protein kinase cascades. *Biochem. J.* **354**, 99-106.
- Fukazawa, H., Uehara, Y., Murakami, Y., Mizuno, S., Hamada, M. and Takeuchi, T. (1994). Labeling of v-Src and BCR-ABL tyrosine kinases with [¹⁴C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. *FEBS Lett.* **340**, 155-158.
- Gajdusek, C. M., Luo, Z. and Mayberg, M. R. (1993). Basic fibroblast growth factor and transforming growth factor β -1: synergistic mediators of angiogenesis *in vitro*. *J. Cell. Physiol.* **157**, 133-144.
- Garlick, J. A. and Taichman, L. B. (1994). Fate of human keratinocytes during reepithelialization in an organotypic culture model. *Lab. Invest.* **70**, 916-924.
- Germer, M., Kanse, S. M., Kirkegaard, T., Kjoller, L., Felding-habermann, B., Goodman, S. and Preissner, K. T. (1998). Kinetic analysis of integrin-dependent cell adhesion on vitronectin – the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. *Eur. J. Biochem.* **253**, 669-674.
- Ghosh, S., Brown, R., Jones, J. C. R., Ellerbroek, S. M. and Stack, M. S. (2000). Urinary-type plasminogen activator (uPA) and uPA receptor localization are regulated by α 3 β 1 integrin in oral keratinocytes. *J. Biol. Chem.* **275**, 23869-23876.
- Goke, M. N., Cook, J. R., Kunert, K. S., Fini, M. E., Gipson, I. K. and Podolsky, D. K. (2001). Trefoil peptides promote restitution of wounded corneal epithelial cells. *Exp. Cell Res.* **264**, 337-344.
- Greenwood, J. A. and Murphy-Ullrich, J. E. (1998). Signaling of de-adhesion in cellular regulation and motility. *Microsc. Res. Tech.* **43**, 420-432.
- Hartsough, M. T. and Mulder, K. M. (1995). Transforming growth factor β activation of p44MAPK in proliferating cultures of epithelial cells. *J. Biol. Chem.* **270**, 7117-7124.
- Higgins, P. J., Chaudhari, P. and Ryan, M. P. (1991). Cell-shape regulation and matrix protein p52 content in phenotypic variants of *ras*-transformed rat kidney fibroblasts. *Biochem. J.* **273**, 651-658.
- Higgins, P. J., Ryan, M. P. and Ahmed, A. (1992). Cell shape-associated transcriptional activation of the p52(PAI-1) gene in rat kidney cells. *Biochem. J.* **288**, 1017-1024.
- Higgins, P. J., Ryan, M. P. and Jelley, D. M. (1997). p52^{PAI-1} gene expression in butyrate-induced flat revertants of *v-ras*-transformed rat kidney cells: mechanism of induction and involvement in the morphologic response. *Biochem. J.* **321**, 431-437.
- Irigoyen, J. P., Besser, D. and Nagamine, Y. (1997). Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway. *J. Biol. Chem.* **272**, 1904-1909.
- Khatib, A.-M., Nip, J., Fallavollita, L., Lehmann, M., Jensen, G. and Brodt, P. (2001). Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor α v β 3. *Int. J. Cancer* **91**, 300-308.
- Kjoller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Ronne, E., Goodman, S. L., Preissner, K. T., Ossowski, L. and Andreasen, P. A. (1997). Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. *Exp. Cell Res.* **232**, 420-429.
- Klemke, R. L., Cai, S., Giannini, A. L., Gallagher, P. J., de Lanerolle, P. and Cheres, D. A. (1997). Regulation of cell motility by mitogen-activated protein kinase. *J. Cell Biol.* **137**, 481-492.
- Kutz, S. M., Nickey, S., White, L. A. and Higgins, P. J. (1997). Induced PAI-

- 1 mRNA expression and targeted protein accumulation are early G1 events in serum-stimulated rat kidney cell. *J. Cell. Physiol.* **170**, 8-18.
- Kutz, S. M., Providence, K. M. and Higgins, P. J. (2001). Antisense targeting of c-fos transcripts inhibits serum- and TGF- β 1-stimulated PAI-1 gene expression and directed motility in renal epithelial cells. *Cell Motil. Cytoskel.* **48**, 163-174.
- Lai, C. F., Feng, X., Nishimura, R., Teitelbaum, S. L., Avioli, L. V., Ross, F. P. and Cheng, S. L. (2000). Transforming growth factor- β up-regulates the β 5 integrin subunit expression via Sp1 and Smad signaling. *J. Biol. Chem.* **275**, 36400-36406.
- Lawrence, D. A., Palaniappan, S., Stefansson, S., Olson, S. T., Francis-Chmura, A. M., Shore, J. D. and Ginsburg, D. (1997). Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. *J. Biol. Chem.* **272**, 7676-7680.
- Legrand, C., Polette, M., Tournier, J. M., de Bentzmann, S., Huet, E., Monteau, M. and Birembaut, P. (2001). uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial cell migration. *Exp. Cell Res.* **264**, 326-333.
- Lin, T. H., Chen, Q., Howe, A. and Juliano, R. L. (1997). Cell anchorage permits efficient signal transduction between ras and its downstream kinases. *J. Biol. Chem.* **272**, 8849-8852.
- Loskutoff, D. J., Curriden, S. A., Hu, G. and Deng, G. (1999). Regulation of cell adhesion by PAI-1. *APMIS* **107**, 54-61.
- Lund, L. R., Romer, J., Bugge, T. H., Nielsen, B. S., Frandsen, T. L., Degen, J. L., Stephens, R. W. and Dano, K. (1999). Functional overlap between two classes of matrix-degrading proteases in wound healing. *EMBO J.* **18**, 4645-4656.
- Martin, P. (1997). Wound healing - aiming for perfect skin regeneration. *Science* **276**, 75-81.
- Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S. and Mignatti, P. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. *EMBO J.* **16**, 2319-2332.
- Mignatti, P. and Rifkin, D. B. (2000). Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. *Adv. Cancer Res.* **78**, 103-157.
- Miyamoto, S., Katz, B. Z., Lafrenie, R. and Yamada, K. M. (1998). Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. *Ann. New York Acad. Sci.* **867**, 119-129.
- Munz, B., Smola, H., Engelhardt, F., Bleuel, K., Brauchle, M., Lein, I., Evans, L. W., Huylebroeck, D., Balling, R. and Werner, S. (1999). Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. *EMBO J.* **18**, 5205-5215.
- Nguyen, D. H. D., Hussaini, I. M. and Gonias, S. L. (1998). Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. *J. Biol. Chem.* **273**, 8502-8507.
- Okedon, L. E., Sato, Y. and Rifkin, D. B. (1992). Urokinase-type plasminogen activator mediates basic growth factor-induced bovine endothelial migration independent of its proteolytic activity. *J. Cell. Physiol.* **150**, 258-263.
- Pawar, S., Kartha, S. and Toback, F. G. (1995). Differential gene expression in migrating renal epithelial cells after wounding. *J. Cell. Physiol.* **165**, 556-565.
- Pepper, M. S., Vassalli, J. D., Montesano, R. and Orci, L. (1987). Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. *J. Cell Biol.* **105**, 2535-2541.
- Pepper, M. S., Sappino, A. P., Montesano, R., Orci, L. and Vassalli, J. D. (1992). Plasminogen activator inhibitor-1 is induced in migrating capillary endothelial cells. *J. Cell. Physiol.* **153**, 129-139.
- Pilcher, B. K., Dumin, J., Schwartz, M. J., Mast, B. A., Schultz, G. S., Parks, W. C. and Welgus, H. G. (1999). Keratinocyte collagenase-1 expression requires an epidermal growth factor receptor autocrine mechanism. *J. Biol. Chem.* **274**, 10372-10381.
- Providence, K. M., Kutz, S. M., Staiano-Coico, L. and Higgins, P. J. (2000). PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. *J. Cell. Physiol.* **182**, 269-280.
- Reidy, M., Irwin, C. and Linder, V. (1995). Migration of arterial wall cells. *Circ. Res.* **78**, 405-414.
- Renshaw, M. W., Ren, X.-D. and Schwartz, M. A. (1997). Growth factor activation of MAP kinase requires cell adhesion. *EMBO J.* **16**, 5592-5599.
- Rheinwald, J. G., Jorgensen, J. L., Hahn, W. C., Terpstra, A. J., O'Connell, T. M. and Plummer, K. K. (1987). Mesosecrein: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. *J. Cell Sci.* **104**, 263-275.
- Rikitake, Y., Kawashima, S., Yamashita, T., Ueyama, T., Ishido, S., Hotta, H., Hirata, K.-I. and Yokoyama, M. (2000). Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1006-1012.
- Romer, J., Lund, L. R., Kriksen, J., Ralkiaer, E., Zeheb, R., Gelehrter, T. D., Dano, K. and Kristensen, P. (1991). Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. *J. Invest. Dermatol.* **97**, 803-811.
- Romer, J., Lund, L. R., Kriksen, J., Pyke, C., Kristensen, P. and Dano, K. (1994). The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. *J. Invest. Dermatol.* **102**, 519-522.
- Romer, J., Bugge, T. H., Pyke, C., Lund, L. R., Flick, M. J., Degen, J. L. and Dano, K. (1996). Impaired wound healing in mice with a disrupted plasminogen gene. *Nat. Med.* **2**, 287-292.
- Roovers, K., Davey, G., Zhu, X., Bottazzi, M. E. and Assoian, R. K. (1999). α 5 β 1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. *Mol. Biol. Cell.* **10**, 3197-3204.
- Ryan, M. P. and Higgins, P. J. (1993). Growth state-regulated expression of p52(PAI-1) in normal rat kidney cells. *J. Cell. Physiol.* **155**, 376-384.
- Ryan, M. P., Kutz, S. M. and Higgins, P. J. (1996). Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. *Biochem. J.* **314**, 1041-1046.
- Sato, Y. and Rifkin, D. B. (1988). Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. *J. Cell Biol.* **107**, 1199-1205.
- Seebacher, T., Manske, M., Zoller, J., Crabb, J. and Bade, E. G. (1992). The EGF-inducible protein EIP-1 of migrating normal and malignant rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the migration tracks. *Exp. Cell Res.* **203**, 504-507.
- Seiffert, D., Mimuro, J., Schleef, R. R. and Loskutoff, D. J. (1994). Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. *Cell Differ. Dev.* **32**, 287-292.
- Song, Q. H., Singh, R. P., Richardson, T. P., Nugent, M. A. and Trinkaus-Randall, V. (2000). Transforming growth factor- β 1 expression in cultured corneal fibroblasts in response to injury. *J. Cell. Biochem.* **77**, 186-199.
- Stefansson, S. and Lawrence, D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking α v β 5 binding to vitronectin. *Nature* **383**, 441-443.
- Wrana, J. L., Overall, C. M. and Sodek, J. (1991). Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor β . Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. *Eur. J. Biochem.* **197**, 519-528.
- Wysocki, A. B., Kusakabe, A. O., Chang, S. and Tuan T. L. (1999). Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. *Wound Repair Regen.* **7**, 154-165.
- Xie, H., Pallero, M. A., Gupta, K., Chang, P., Ware, M. F., Witke, W., Kwiatkowski, D. J., Lauffenburger, D. A., Murphy-Ullrich, J. E. and Wells, A. (1998). EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLC γ signaling pathway. *J. Cell Sci.* **111**, 615-624.
- Yamada, K. M. and Clark, R. A. F. (1996). Provisional matrix. In *The Molecular Biology of Wound Repair* (ed. R. A. F. Clark), pp. 51-93. Plenum Press, NY.
- Yamada, K. M., Gailit, J. and Clark, R. A. F. (1996). Integrins in wound repair. In *The Molecular and Cellular Biology of Wound Repair* (ed. R. A. F. Clark), pp. 311-354. Plenum Press, NY.
- Yonekura, A., Osaki, M., Hirota, Y., Tsukazaki, T., Miyazaki, Y., Matsumoto, T., Ohtsuru, A., Namba, H., Shindo, H. and Yamashita, S. (1999). Transforming growth factor- β stimulates articular chondrocyte cell growth through p44/42 MAP kinase (ERK) activation. *Endocr. J.* **46**, 545-553.
- Zahm, J. M., Kaplan, H., Herar, A. L., Doriot, F., Pierrot, D., Somelette, P. and Puchelle, E. (1997). Cell migration and proliferation during the in vitro wound repair of the respiratory epithelium. *Cell Motil. Cytoskel.* **37**, 33-43.
- Zambruno, G., Marchisio, P. C., Marconi, A., Vascieri, C., Melchiori, A.,

- Giannetti, A. and De Luca, M. (1995). Transforming growth factor- β 1 modulates β 1 and β 5 integrin receptors and induces the *de novo* expression of the α v β 6 heterodimer in normal human keratinocytes: implications for wound healing. *J. Cell Biol.* **129**, 853-865.
- Zavadil, J., Bitzer, M., Liang, D., Yang, Y.-C., Massimi, A., Kneitz, S., Piek, E. and Bottinger, E. P. (2001). Genetic programs of epithelial cell plasticity directed by transforming growth factor- β . *Proc. Natl. Acad. Sci. USA* **98**, 6686-6691.
- Zhou, H. M., Nichols, A., Meda, P. and Vassalli, J. D. (2000). Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. *EMBO J.* **19**, 4817-4826.
- Zhu, X. and Assoian, R. K. (1995). Integrin-dependent activation of MAP kinase: a link to shape-dependent cell proliferation. *Mol. Biol. Cell* **6**, 273-282.
- Zicha, D., Genot, E., Dunn, G. A. and Kramer, I. M. (1999). TGF β 1 induces a cell-cycle-dependent increase in motility of epithelial cells. *J. Cell Sci.* **112**, 447-454.

Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene

Kirwin M. Providence¹, Lisa A. White¹, Jianzhong Tang¹, John Gonclaves², Lisa Staiano-Coico² and Paul J. Higgins^{1,*}

¹Center for Cell Biology & Cancer Research, Albany Medical College, Albany, NY 12208, USA

²Department of Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA

*Author for correspondence (e-mail: higginp@mail.amc.edu)

Accepted 9 July 2002

Journal of Cell Science 115, 3767-3777 © 2002 The Company of Biologists Ltd

doi:10.1242/jcs.00051

Summary

Several proteases and their co-expressed inhibitors modulate the interdependent processes of cell migration and matrix proteolysis during wound repair. Transcription of the gene encoding plasminogen activator inhibitor type 1 (PAI-1), a serine protease inhibitor important in the control of barrier proteolysis and cell-to-matrix adhesion, is spatially-temporally regulated following epithelial denudation injury *in vitro* as well as *in vivo*. Using a well-defined culture model of acute epidermal wounding and reepithelialization, PAI-1 mRNA/protein synthesis was induced early after monolayer scraping and restricted to cells comprising the motile cohort. PAI-1 levels in locomoting cells remained elevated (relative to the distal, contact-inhibited monolayer regions) throughout the time course of trauma repair. Targeted PAI-1 downregulation by transfection of antisense PAI-1 expression constructs significantly impaired keratinocyte migration and monolayer scrape wound closure. Injury-induced PAI-1 transcription closely paralleled growth state-dependent controls on the PAI-1 gene. An E-box motif (CACGTG) in the PAI-1 proximal promoter (located at nucleotides -160 to -165), previously shown to be necessary for serum-induced PAI-1 expression, was bound by nuclear factors from wound-stimulated but not quiescent, contact-inhibited, keratinocytes. UV crosslinking approaches to identify E-box-binding factors coupled with deoxyoligonucleotide affinity chromatography and gel retardation assays confirmed at least one major E-box-binding protein in both serum- and wound-activated cells

to be USF-1, a member of the helix-loop-helix family of transcription factors. An intact hexanucleotide E-box motif was necessary and sufficient for USF-1 binding using nuclear extracts from both serum- and wound-simulated cells. Two species of immunoreactive USF-1 were identified by western blotting of total cellular lysates that corresponded to the previously characterized phosphorylated and non-phosphorylated forms of the protein. USF-1 isolated by PAI-1 promoter-DNA affinity chromatography was almost exclusively phosphorylated. Only a fraction of the total cellular USF-1 in proliferating cultures, by comparison, was phosphorylated at any given time. PAI-1 E-box binding activity, assessed by probe mobility shift criteria, increased within 2 hours of monolayer scrape injury, a time frame consistent with wound-stimulated increases in PAI-1 transcription. Relative to intact cultures, scrape site-juxtaposed cells had significantly greater cytoplasmic and nuclear USF-1 immunoreactivity correlating with the specific *in situ*-restricted expression of PAI-1 transcripts/protein in the wound-edge cohort. USF-1 immunocytochemical staining declined significantly with increasing distance from the denudation site. These data are the first to indicate that binding of USF-1 to its target motif can be induced by 'tissue' injury *in vitro* and implicate USF-1 as a transcriptional regulator of genes (e.g. PAI-1) involved in wound repair.

Key words: Keratinocytes, PAI-1, Reepithelialization, Gene targeting

Introduction

Cellular locomotion across planar surfaces requires lamellipodium extension, creation of new adhesive contacts, cell body contraction and trailing edge detachment (Lauffenburger and Horwitz, 1996; Friedl and Bocker, 2000; Wells, 2000; Ridley, 2001). Stimulated cell movement through 3D matrices, by contrast, imposes a resistance to cell migration that necessitates both shape adaptations and proteolytic activity (Murphy and Gavrilovic, 1999; Friedl and Bocker, 2000). Indeed, growth factor-induced cell migration during wound re-

epithelialization, tumor metastasis and in normal as well as pathologic angiogenesis involves participation of several, frequently interacting, protease systems. Stromal invasion in these contexts is often highly dependent on the generation of plasmin by urokinase plasminogen activator (uPA); uPA activity is regulated, in turn, by its fast-acting type-1 inhibitor (PAI-1) (Andreasen et al., 1997; Bajou et al., 1998; Farina et al., 1998; Lund et al., 1999; Zhou et al., 2000; Legrand et al., 2001). This cascade directly influences the overall tissue site proteolytic balance and is a critical determinant in directed cell

movement, provisional matrix remodeling and extracellular matrix (ECM) invasion (Pepper et al., 1987; Pepper et al., 1992; Okedon et al., 1992; Jeffers et al., 1996; Mazzeri et al., 1997; Wysocki et al., 1999; Providence et al., 2000; Providence et al., 2002; Reijerkerk et al., 2000; Brooks et al., 2001). Recent studies in PAI-1^{-/-} mice confirmed the importance of this SERPIN in tumor spread and the associated angiogenic response (Bajou et al., 1998; Bajou et al., 2001; Gutierrez et al., 2000; McMahon et al., 2001; Stefansson et al., 2001). A critical balance between proteases and their specific inhibitors, thus, has been suggested as necessary to maintain an ECM scaffold structure compatible with efficient cellular locomotion (Bajou et al., 2001).

Growth factor-initiated changes in the expression, focalization and/or relative activity of uPA/PAI-1 may modulate cell migration either by controlling the rate and extent of ECM barrier proteolysis or altering cellular adhesive interactions with the ECM (Pepper et al., 1992; Seebacher et al., 1992; Stefansson and Lawrence, 1996; Mignatti and Rifkin, 2000). Co-expression of uPA, its surface-anchored receptor (uPAR) and PAI-1, for example, are required for optimal Matrigel invasion by lung tumor cells (Liu et al., 1995). Peptides that inhibit binding of uPA to its receptor ablated transforming growth factor- β 1 (TGF- β 1)-induced planar motility by transformed keratinocytes and significantly attenuated invasion across Matrigel barriers (Santibanez et al., 1999). PAI-1 levels are consistently elevated, moreover, in aggressive tumor phenotypes and PAI-1 expression is a major molecular feature of the TGF- β 1-initiated epithelial-to-mesenchymal transition in various cell systems (Santibanez et al., 1999; Akiyoshi et al., 2001; Zavadil et al., 2001). Variances in PAI-1 synthesis (Providence et al., 2000) and/or site-localization (Kutz et al., 1997), therefore, would be expected to specifically impact on cellular migration by affecting uPA activity as well as uPAR/vitronectin- or integrin/vitronectin-dependent contacts (Ciambone and McKeown-Longo, 1990; Deng et al., 1996; Chapman, 1997; Stefansson and Lawrence, 1996; Loskutoff et al., 1999). Targeted downregulation of PAI-1 synthesis with antisense expression vectors and use of function-blocking antibodies, in fact, inhibited basal as well as TGF- β 1-stimulated epithelial cell motility in both 2- and 3-D model systems (Providence et al., 2000; Providence et al., 2002; Brooks et al., 2001; Kutz et al., 2001; Chazaud et al., 2002).

PAI-1 gene expression under conditions of induced migration is predominantly transcriptional (Pawar et al., 1995; Providence et al., 2000; Kutz et al., 2001). Multiple promoter elements mediate stimulus-specific controls on PAI-1 transcription (e.g. Westerhausen et al., 1991; Ryan et al., 1996; Slack and Higgins, 1999). One prominent regulatory sequence is the hexanucleotide E-box motif (CACGTG) that is recognized by several members of the helix-loop-helix family of transcription factors (e.g. MYC, MAX, TFE3, USF-1, USF-2, HIF-1) (Riccio et al., 1992; Hua et al., 1998; Hua et al., 1999; Dennler et al., 1998; White et al., 2000) and the snail zinc-finger superfamily (Nieto, 2002; Hajra et al., 2002). A consensus E-box, located at nucleotides -160 to -165 upstream of the transcription start site in the PAI-1 gene, is required for PAI-1 promoter-directed reporter gene activation in growing EC-1 cells as well as in hepatocytes subjected to mild hypoxia (Kietzmann et al., 1999; White et al., 2000). Using an *in vitro*

model of the epidermal response to injury, we now report that monolayer wounding stimulates nuclear protein binding to a PAI-1 E-box-specific probe in the same cohort of cells induced to express PAI-1 mRNA transcripts/protein. Deoxyoligonucleotide affinity chromatography revealed USF-1 to be a major PAI-1 E-box-binding factor. Monolayer wounding, moreover, stimulated USF-1 nuclear translocation and PAI-1 E-box occupancy in wound-proximal cells. These data suggest that the E-box may function as a major transcriptional control element for migration-associated genes in much the same manner as it has been implicated in the regulation of cell cycle progression genes (e.g. Cogswell et al., 1995; White et al., 2000).

Materials and Methods

Cell culture

HaCaT (Li et al., 2000), RK (Boehm et al., 1999) and EC-1 (Kutz et al., 2001) epithelial cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS). Confluent cultures were washed with HBSS and maintained in serum-free DMEM for 3 days to initiate a state of growth-arrest (Ryan et al., 1996). Cells were stimulated globally by addition of FBS (to a final concentration of 20%) directly to the quiescence maintenance medium (Ryan et al., 1996) or more focally by scrape injury (Providence et al., 2000).

Motility assessments and collection of cell subpopulations

Denudation zones were created by pushing the narrow end of a sterile P1000 plastic pipette tip through the quiescent, contact-inhibited, epithelial monolayer. Wound closure rates, a function of planar motility in this directional 2D migration assay (Kutz et al., 2001), were calculated from measurements made using an inverted microscope fitted with a calibrated ocular grid (Providence et al., 2000). 'Activated' cells (i.e. those immediately adjacent to the denudation site, including cells that locomoted into the wound 'bed') were harvested by pushing the wide end of a P1000 pipette tip along the original injury tract, displacing cells directly at, and 5 mm from, the migratory edge. Scrape-released cells were aspirated and collected by centrifugation at 1400 g. Cells located 40 mm from the original wound border (i.e. in the intact distal monolayer) were similarly harvested. To assess the effect of targeted perturbation of PAI-1 synthesis on wound-induced motility, RK cells were transfected with PAI-1 antisense and sense constructs created in the R_c/CMV expression vector (Higgins et al., 1997).

Northern blot analysis

Total cellular RNA was isolated and denatured at 55°C for 15 minutes in 1× MOPS, 6.5% formaldehyde, and 50% formamide prior to electrophoresis on agarose/formaldehyde gels (1.2% agarose, 1.1% formaldehyde, 1× MOPS). RNA was transferred to Nytran membranes by capillary action in 10× SSC (3 M NaCl, 0.3 M sodium citrate, pH 7.0), UV crosslinked and incubated for 2 hours at 42°C in 50% formamide, 5× Denhardt's solution, 1% SDS, 100 µg/ml sheared/heat-denatured salmon sperm DNA (ssDNA) and 5× SSC. RNA blots were hybridized simultaneously with ³²P-labeled cDNA probes to PAI-1 and A-50 (RK and EC-1 cells) or PAI-1 and GAPD (HaCaT cells) for 24 hours at 42°C in 50% formamide, 2.5× Denhardt's solution, 1% SDS, 100 µg/ml ssDNA, 5× SSC and 10% dextran sulfate. Membranes were washed three times in 0.1× SSC/0.1% SDS for 15 minutes each at 42°C followed by three washes at 55°C prior to exposure to film.

Nuclear extracts

Cells were trypsinized, harvested by centrifugation, resuspended in 400 μ l of cold buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT), placed on ice for 15 minutes, then vortexed for 10 seconds after addition of 25 μ l 10% Nonidet NP-40. Nuclei were collected by centrifugation for 30 seconds at 14,000 *g*, resuspended in 50 μ l of cold lysis buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing leupeptin, aprotinin, chymostatin, pepstatin A, antipain (each at a final concentration of 10 μ g/ml), rocked at 4°C for 15 minutes and extracts clarified at 10,000 *g* for 5 minutes. For phosphatase treatments, isolated nuclei were lysed (Cheung et al., 1999) and 5 μ g nuclear extract protein incubated with potato acid phosphatase in PIPES/KOH digestion buffer, pH 6.5, for 2 hours at 37°C prior to electrophoresis on SDS/12% acrylamide gels and western blotting for USF-1 (as indicated below).

Mobility shift assay

Double-stranded deoxyoligonucleotides (3–5 pM) were incubated at 37°C for 10 minutes with T4 polynucleotide kinase (5–10 units/ μ l) in 70 mM Tris-HCl buffer, pH 7.6, containing 10 mM MgCl₂, 5 mM DTT and [γ -³²P]dATP (3000 Ci/mmol). Probes were purified by filtration through 10 kDa cellulose spin columns. Constructs used were as follows (only the coding strand is indicated):

PAI-1 E box, 5'-TACACACACGGTGTCCCAG-3';

PAI-1 mutant E-box #1, 5'-TACACACACGGATCCCAG-3';

PAI-1 mutant E-box #2, 5'-TACACATCCGTGTCCCAG-3';

standard consensus E-box, 5'-GGAAGCAGACCACGTGTCT-GTGCTTCC-3';

AP-1 consensus sequence, 5'-CGCTTGATGACTCAGCCGAA-3'.

Nuclear extracts were incubated with 50,000–100,000 cpm ³²P end-labeled target deoxyoligonucleotides in 5 \times gel shift buffer (20% glycerol, 5 mM MgCl₂, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.4 mg/ml dIdC). Following room temperature incubation for 20 minutes, gel loading buffer (25 mM Tris-HCl, pH 7.5, 0.02% bromophenol blue, 0.02% xylene cyanol, 4% glycerol) was added. Complexes were separated on Tris/glycine gels (Tris/glycine buffer: 5 mM Tris-HCl, 2 mM EDTA, 100 mM glycine) containing 4% acrylamide, 0.5% bisacrylamide, 2.5% glycerol, 0.75% ammonium persulfate and 0.085% TEMED). Antibodies (1–2 μ g per reaction) were added to the formed extract protein/³²P-labeled DNA probe complexes and maintained at room temperature for 20 minutes prior to electrophoresis for supershift assays (White et al., 2000).

UV crosslinking

A PAI-1 wild-type (WT) E-box probe body-labeled with ³²P for use as a probe in mobility shift assays was generated by PCR using a primer set corresponding to promoter region nucleotides –171 to –166 and –159 to –154 and purified on a 10 kDa spin column. Nuclear extract-probe binding reactions were incubated in a 96-well microtiter plate for 20 minutes at room temperature prior to UV irradiation (4.8 to 24.0 μ Joules/cm²) followed by DNase-I treatment (2 μ g/ml). Sample buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 1% SDS, 1% 2-mercaptoethanol, 0.01% bromophenol blue) was added, the complexes boiled and resolved on SDS/polyacrylamide slab gels (9% acrylamide, 0.24% bis-acrylamide, 0.375 M Tris-HCl, pH 8.8, 0.1% SDS, 0.03% ammonium persulfate, 0.025% TEMED).

Immunocytochemistry

Media were aspirated and the cells washed 3 \times in PBS prior to fixation for 10 minutes in 3% formaldehyde. After three PBS washes (5 minutes each), fixed cells were permeabilized with 0.5% Triton X-100/PBS for 10 minutes at 4°C, washed three times in PBS, incubated

in glycine (10 mg/ml) for 15 minutes, and incubated with antibodies to USF-1 (or preimmune IgG) followed by fluorescein isothiocyanate (FITC)-labeled secondary antibodies. Cells were visualized by incubation in propidium iodide which yields red nuclear fluorescence under UV light. Coverslips were mounted in anti-fade reagent for confocal microscopy. For immunodetection of PAI-1, cultures were fixed in 100% methanol for 20 minutes at –20°C then rehydrated by rinsing in PBS prior to sequential incubations with PAI-1 antibody followed by FITC-conjugated secondary antibody.

Tethered deoxyoligonucleotide protein binding and western blotting

The PAI-1 18 bp wild-type E-box deoxyoligonucleotide was ligated to a biotinylated 16-mer target sequence tethered to streptavidin-coated magnetic particles using the Boehringer Mannheim DNA-Binding Protein Purification kit. Nuclear protein binding to the PAI-1 'bait' construct was done in the presence of poly dIdC and poly L-lysine, the mixture vortexed, particles harvested with a magnetic separator and washed, and bound proteins eluted by boiling in electrophoresis sample buffer (50 mM Tris/HCl, pH 6.8, 10% glycerol, 1% SDS, 1% 2-mercaptoethanol) prior to separation on SDS/12% acrylamide slab gels. Protein transfers were probed with antibodies to USF-1 (c-20) or c-FOS (4-1D-G) (Santa Cruz Biotechnology) and antigen:antibody complexes visualized by horseradish peroxidase-conjugated secondary antibodies and ECL detection reagent (Amersham Pharmacia) using X-OMAT AR-5 film (Li et al., 2000).

PAI-1-GFP chimera expression constructs

The human PAI-1 promoter sequence from –800 to +71 was PCR-amplified for 30 cycles using the p800-Luc reporter plasmid as a template and Platinum *Taq* polymerase. The promoter fragment was gel-purified for subsequent cloning into the *SacI/KpnI* sites of the promoter-less expression vector pEGFP-1 (Clontech, Palo Alto, CA). The full-length human PAI-1 coding sequence (approximately 1.3 kb) was derived by RT-PCR from total RNA isolated from human foreskin fibroblasts, amplified by PCR using Platinum *Taq* polymerase, gel-purified and expressed as a GFP fusion protein by *T4* ligase insertion into the *KpnI/EcoRI* sites of pEGFP-N3. The same PAI-1 coding region was also transferred into the *BamHI/AgeI* site of the PAI-1 promoter-derived pEGFP-1 vector. All constructs were sequence verified. RK cells were seeded into 35 mm dishes and allowed to reach a density of 1×10^5 cells/cm² prior to transfection with 1–2 μ g DNA using Lipofectamine-Plus. Transfected cells were trypsinized and plated at low cell density in EGF-supplemented (1 ng/ml) growth medium. In some cases, transfected cells were removed from the culture dish prior to microscopy by incubation in 0.2% saponin in Ca²⁺/Mg²⁺-free PBS leaving a substrate-attached PAI-1-rich matrix (Higgins et al., 1997).

Results

PAI-1 synthesis is induced in migrating epithelial cells and required for optimal in vitro wound repair

Time-lapse videomicroscopy of the epithelial response to in vitro wounding resulted in the identification of two spatially distinct subpopulations of cells that are activated by scrape-injury and function in concert to re-establish a confluent monolayer (Providence et al., 2000). The 'leading edge' cohort (i.e. cells immediately adjacent to the wound border) quickly transition from a cuboidal to flattened phenotype, become polarized (i.e. extend membrane ruffles and lamellipodia along the cellular 'face' juxtaposed to the denuded zone) and begin

to migrate within 1-2 hours after initial injury. Mitotic bodies were not evident in the motile front during the time course of wound coverage. Addition of the thymidine analogue BrdU at the time of scraping and immunochemical visualization of DNA-synthesizing cells at various times post-trauma confirmed that migrating cells did not enter S phase (not shown). Significant nuclear labeling was evident, however, in a band of cells located approximately 1-2 mm from, and parallel to, the long axis of the injury site (for details, see Providence et al., 2000). This margin-displaced 'proliferative' cohort provides a reservoir of new cells to support the continued progression and cohesiveness of the migrating front prior to the increase in S phase activity in the neoepidermis. Functional compartmentalization in this *in vitro* model, therefore, closely recapitulates specific early events associated with acute epidermal injury repair *in vivo* (Coulombe, 1997).

PAI-1 is highly expressed in migratory cells *in vitro* as well as *in vivo* (Pepper et al., 1992; Romer et al., 1991; Providence et al., 2000). Similarly, elevated *de novo* synthesis of PAI-1 by two keratinocyte cell lines, RK (determined immunocytochemically) and HaCaT (by western blotting), in the *in vitro* monolayer wound model is restricted to cells immediately juxtaposed to the denudation site and which have acquired morphologic characteristics of an early motile phenotype (Fig. 1). Leading-edge cells extending cytoplasmic projections into the denuded area were particularly immunoreactive with PAI-1 antibodies. Differential harvest of locomoting RK, HaCaT and EC-1 epithelial cells indicated, moreover, that PAI-1 transcripts were significantly increased in cells harvested along the site of the original wound track (13- to 27-fold relative to the distal quiescent, unperturbed, monolayer cells) and remained elevated throughout the repair process (Fig. 1). The difference in PAI-1 mRNA expression kinetics between RK/EC-1 and HaCaT populations was attributable to the relatively protracted time course of wound resolution (24-36 hours vs. 48-72 hours) by HaCaT cells. Visual examination of the motile front population suggested that the newly synthesized PAI-1 was particularly abundant at a plane of focus corresponding to the cellular undersurface-culture substrate region. Transfection of RK cells with a GFP-tagged PAI-1 expression vector, in which transcription of the chimeric PAI-1-GFP insert is under the control of PAI-1 promoter sequences, provided for the direct visualization of PAI-1-GFP protein in the 'matrix' of saponin-dislodged keratinocytes as well as in the migratory tracks of growth factor-stimulated cells (Fig. 2). This approach to insert expression control (i.e. using PAI-1 upstream elements to drive PAI-1-GFP transcription) was selected since the time course of PAI-1-GFP chimera induction closely approximated that of the endogenous PAI-1 gene (e.g. Ryan et al., 1996). The PAI-1 promoter-PAI-1 coding-GFP construct was transfected into confluent RK monolayers

followed by incubation in serum-free medium prior to monolayer scraping. By 5 hours, scrape-activated cells had migrated well into the wound 'bed' exhibiting PAI-1-GFP-decorated migration tracks perpendicular to the long axis of the original scrape injury (not shown). These findings (e.g. Fig. 2) suggested that PAI-1 might function as a component of the basal epidermal cell motile apparatus as it appears to do in other cell types (Stefansson and Lawrence, 1996; Waltz et al., 1997; Brooks et al., 2001). To evaluate this possibility, RK cells were transfected with the PAI-1 antisense expression vector Rc/CMVIAP, cultured under quiescence conditions, then scrape injured. Two criteria were specifically evaluated including effects on PAI-1 synthesis and on 2D planar motility. The resultant attenuation of wound-induced PAI-1 protein synthesis in Rc/CMVIAP transfectants (confirmed by western blotting) reflected a significant inhibition of injury site closure (Fig. 3).

Monolayer wounding stimulates PAI-1 E-box-binding activity

Since PAI-1 expression was clearly a critical modulator of epithelial cell migration, it was important to clarify molecular events involved in PAI-1 expression control in response to





Fig. 1. Monolayer injury stimulates PAI-1 synthesis specifically in wound-edge cells. Quiescent contact-inhibited cultures of RK, HaCaT and EC-1 cells were maintained either intact or scrape-wounded with a pipette tip. RK cultures were fixed and PAI-1 protein visualized by immunocytochemistry (A,B). Control quiescent RK cells expressed relatively low levels of PAI-1 (A). Within 6 hours after scraping, PAI-1 was readily detected in motile RK cells immediately juxtaposed to the injury site (B; arrow indicates direction of migration into the denuded area). Western analysis of lysates of HaCaT cells differentially harvested 24 hours after scrape-trauma confirmed a significant increase in PAI-1 expression by epithelial cells bordering the injury site compared with cells in the distal uninvolved monolayer (C). PAI-1 mRNA transcripts were upregulated in cells harvested from the wound edge within 5 hours after scrape-injury. PAI-1 mRNA abundance (normalized to A-50 and GAPD hybridization signal for EC-1/RK and HaCaT cells, respectively) remained elevated over the time course of wound repair (D). RK total RNA was not isolated at the 7 hour post-wounding time point in the analysis series summarized in D. The difference in PAI-1 mRNA kinetic profiles for HaCaT versus EC-1/RK cells reflects the relatively protracted time frame for HaCaT monolayer injury site closure compared with RK/EC-1 populations (i.e. 48-72 hours versus 24-36 hours).

Fig. 2. Visualization of PAI-1-GFP in cellular migration tracks. Schematic of a pEGFP-1-based vector in which a chimeric transcript consisting of 1.3 kb of PAI-1 coding sequences and GFP is expressed under the control of a 0.8 kb PAI-1 'promoter' (A).

Transfection of RK cells and re-seeding in serum-containing medium resulted in synthesis of PAI-1-GFP detected initially in perinuclear Golgi-like structures (B). Approximately 6-12 hours later, PAI-1-GFP can be found in the matrix (probably vitronectin)-rich undersurface region upon removal of cells with saponin (C). The green 'footprint' of a single cell is shown in C. Seeding of PAI-1 promoter-PAI-1 coding-GFP transfectants at low density in

EGF-containing medium provides for the clear visualization of the chimeric PAI-1-GFP protein in cellular migration trails (D). The small bright image at the extreme right of the trail is the cell body. Transfection of RK cells with the PAI-1 promoter-PAI-1 coding-GFP vector followed by growth to confluency and subsequent scrape injury indicated that the resulting motile population deposited GFP-'tagged' PAI-1 into the cellular migration trails similar to that illustrated in D.



monolayer wounding. A search of the 5' flanking region of the PAI-1 gene, originally to identify potential cis-acting elements involved in growth state-dependent gene expression (Ryan et al., 1996; Boehm et al., 1999), identified a consensus E-box motif (CACGTG) at nucleotides -165 to -160 upstream of the transcriptional start site (White et al., 2000). This region is protected from DNase I digestion in growing epithelial cells (Johnson et al., 1992). E-box-binding activity consisting of two closely-spaced 'dumbbell-shaped' upper and lower bands,

assessed using an 18 bp PAI-1 sequence as a target in which the CACGTG motif was flanked both 5' and 3' by PAI-1-specific sequences, was evident in RK (Fig. 4), EC-1 and HaCaT (see below) cells. This probe shift pattern was maintained when an unlabeled AP-1 deoxyoligonucleotide (5'-CGCTTGATGACTCAGCCGGAA-3'), in 100-fold molar excess, was included in the reaction mixture. Band shifts were successfully competed, however, upon simultaneous addition of a 100-fold molar excess of an unlabeled wild-type (self)




Fig. 3. Targeted PAI-1 downregulation inhibits wound-stimulated cell motility. RK cells were transfected with a non-insert-bearing vector (Rc/CMV) or with constructs in which full-length PAI-1 coding sequences were cloned in antisense (Rc/CMVIAP) or sense (Rc/CMVPAl) orientation (A). Cultures were grown to confluency and scrape-wounded. Extent of repair-associated migration (% wound closure) was measured over a 24 hour period (B). There was no difference in stimulated motility among Rc/CMV- or Rc/CMVPAl-transfectants compared with non-transfected controls (RK). The rate of monolayer scrape repair by Rc/CMVIAP (antisense PAI-1)-transfected cells, in contrast, was significantly impaired (asterisk) relative to control RK cultures or to sense (Rc/CMVPAl) or empty vector (Rc/CMV) transfectants. Data plotted is mean \pm standard deviation of three independent wound repair determinations. Inset in B is a western blot of PAI-1 levels in the various cell types at the 24 hour time point illustrating downregulation of PAI-1 expression in the Rc/CMVIAP transfectants.




Fig. 4. Binding of a PAI-1 E-box probe by nuclear proteins from growing and wound-stimulated RK cells. The 18 bp ^{32}P -end labeled PAI-1 E-box probe (see Materials and Methods) was incubated with 10 μg of the nuclear protein fraction isolated from growing (A) or quiescent as well as wound-edge (B) RK cells and complexes resolved by gel electrophoresis. Two closely-spaced, 'dumbbell-shaped', bands (arrows) were evident in shifts produced by nuclear extracts derived from growing cells in the absence (none) of competing sequences (A). Incubation with the unlabeled WT PAI-1 18 bp E-box deoxyoligonucleotide (self) or the unlabeled standard consensus (SC) E-box construct (i.e. a CACGTG motif flanked by non-PAI-1 sequences) (both at a 50- to 100-fold molar excess) effectively blocked complex formation with the labeled probe. The AP-1 deoxyoligonucleotide and a mutant E-box construct (5'-CACGGA-3'), the latter in the context of PAI-1 flanking sequences, each failed to compete for probe binding (A). In contrast to PAI-1 probe patterns developed with nuclear extracts from quiescent (Q) RK cultures and which failed to form complexes that co-migrated with the slower mobile (i.e. upper) band, extracts prepared from wound-edge keratinocytes 2 hours post-scraper injury (W) produced the characteristic two-band complex (B).

competitor or a standard consensus (SC) E-box construct (i.e. an E-box hexanucleotide motif with non-PAI-1 flanking sequences). A mutant E-box motif (either CACGGA or TCCGTG) flanked by PAI-1-specific sequences failed to compete for probe binding (Fig. 4). These same mutant constructs were also incapable of forming shifted complexes when ^{32}P end-labeled and used as targets in gel retardation assays (see below). Collectively, these findings indicate a requirement, and specificity, for an intact consensus hexanucleotide E box for protein binding to the homologous site in the PAI-1 gene. Once probe E-box site occupancy by nuclear factors isolated from constitutively-growing, PAI-1-expressing, RK cells was established, it was necessary to determine whether a similar binding activity could be detected in wound-stimulated cultures and, if so, the kinetics of site occupancy relative to wound-induced expression of the endogenous PAI-1 gene. Nuclear extracts from differentially harvested wound-edge and distal quiescent monolayer cells were incubated with the ^{32}P -labeled 18 bp PAI-1 E-box probe and the formed complexes resolved by electrophoresis. Relative to cells that are in immediate proximity to the denudation injury and that have the demonstrable characteristic 2-band pattern (upper and lower) probe-binding activity,

nuclear extracts of distal monolayer isolates generally formed only a single complex corresponding in mobility to the lower band (Fig. 4). E-box-binding activity was evident soon after scrape injury in wound-edge cells consistent with the subsequent increase in PAI-1 transcripts in the migrating cohort (Fig. 1).

USF-1 is a PAI-1 E-box binding protein

An intact E-box site at nucleotides -160 to -165 in the proximal promoter of the rat PAI-1 gene is an important platform for protein binding in response to proliferative stimuli, mild hypoxia as well as to individual growth factors including TGF- β 1 (Kietzmann et al., 1999; White et al., 2000) (L.A.W. and P.J.H., unpublished). In order to identify specific transcriptional effectors capable of binding to the PAI-1 E-box site (based on data summarized in Fig. 4), a ^{32}P body-labeled, PCR-amplified, fragment of the PAI-1 promoter containing the CACGTG motif was UV crosslinked to nuclear proteins isolated from growing EC-1 cells. A major complex of approximately 44-45 kDa was resolved after DNase-1 digestion of the probe-extract reaction products and electrophoresis on SDS-acrylamide gels (Fig. 5). Addition of proteinase K to the UV-irradiated nuclear extract/deoxyoligonucleotide binding reaction for a 5 minute incubation before gel electrophoresis eliminated the 44-45 kDa band, suggesting involvement of a crosslinked nuclear protein in the formed complex (not shown). Prominent among E-box-binding proteins in this mass range are several helix-loop-helix transcription factors most notably members of the USF1/2 family (Littlewood and Evan, 1995). Tethered deoxyoligonucleotide affinity chromatography was used, therefore, to isolate PAI-1 E-box-binding proteins from the nuclear fraction of growing EC-1 cells. Bound proteins were eluted and western blotting, in fact, confirmed USF-1 as one PAI-1 E-box target sequence binding element (Fig. 5). Two immunoreactive USF-1 species, corresponding in mobility to USF-1 and phospho-USF-1 (Galibert et al., 2001), were resolved in extracts of growing EC-1 cells (Fig. 5). Blot analysis suggested an approximately threefold increase in USF-1 levels in growing cells compared with quiescent cells (L.A.W. and P.J.H., unpublished). Phosphorylation of USF-1 is necessary for DNA binding (Cheung et al., 1999) and, consistent with this requirement, the predominant form of USF-1 eluted from PAI-1 deoxyoligonucleotide affinity columns co-migrated with the 45 kDa (phospho-USF-1) species (Fig. 5). That the slower migrating 45 kDa species was phospho-USF-1 was confirmed by potato acid phosphatase treatment of nuclear extracts from serum-stimulated cells (which have abundant levels of the 45 kDa USF-1 immunoreactive protein) prior to western analysis. Once identified, it was important to assess whether E-box-dependent USF-1 binding could be resolved in nuclear extracts of scrape injury-stimulated cells (since PAI-1 transcripts were upregulated specifically in wound-edge keratinocytes; Fig. 1). Initial analysis of wounded monolayers indicated that increased levels of immunoreactive USF-1 were evident in cells immediately adjacent, and in close proximity, to the denuded site. Compared with intact cultures, scrape injury-juxtaposed cells had significantly greater cytoplasmic and nuclear USF-1 immunoreactivity (Fig. 6) correlating with the




Fig. 5. Identification of USF-1 as PAI-1 E-box probe-binding factor. A 32 P-body labeled PAI-1 wild-type (WT) E-box deoxyoligonucleotide probe was generated by PCR. Gel-purified probe was incubated with nuclear extracts from serum-stimulated EC-1 cells prior to UV irradiation and treated with DNase-I; the complexes were then boiled in sample buffer and resolved on SDS/9% polyacrylamide slab gels (A). A single major band at 44–45 kDa was resolved in the lane containing probe crosslinked to EC-1 nuclear extract (Probe+Extract). This band was not detected upon electrophoresis of probe alone (Free Probe) or in reactions where the probe was DNase-digested prior to addition of nuclear extract and UV crosslinking (Probe Digest). One low molecular weight nonspecific (ns) band was evident with the latter control. PAI-1 E-box-binding proteins were isolated from the nuclear fraction of growing EC-1 cells by tethered deoxyoligonucleotide affinity chromatography (B). Bound proteins were eluted and separated by gel electrophoresis. Western blotting confirmed USF-1 as one PAI-1 E-box target sequence binding element (B, Column). Two USF-1 species, corresponding in mobility to USF-1 (44 kDa) and phospho-USF-1 (P-USF-1, 45 kDa), were resolved by western analysis of extracts derived from growing EC-1 cells (B, Growing Cells). The predominant form of USF-1 eluted from PAI-1 deoxyoligonucleotide affinity columns co-migrated with the slower mobility (i.e. phosphorylated) USF-1 species. Acid phosphatase treatment (Phos) of nuclear extracts from serum-stimulated cells prior to gel electrophoresis and western blotting significantly decreased the abundance of the anti-USF-1 immunoreactive 45 kDa (P-USF-1) band compared with non-phosphatase-treated (Control) extracts (C).

specific in situ-restricted expression of PAI-1 transcripts/protein in the wound-edge cohort (Fig. 1). Mobility shift studies were designed, therefore, to evaluate whether this augmented USF-1 nuclear accumulation, at least following wound stimulation, correlated with an increase in USF-1 PAI-1 E-box construct binding activity. Nuclear extracts from constitutively growing HaCaT and RK cells produced the typical upper and lower doublet band shift pattern with the target 18 bp PAI-1 E-box probe. The upper band was specifically supershifted by antibodies to USF-1 indicating that at least one contributing factor in this slower migrating complex was USF-1 (Fig. 6). Extracts from quiescent cells (i.e. contact-inhibited cultures maintained in serum-free medium

for 3 days) did not form the upper banding component with the target PAI-1 probe and the complexes that were resolved were generally unreactive with USF-1 antibodies. Comparison of the probe gel retardation patterns obtained with extracts from growing RK cells to those developed with nuclear extracts isolated from wound-edge harvested cells (2 hours post-scraper injury), in contrast, confirmed that the upper component in the doublet complex resolved with extracts from injury site cells, like that in proliferating keratinocytes, could also be supershifted by USF-1 antibodies (Fig. 6).

Discussion

Recapitulation of events associated with injury repair in vivo (i.e. regional uPA/PAI-1 expression, spatial/temporal distinctions among the differentiated, motile and proliferative compartments) (Romer et al., 1991; Romer et al., 1994; Reidy et al., 1995) are modeled, in certain systems, during cell migration into the denuded areas of a scrape-injured monolayer (Pepper et al., 1987; Pepper et al., 1992; Garlick and Taichman, 1994; Pawar et al., 1995; Coulombe, 1997; Zahm et al., 1997; Providence et al., 2000). PAI-1 mRNA/protein are rapidly synthesized by keratinocytes immediately adjacent to experimentally-created wounds and remain elevated over the course of monolayer 'healing', similar to findings in the wounded epidermis (Romer et al., 1991; Jensen and Lavker, 1996; Providence et al., 2000). PAI-1 deposition into migration tracks, moreover, is a characteristic of a mobile cohort (Seebacher et al., 1992; Pepper et al., 1992), although whether such accumulation is due to encoded 'trafficking' information, resulting in specific targeting to the cellular undersurface region, remains to be determined. Use of the serum/EGF-responsive PAI-1 promoter to drive expression of a chimeric PAI-1-GFP transcript, nevertheless, is the first demonstration of PAI-1 localization in migratory trails during the real time of stimulated expression. PAI-1 synthesis, moreover, is an essential component of the motile program in cultured basal keratinocytes since PAI-1 downregulation with the Rc/CMVIAP vector effectively attenuated scrape injury closure. The present observations in established keratinocytes confirm wound repair anomalies reported for the PAI-1-deficient 4HH cell line, in which PAI-1 synthesis is specifically ablated by stable antisense targeting (Higgins et al., 1997; Providence et al., 2000). The kinetics of induction and in situ distribution of this protein are, in fact, consistent with a function in cell locomotion. Indeed, the approximately 10 hour offset in maximal PAI-1 transcript expression in wounded HaCaT versus RK/EC-1 monolayers actually reflects cell type differences in injury closure rates and supports the concept that this gene is regulated as a function of cellular motile status. The PAI-1 insert, as used in the Rc/CMV expression system, when ligated in the antisense configuration in a T7/T3 selectable promoter vector (Higgins et al., 1997) yielded a transcript that hybridized to both the 2.2- and 3.0-kb species of human PAI-1 mRNA (Li et al., 2000). Planar migratory defects observed in Rc/CMVIAP transfectants in both the RK and EC-1 cell types, moreover, correlated with significant reductions in de novo PAI-1 synthesis. Similar findings in HaCaT keratinocytes expressing inducible PAI-1 antisense transcripts (Li et al., 2000) strongly suggest that the motile deficit in each case was a direct result of an antisense effect on




Fig. 6. USF-1 in situ localization and PAI-1 E-box-binding activity in wound-proximal keratinocytes. Compared with quiescent intact monolayer regions (A), HaCaT cells juxtaposed to the wound site (arrow in B indicates direction of migration into a denuded zone) exhibit significant cytoplasmic and nuclear immunocytochemical reactivity for USF-1 (B). In both panels A and B, nuclei are stained (red) with propidium iodide while green speckles indicate immunoreactive USF-1. Cells situated more distal (d) from the wound edge had considerably lower cytoplasmic and nuclear USF-1 (B). Nuclear USF-1 accumulation could be detected as early as 2 hours post-monolayer scraping (preceding the increase in PAI-1 transcripts) and remained evident throughout the period of wound repair. The protracted (48–72 hour) time course of injury resolution in HaCaT cultures reflected (even at 24 hours after wounding) continued PAI-1 expression (Fig. 1) and nuclear USF-1 localization (B) by the migrating epithelium. The typical upper and lower dumbbell-shaped gel retardation pattern was resolved upon incubation of nuclear extracts from growing (G), but not quiescent (Q), HaCaT and RK cultures with the 32 P-labeled 18 bp PAI-1 E-box probe (C). The upper band was specifically supershifted upon addition of antibodies to USF-1 after formation of the protein-probe complex. Similarly, the USF-1-containing upper complex was also resolved upon incubation of nuclear extracts from RK cells harvested from the wound site (D). The upper-lower doublet retardation pattern was evident as early as 2 hours after scrape injury (2 hr edge) and, like growing RK cultures (G), addition of USF-1 antibodies specifically supershifted this upper complex.

PAI-1 synthesis with concomitant modulation of cellular adhesive traits.

De novo synthesized PAI-1 protein accumulates in the cellular undersurface region likely in a complex with matrix vitronectin (Higgins and Ryan, 1989; Seiffert et al., 1994; Lawrence et al., 1997), although PAI-1 has been suggested to also associate with fibronectin and/or laminin deposits in migration tracks (Seebacher et al., 1992). This SERPIN is well-positioned, therefore, to modulate integrin-ECM or uPA/uPAR-ECM interactions as well as ECM barrier proteolysis. PAI-1 may dissociate bound vitronectin from the uPAR, detaching cells that use this receptor as a vitronectin anchor (Deng et al., 1996; Deng et al., 2001; Kjoller et al., 1997; Loskutoff et al., 1999). Alternatively, PAI-1 may directly inhibit α v integrin-mediated attachment to vitronectin by blocking accessibility to the RGD sequence located proximal

to the uPAR binding site (Stefansson and Lawrence, 1996; Loskutoff et al., 1999). uPAR-associated uPA/PAI-1 complexes, furthermore, are internalized by endocytosis promoting uPA receptor recycling (Andreasen et al., 1997) and, thereby, vitronectin-dependent cell movement. Transgenic approaches suggest, however, that PAI-1 promotes vitronectin-independent angiogenesis specifically by inhibiting plasmin proteolysis, and thus preserves an appropriate matrix 'scaffold' to support cell migration or provide required neovessel stability (Bajou et al., 2001). These findings highlight the complexity of cellular motile controls that collectively reflect the level of expression of participating elements, the nature of the 'matrix' encountered, the system context (i.e., 2D vs 3D migration) and the growth factor environment. The rapid kinetics of wound-stimulated PAI-1 induction and relatively short matrix-associated half-life (Higgins and Ryan, 1989) suggests that this protein may influence cellular adhesive events for a specified duration during injury repair.

Similar to PAI-1 induction under conditions of mitogenic stimulation (White et al., 2000) is the rapid wound-related recruitment of USF-1 to the same defined E-box site in the PAI-1 promoter. Site occupancy, moreover, likely requires conservation of the CANNTG motif as mutations outside of the two central nucleotides resulted in loss of competitive binding activity. USF dimers as well as TFE3, HIF and MYC/MAX family member homo- or heterodimers recognize E-box motifs within certain genes including p53 and PAI-1 (e.g. Riccio et al., 1992; Reisman and Rotter, 1993; Hua et al., 1998; Hua et al., 1999; Dennler et al., 1998; Kietzmann et al., 1999; White et al., 2000) and present data are consistent with the preference

of USF proteins for CACGTG or CACATG sequences (Littlewood and Evan, 1995; Ismail et al., 1999). Successful PAI-1 probe competition by a CACGTG 'core' flanked by non-PAI-1 sequences and failure of specific E-box mutants with PAI-1 homologous flanking DNA to similarly compete (or to produce band shifts when used as targets) indicate, furthermore, that an intact hexanucleotide E-box motif is necessary and sufficient for USF-1 binding in both serum- and wound-simulated cells. The enrichment for phospho-USF-1 by DNA affinity chromatography of extracts from growing cells compared with the relative abundance of phospho- and non-phosphorylated species resolved by western blotting of cell extracts indicated that USF-1 that bound to DNA was almost exclusively phosphorylated, whereas only a fraction of the total cellular USF-1 in proliferating cultures was phosphorylated at any given time. These data are consistent with the known

phosphorylation requirement of certain HLH factors for E-box motif recognition (Nozaki et al., 1997; Cheung et al., 1999).

The mechanism of USF-1 functional mobilization (i.e. DNA-binding) in response to wounding is speculative. Monolayer injury is associated with the induced expression of several growth factors (e.g. FGF, HB-EGF, TGF- β) and with MAP kinase activation in cells bordering the denudation site (Sato and Rifkin, 1988; Dieckgraefe et al., 1997; Song et al., 2000; Ellis et al., 2001). Certain growth factors, particularly those of the TGF- β family, stimulate occupancy of E-box sequences in several genes including PAI-1 (Riccio et al., 1992; Hua et al., 1998; Hua et al., 1999) as well as activate MAP kinases (Kutz et al., 2001; Yue and Mulder, 2001). Specific E-box-binding factors, including USF-1 and TFE3, are phosphorylated at consensus MAP kinase target residues (Galibert et al., 2001; Weilbaecher et al., 2001) facilitating DNA site interactions. At least one member of the stress family of MAP kinases (p38) does, in fact, phosphorylate USF-1 (Galibert et al., 2001), although other growth-related kinases may also target USF-1. In synchronized cells, for example, the DNA-binding activity of USF-1 is regulated by cyclin A-p34^{cdc2} or cyclin B1-p34^{cdc2}-dependent phosphorylation within the USF-specific region (USR), the likely target site (Cheung et al., 1999). Phosphorylation of residues within the USR appears to initiate a conformational switch that exposes the DNA-binding domain (Cheung et al., 1999). Similar to the requirements for interaction of MAX with its target E-box sequence, USF-1 DNA-binding activity may be regulated, therefore, in a growth state- or wound-responsive manner apart from direct controls on USF-1 or MAX synthesis (Miltenberger et al., 1995; Lun et al., 1997). One possibility is that MAP kinase activation in the injured epithelium, dependent or independent of an autocrine growth factor-initiated loop, results in USF-1 phosphorylation and subsequent trans-activation of specific USF-1 target genes (e.g. PAI-1) as part of the switch from a sessile to motile phenotype.

This work was supported by grants from the NIH (GM57242, GM42461) and the US Army (DAMD17-98-1-8015 and DAMD17-00-1-0124).

References

- Akiyoshi, S., Ishii, M., Nemoto, N., Kawabata, M., Aburatani, H. and Miyazano, K. (2001). Targets of transcriptional regulation by transforming growth factor- β : Expression profile analysis using oligonucleotide arrays. *Jpn. J. Cancer Res.* **92**, 252-268.
- Andreasen, P. A., Kjoller, L., Christensen, L. and Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. *Int. J. Cancer* **72**, 1-22.
- Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D. and Foidart, J. M. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. *Nat. Med.* **4**, 923-928.
- Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K. et al. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. *J. Cell Biol.* **152**, 777-784.
- Boehm, J. R., Kutz, S. M., Sage, E. H., Staiano-Coico, L. and Higgins, P. J. (1999). Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor- β 1. *J. Cell. Physiol.* **181**, 96-106.
- Brooks, T. D., Slomp, J., Quax, P. H. A., de Bart, A. C. W., Spencer, M. T., Verheijen, J. H. and Charlton, P. A. (2001). Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. *Clin. Exp. Metastasis* **18**, 445-453.
- Chazaud, B., Ricoux, R., Christov, C., Plonquet, A., Gherardi, R. K. and Barlovatz-Meimon, G. (2002). Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. *Am. J. Path.* **160**, 237-246.
- Chapman, H. A. (1997). Plasminogen activators, integrins, the coordinate regulation of cell adhesion and migration. *Curr. Opin. Cell Biol.* **9**, 714-724.
- Cheung, E., Mayr, P., Coda-Zabetta, F., Woodman, P. G. and Boam, D. S. W. (1999). DNA-binding activity of the transcription factor upstream stimulatory factor 1 (USF-1) is regulated by cyclin-dependent phosphorylation. *Biochem. J.* **344**, 145-152.
- Ciambrone, G. J. and McKeown-Longo, P. J. (1990). Plasminogen activator inhibitor type 1 stabilizes vitronectin-dependent adhesions in HT-1080 cells. *J. Cell Biol.* **111**, 2183-2195.
- Cogswell, J. P., Godlevski, M. M., Bonham, M., Bisi, J. and Babiss, L. (1995). Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter. *Mol. Cell. Biol.* **15**, 2782-2790.
- Coulombe, P. A. (1997). Towards a molecular definition of keratinocyte activation after acute injury to stratified epithelia. *Biochem. Biophys. Res. Commun.* **18**, 231-238.
- Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. and Loskutoff, D. J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? *J. Cell Biol.* **134**, 1563-1571.
- Deng, G., Curriden, S. A., Hu, G., Czekay, R.-P. and Loskutoff, D. J. (2001). Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. *J. Cell. Physiol.* **189**, 23-33.
- Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S. and Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J.* **17**, 3091-3100.
- Dieckgraefe, B. K., Weems, D. M., Santoro, S. A. and Alpers, D. H. (1997). ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. *Biochem. Biophys. Res. Commun.* **233**, 389-394.
- Ellis, P. D., Hadfield, K. M., Pascall, J. C. and Brown, K. D. (2001). Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogen-activated protein kinase cascades. *Biochem. J.* **354**, 99-106.
- Farina, A. R., Coppa, A., Tiberio, A., Tacconelli, A., Turco, A., Colletta, G., Gulino, A. and Mackay, A. R. (1998). Transforming growth factor- β 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. *Int. J. Cancer* **75**, 721-730.
- Friedl, P. and Bockner, E. B. (2000). The biology of cell locomotion within three-dimensional extracellular matrix. *Cell. Mol. Life Sci.* **57**, 41-64.
- Galibert, M.-D., Carreira, S. and Goding, C. R. (2001). The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced tyrosinase expression. *EMBO J.* **20**, 5022-5031.
- Garlick, J. A. and Taichman, L. B. (1994). Fate of human keratinocytes during reepithelialization in an organotypic culture model. *Lab. Invest.* **70**, 916-924.
- Gutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A. and Castellino, F. J. (2000). Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. *Cancer Res.* **60**, 5839-5847.
- Hajra, K. M., Chen, D. Y. S. and Fearon, E. R. (2002). The SLUG zinc-finger protein represses E-cadherin in breast cancer. *Cancer Res.* **62**, 1613-1618.
- Higgins, P. J. and Ryan, M. P. (1989). Biochemical localization of the transformation-sensitive p52 kDa (p52) protein to the substratum contact regions of cultured rat fibroblasts. Butyrate induction, characterization, and quantification of p52 in *v-ras* transformed cells. *Biochem. J.* **257**, 173-182.
- Higgins, P. J., Ryan, M. P. and Jelley, D. M. (1997). p52^{PAI-1} gene expression in butyrate-induced flat revertants of *v-ras*-transformed rat kidney cells: mechanism of induction and involvement in the morphologic response. *Biochem. J.* **321**, 431-437.
- Hua, X., Liu, X., Ansari, D. O. and Lodish, H. F. (1998). Synergistic cooperation of TFE3 and smad proteins in TGF- β -induced transcription of the plasminogen activator inhibitor-1 gene. *Genes Dev.* **12**, 3084-3095.
- Hua, X., Miller, Z. A., Wu, G., Shi, Y. and Lodish, H. F. (1999). Specificity in transforming growth factor β -induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription

- factor muE3, and Smad proteins. *Proc. Natl. Acad. Sci. USA* **96**, 13130-13135.
- Ismail, P. M., Lu, T. and Sawadogo, M. (1999). Loss of USF transcriptional activity in breast cancer cell lines. *Oncogene* **18**, 5582-5591.
- Jeffers, M., Rong, S. and Vande Woude, G. F. (1996). Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. *Mol. Cell. Biol.* **16**, 1115-1125.
- Jensen, P. J. and Lavker, R. M. (1996). Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo. *Cell Growth Differ.* **7**, 1793-1804.
- Johnson, M., Bruzdinski, C., Winograd, S. S. and Gelehrter, T. D. (1992). Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene. *J. Biol. Chem.* **267**, 12202-12210.
- Kietzmann, T., Roth, U. and Jungermann, K. (1999). Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. *Blood* **94**, 4177-4185.
- Kjoller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Ronne, E., Goodman, S. L., Preissner, K. T., Ossowski, L. and Andreassen, P. A. (1997). Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. *Exp. Cell Res.* **232**, 420-429.
- Kutz, S. M., Nickey, S., White, L. A. and Higgins, P. J. (1997). Induced PAI-1 mRNA expression and targeted protein accumulation are early G1 events in serum-stimulated rat kidney cells. *J. Cell. Physiol.* **170**, 8-18.
- Kutz, S. M., Hordines, J., McKeown-Longo, P. J. and Higgins, P. J. (2001). TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. *J. Cell Sci.* **114**, 3905-3914.
- Lawrence, D. A., Palaniappan, S., Stefansson, S., Olson, S. T., Francis-Chmura, A. M., Shore, J. D. and Ginsburg, D. (1997). Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. *J. Biol. Chem.* **272**, 7676-7680.
- Lauffenburger, D. A. and Horwitz, A. F. (1996). Cell migration: a physically integrated molecular process. *Cell* **84**, 359-369.
- Legrand, C., Polette, M., Tournier, J. M., de Bentzmann, S., Huet, E., Monteau, M. and Birembaut, P. (2001). uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial cell migration. *Exp. Cell Res.* **264**, 326-333.
- Li, F., Goncalves, J., Faughnan, K., Steiner, M. G., Pagan-Charry, I., Esposito, D., Chin, B., Providence, K. M., Higgins, P. J. and Staiano-Coico, L. (2000). Targeted inhibition of wound-induced PAI-1 expression alters migration and differentiation in human epidermal keratinocytes. *Exp. Cell Res.* **258**, 245-253.
- Liu, G., Shuman, M. A. and Cohen, R. L. (1995). Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. *Int. J. Cancer* **60**, 501-506.
- Littlewood, T. D. and Evan, G. I. (1995). Helix-loop-helix proteins. *Protein Profiles* **2**, 612-703.
- Loskutoff, D. J., Curriden, S. A., Hu, G. and Deng, G. (1999). Regulation of cell adhesion by PAI-1. *APMIS* **107**, 54-61.
- Lun, Y., Sawadogo, M. and Perry, M. (1997). Autoactivation of *Xenopus* MyoD transcription and its inhibition by USF. *Cell Growth Differ.* **8**, 275-282.
- Lund, L. R., Romer, J., Bugge, T. H., Nielsen, B. S., Frandsen, T. L., Degen, J. L., Stephens, R. W. and Dano, K. (1999). Functional overlap between two classes of matrix-degrading proteases in wound healing. *EMBO J.* **18**, 4645-4656.
- Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S. and Mignatti, P. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. *EMBO J.* **16**, 2319-2332.
- McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K., Westrick, R. J., Ginsburg, D., Brooks, P. C. and Lawrence, D. A. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. *J. Biol. Chem.* **276**, 33964-33968.
- Mignatti, P. and Rifkin, D. B. (2000). Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. *Adv. Cancer Res.* **78**, 103-157.
- Miltenberger, R. J., Sukow, K. A. and Farnham, P. J. (1995). An E-box-mediated increase in *cad* transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. *Mol. Cell. Biol.* **15**, 2527-2535.
- Murphy, G. and Gavrilovic, J. (1999). Proteolysis and cell migration: creating a path? *Curr. Opin. Cell Biol.* **11**, 614-621.
- Nieto, M. A. (2002). The snail superfamily of zinc-finger transcription factors. *Nat. Rev. Mol. Cell. Biol.* **3**, 155-166.
- Nozaki, N., Naoe, T. and Okazaki, T. (1997). Immunoaffinity purification and characterization of CACGTG sequence-binding proteins from cultured mammalian cells using an anti c-myc monoclonal antibody recognizing the DNA-binding domain. *J. Biochem.* **121**, 550-559.
- Okedon, L. E., Sato, Y. and Rifkin, D. B. (1992). Urokinase-type plasminogen activator mediates basic growth factor-induced bovine endothelial migration independent of its proteolytic activity. *J. Cell. Physiol.* **150**, 258-263.
- Pawar, S., Kartha, S. and Toback, F. G. (1995). Differential gene expression in migrating renal epithelial cells after wounding. *J. Cell. Physiol.* **165**, 556-565.
- Pepper, M. S., Vassalli, J. D., Montesano, R. and Orci, L. (1987). Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. *J. Cell Biol.* **105**, 2535-2541.
- Pepper, M. S., Sappino, A. P., Montesano, R., Orci, L. and Vassalli, J. D. (1992). Plasminogen activator inhibitor-1 is induced in migrating capillary endothelial cells. *J. Cell. Physiol.* **153**, 129-139.
- Providence, K. M., Kutz, S. M., Staiano-Coico, L. and Higgins, P. J. (2000). PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. *J. Cell. Physiol.* **182**, 269-280.
- Providence, K. M., Staiano-Coico, L. and Higgins, P. J. (2002). A quantifiable in vitro model to assess the effects of PAI-1 gene targeting on epithelial cell motility. In *Wound Healing: Methods and Protocols* (ed. A. Burns-Harring and L. A. DiPietro). Totowa, NJ: Humana Press (in press).
- Reidy, M., Irwin, C. and Linder, V. (1995). Migration of arterial wall cells. *Circ. Res.* **78**, 405-414.
- Reijerkerk, A., Voest, E. E. and Gebbink, M. F. (2000). No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. *Eur. J. Cancer* **36**, 1695-1705.
- Reisman, D. and Rotter, V. (1993). The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. *Nucleic Acids Res.* **21**, 345-350.
- Riccio, A., Pedone, P. V., Lund, L. R., Olsen, T., Olsen, H. S. and Andreassen, P. A. (1992). Transforming growth factor β 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor 1 in the type-1 plasminogen activator inhibitor gene. *Mol. Cell. Biol.* **12**, 1846-1855.
- Ridley, A. J. (2001). Rho GTPases and cell migration. *J. Cell Sci.* **114**, 2713-2722.
- Romer, J., Lund, L. R., Kriksen, J., Ralkiaer, E., Zeheb, R., Gelehrter, T. D., Dano, K. and Kristensen, P. (1991). Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. *J. Invest. Dermatol.* **97**, 803-811.
- Romer, J., Lund, L. R., Kriksen, J., Pyke, C., Kristensen, P. and Dano, K. (1994). The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. *J. Invest. Dermatol.* **102**, 519-522.
- Ryan, M. P., Kutz, S. M. and Higgins, P. J. (1996). Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. *Biochem. J.* **314**, 1041-1046.
- Santibanez, J. F., Frontelo, P., Iglesias, M., Martinez, J. and Quintanilla, M. (1999). Urokinase expression and binding activity associated with the transforming growth factor β 1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. *J. Cell. Biochem.* **74**, 61-73.
- Sato, Y. and Rifkin, D. B. (1988). Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. *J. Cell Biol.* **107**, 1199-1205.
- Seebacher, T., Manske, M., Zoller, J., Crabb, J. and Bade, E. G. (1992). The EGF-inducible protein EIP-1 of migrating normal and malignant rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the migration tracks. *Exp. Cell Res.* **203**, 504-507.
- Seiffert, D., Mimuro, J., Schleef, R. R. and Loskutoff, D. J. (1994). Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. *Cell Differ. Dev.* **32**, 287-292.
- Slack, J. K. and Higgins, P. J. (1999). Attenuation of plasminogen activator inhibitor type-1 promoter activity in serum-stimulated renal epithelial cells by a distal 5' flanking region. *Cell Motil. Cytoskel.* **44**, 168-176.
- Song, Q. H., Singh, R. P., Richardson, T. P., Nugent, M. A. and Trinkaus-Randall, V. (2000). Transforming growth factor- β 1 expression in cultured corneal fibroblasts in response to injury. *J. Cell. Biochem.* **77**, 186-199.

- Stefansson, S. and Lawrence, D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking $\alpha v \beta 5$ binding to vitronectin. *Nature* **383**, 441-443.
- Stefansson, S., Petitsclerc, E., Wong, M. K., McMahon, G. A., Brooks, P. C. and Lawrence, D. A. (2001). Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. *J. Biol. Chem.* **276**, 8135-8141.
- Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y. and Chapman, H. A. (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. *J. Clin. Invest.* **100**, 58-67.
- Weilbaecher, K. N., Motyckova, G., Huber, W. E., Takemoto, C. M., Hemesath, T. J., Xu, Y., Hershey, C. L., Dowland, N. R., Wells, A. G. and Fisher, D. E. (2001). Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. *Mol. Cell* **8**, 749-758.
- Wells, A. (2000). Tumor invasion: role of growth factor-induced cell motility. *Adv. Cancer Res.* **78**, 31-101.
- Westerhausen, D. R., Jr, Hopkins, W. E. and Billadello, J. J. (1991). Multiple transforming growth factor- β -inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. *J. Biol. Chem.* **266**, 1092-1100.
- White, L. A., Bruzdinski, C., Kutz, S. M., Gelehrter, T. D. and Higgins, P. J. (2000). Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. *Exp. Cell Res.* **260**, 127-135.
- Wysocki, A. B., Kusakabe, A. O., Chang, S. and Tuan, T. L. (1999). Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. *Wound Repair Regen.* **7**, 154-165.
- Yue, J. and Mulder, K. M. (2001). Transforming growth factor- β signal transduction in epithelial cells. *Pharmacol. Therapeut.* **91**, 1-34.
- Zahm, J. M., Kaplan, H., Herar, A. L., Doriot, F., Pierrot, D., Somelette, P. and Puchelle, E. (1997). Cell migration and proliferation during the in vitro wound repair of the respiratory epithelium. *Cell Motil. Cytoskel.* **37**, 33-43.
- Zavadil, J., Bitzer, M., Liang, D., Yang, Y.-C., Massimi, A., Kneitz, S., Piek, E. and Bottinger, E. P. (2001). Genetic programs of epithelial cell plasticity directed by transforming growth factor- β . *Proc. Natl. Acad. Sci. USA* **98**, 6686-6691.
- Zhou, H. M., Nichols, A., Meda, P. and Vassalli, J. D. (2000). Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. *EMBO J.* **19**, 4817-4826.

APPENDIX 3

Research Signpost

37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India



Recent Res. Devel. Mol. Biol., 1(2003): 1-12 ISBN: 81-271-0032-3

Use of chromatin immunoprecipitation to identify E box-binding transcription factors in the promoter of the growth state-regulated human PAI-I gene

Li Qi and Paul J. Higgins

Center for Cell Biology and Cancer Research, Albany Medical College, Albany
New York 12208, USA

Abstract

Genes encoding proteins required for G_1 transit and entry into DNA synthetic phase are activated within a defined time frame and for a specified duration following mitogen-induced recruitment of quiescent cells into the proliferative cycle. Cooperation between integrins and growth factor receptors is required to optimally relay mitogenic signals likely reflecting specific adhesive or "shape" controls on cell cycle progression. The induced expression of plasminogen activator inhibitor type-1 (PAI-1) occurs as part of the immediate-early response to serum. PAI-1 transcription is maximal within 4 hours of growth factor addition to quiescent cells with a rapid decline to basal levels prior to S phase entry. The PAI-1 gene encodes a serine

Correspondence/Reprint request: Dr. Paul J. Higgins, Ph.D., Center for Cell Biology & Cancer Research, Albany Medical College (Mail Code 165), 47 New Scotland Avenue, Albany, New York 12208, USA. E-mail: higginsp@mail.amc.edu

protease inhibitor (SERPIN) that regulates cell-to-substrate attachment and generation of the trypsin-like protease plasmin. By virtue of its ability to modulate cell-to-matrix interactions, PAI-1 may be a critical element in the growth program affecting both adhesion-dependent G_0/G_1 and G_1/S transitions as well as cell survival. E box motifs (5'-CACGTG-3'), important in the transcription of several growth state-dependent genes, have been mapped to growth factor-response sites in the PAI-1 promoter. Nuclear extract immunodepletion and supershift/complex-blocking approaches identified one PAI-1 E box-binding protein to be upstream stimulatory factor-1 (USF-1). Dinucleotide substitutions (CACGTG→TCCGTG) that ablate USF-1 occupancy of the E box site also attenuate PAI-1 promoter activity in growing cells. Changes in USF-1/E box interactions as a function of cell cycle progression may well influence PAI-1 transcriptional kinetics during G_1 transit. This review describes basic mechanisms operative in growth cycle-dependent PAI-1 gene expression and the use of the relatively new technique of chromatin immunoprecipitation to provide insights to *in vivo* promoter site occupancy. The available data support the hypothesis that specific E box motifs in the PAI-1 gene, previously implicated as growth factor-response elements, function as platforms for recruitment of transcriptional repressor/activator complexes during the $G_0 \rightarrow G_1$ transition.

Growth state-dependent PAI-1 gene expression

Mitogenic stimulation of quiescent (G_0) cells initiates a cascade of gene activity required for G_0/G_1 transit and subsequent progression through the cell cycle [1-4]. Such growth-associated genes are generally activated within temporally-defined "windows" and segregate among the immediate-early (IER), delayed-early (or mid) and late response sets [1,2,5-10]. While a significant fraction of IER genes encode transcription factors (which subsequently target the delayed-early and late genes that sustain the proliferative response) (Fig. 1), many structural proteins that comprise the cytoskeletal network, extracellular matrix (ECM), and cell-to-matrix adhesive complexes including certain matrix-active proteases and their inhibitors are also encoded by IER genes [7,11]. Recruitment of quiescent fibroblasts into the growth cycle, for example, is accompanied by the increased synthesis of actin, tropomyosin, alpha-actinin, vinculin, fibronectin, the $\beta 1$ integrin, and ECM-remodeling proteases (e.g., urokinase plasminogen activator; uPA) [3,6,7,12-14]. This suggests a role for cytoarchitectural and ECM-modulating proteins in proliferative activation [10,15] and is consistent with earlier work implicating cell shape/spreading in cell growth control [16-18]. Indeed, cooperation between integrins and growth factor receptors is essential for transduction of mitogenic signals [19-22]. Cytostructural "reformatting" as part of the cellular response to serum growth factors is likely necessary, therefore, for transition through the adhesion-dependent restriction point in late G_1 (Fig. 2).

Prominent among the repertoire of genes activated in response to serum is that encoding the type 1 inhibitor of plasminogen activator (PAI-1) [15,23,24]. Synthesis of PAI-1 mRNA occurs rapidly and transiently upon addition of serum to quiescent cells [23,25,26] (Fig. 3) as well as during compensatory regeneration following tissue injury [27,28]. PAI-1 complexes with urokinase and tissue-type plasminogen activators limiting, thereby, the generation of plasmin, a broad spectrum protease involved in fibrin surveillance and extracellular matrix turnover [29]. PAI-1 may function, therefore, as




Figure 1. Relative time course for transcription of immediate-early (early), delayed-early (mid) and late genes following stimulation of quiescent cells with serum growth factors (SGF) superimposed on a topographic map of G₁ progression. Re-entry into a cycling G₁ state from a condition of G₀ arrest involves the rapid induction of early gene transcripts, many of which encode transcription factors, coincident with the G₀→G₁ transition. Metabolic genes and those encoding proteins essential for DNA synthesis, are highly represented among the mid and late gene sets. Expression of cyclin A, a late gene product, is adhesion-dependent as is S phase entry (at least for normal cells).




Figure 2. Stimulation of quiescent cells with serum growth factors (SGF) initiates transcriptional reprogramming required for proliferative commitment as well as for cellular structural reorganization [15,24]. Specific growth "activated" changes in cytoarchitecture (i.e., increased cell spreading, formation of new matrix contact sites) [e.g., 15] modulates growth factor signaling events to maintain expression of gene products involved in cell cycle progression. Such growth-associated alterations in cell structure are necessary for exit from G₀ into G₁ and for transition through the adhesion-dependent restriction point.




Figure 3. Kinetics of PAI-1 mRNA accumulation in response to serum (top panel). Subconfluent IMR-90 human diploid fibroblasts were serum-deprived for 3 days then stimulated with medium containing FBS (20% final concentration). At the indicated times post-stimulation, RNA was isolated for Northern blotting. Induced PAI-1 transcripts (3.0 and 2.2 kb species) were maximal 2 hours after serum addition. GAPD mRNA levels gradually increase as a function of time after serum addition. BrdU was added at the time of stimulation for immunocytochemical visualization of S phase cells (bottom panels). DNA synthesis was synchronously detected between 12 and 16 hours following release from G_0 . Collectively, these data indicate that there is a rapid decline in PAI-1 transcripts prior to entry into S phase.

part of a global program of tissue remodeling/wound repair [24] or, more specifically, within the context of the growth-activated phenotype [15], to create an adhesive environment permissive for anchorage-dependent cell proliferation and/or migration (Fig. 2). PAI-1 protein does, in fact, accumulate in the cellular undersurface likely in a complex with matrix vitronectin [30-33]. This serine protease inhibitor is well-

positioned, therefore, to modulate integrin-ECM or uPA/uPAR (uPAR)-ECM interactions as well as pericellular proteolytic activity [29,34]. Since PAI-1 protein deposition occurs quickly after serum-stimulation [15,26], changes in PAI-1 expression may subsequently impact on the stability of newly formed focal contacts [35] affecting, thereby, maintenance of the growth-activated phenotype. The rapid kinetics of PAI-1 undersurface deposition following mitogenic stimulation and short matrix-associated half-life are consistent with recent suggestions that this protein may influence cellular adhesive characteristics for a specified duration within the context of "activated" cell growth [15,26,36,37]. Indeed, PAI-1 has dramatic effects on cell-to-ECM attachment [34,38]. It appears that PAI-1, α_v integrins, and uPA likely function coordinately to regulate cell-to-substrate adhesion (a necessary prerequisite for G₁/S transition [39,40]), cell shape (and shape-dependent metabolic pathways [41-43]), and adhesive events important in the control of cell motility [44-49]. The actual mechanism(s) by which PAI-1 influences cellular adhesive state is the subject of considerable speculation. Recent findings suggest that PAI-1 may dissociate vitronectin from the uPAR, detaching cells that utilize this receptor as a vitronectin anchor [33,50-52]. Alternatively, PAI-1 may directly inhibit α_v integrin-mediated attachment to vitronectin by blocking accessibility to the RGD sequence located proximal to the uPAR binding site [33,46]. uPAR-associated uPA/PAI-1 complexes, moreover, are internalized by endocytosis promoting uPA receptor recycling and, thereby, vitronectin-dependent cell movement [53]. PAI-1 may also influence cell adhesion directly, functioning as one component in the molecular complex that bridges the cell and the ECM [34,38,54]. Clearly, the association between the activated phenotype and targeted accumulation of PAI-1 in close proximity to newly formed focal adhesions [26] is consistent with this function. Most recently, PAI-1 has been found to inhibit insulin-induced signaling by competing with the $\alpha_v\beta_3$ integrin for vitronectin binding in a uPA receptor-independent manner reinforcing the pivotal role of PAI-1 in cellular transduction pathways [55]. PAI-1 has emerged, therefore, as a key element in a global program of tissue remodeling where it likely regulates the adhesive environment permissive for anchorage-dependent cell proliferation and/or migration [15,24,35,39].

Cell cycle controls on PAI-1 transcription

Assessment of G₁ transit (using BrdU incorporation to delineate onset of S phase) indicated that maximal PAI-1 transcript levels are restricted to approximately early-to-mid-G₁ and decline prior to entrance into the DNA synthetic phase (**Fig. 3**). Cell cycle-associated transcriptional controls, thus, are super-imposed on this growth state-dependent program of PAI-1 gene regulation following exit from G₀ [25,26]. The PAI-1 gene, in fact, exhibits a dual mode of regulation upon entry of G₀-arrested cells into a cycling G₁ condition [23] with the amplitude of induction as well as the maintenance of expression through the G₁ phase being anchorage responsive [23,25]. Late in G₁ phase, however, secondary events predominate and likely mediate a rapid decline in mRNA abundance [57]. Such adhesion-dependent effects, unlike the initial inductive event, require on-going protein synthesis [23] and highlight the complexity of PAI-1 gene control during G₁ progression [25].

While the specific signals for PAI-1 promoter activation during the G₀-G₁ transition are unknown, the E box at nucleotides -165 to -160 in the rat PAI-1 5' flanking genomic

region is footprinted in growing cells [58]. This site is critical for PAI-1 expression since incorporation of the dinucleotide substitution CACGTG→TCCGTG in a CAT reporter construct driven by 764 bp of PAI-1 promoter sequences reduced serum-stimulated CAT expression by 74% [57]. The helix-loop-helix/leucine zipper (HLH-Zip) protein upstream stimulatory factor-1 (USF-1) binds to an E box probe target with PAI-1-specific flanking sequences in a growth state-dependent manner [49,57]. First described as HLH-Zip *trans*-activators of adenovirus major-late promoter expression via an upstream E box motif (CACGTG), USF-1 and USF-2 influence expression of several cellular genes (e.g., fibrinogen, class 1 alcohol dehydrogenase, cyclin D1, p53, and human PAI-1) [59-61]. These factors likely facilitate TFII-D binding to the TATA box [59,62]. While USF may also stimulate Inr-dependent transcription by stabilizing the TFII-1 preinitiation complex [63,64], the MYC protein negatively influences Inr-mediated transcriptional responses by sequestering TFII-1 [65]. Depending upon the promoter configuration (TATA box, Inr, and/or an E box motif), the availability of specific HLH-Zip transcription factors with E box recognition domains (e.g., USF and MYC), and elements composing the preinitiation complex, therefore, the effects on transcription may be quite different [66-68]. While USF can be a stimulatory factor, in several systems USF-1 and 2 have repressive or negative regulatory influences [69-70]. Transcriptional inhibition appears due to direct interference with the *trans*-activator TFE3. Indeed, it has been suggested that USF is not an efficient *trans*-activator and that displacement of a strong activator by USF down-regulates gene expression [70]. Since USF-1 effectively converts VP16 into a *trans*-activator, E box occupancy by USF may recruit other regulatory proteins to the site in addition to functioning independently. Clearly, such effects may be inhibitory as well as stimulatory [71] and likely involve direct protein-protein interactions (e.g., sequestration of Fra1 by USF resulting in transcriptional repression; formation of USF-2/Fos dimers [71,72]). Simple identification of USF-1 as an E box-bound species does not resolve this issue as overexpression of USF-1 or USF-2 as homodimers effectively repressed rRNA transcription in CHO cells whereas USF-1/USF-2 heterodimeric complexes *trans*-activated gene expression [73]. Indeed, repression is a critical aspect of cell cycle-dependent PAI-1 gene control. Decreased PAI-1 mRNA abundance prior to S phase entry of serum-stimulated cells correlated with increases in E2F1 protein levels while pharmacologic inhibition of pRB phosphorylation prevented the late G₁ decline in PAI-1 transcripts [37]. pRB phosphorylation blockade prevents E2F-pRB dissociation and E2F1-dependent PAI-1 suppression. These data strongly implicate E2F1 as a negative regulator of cell cycle-dependent PAI-1 gene transcription, although no actual E2F1-DNA complexes were resolved [37]. Overexpression of E2F1-3 family members each inhibited cell cycle-dependent expression of the PAI-1 gene whereas E2F4 and 5 were without effect; both the DNA-binding and *trans*-activation domains of E2F1 are required for this suppressive effect [36].

E box elements in growth state-responsive regions of the PAI-1 promoter are occupied by USF-1

The footprinted E box motif located at nucleotides -160 to -165 (upstream of the transcription start site) in the promoter of the rat PAI-1 gene [58] binds USF-1 [57]. Site occupancy, moreover, or at least an intact consensus CACGTG hexanucleotide

sequence, is required for PAI-1 promoter-driven CAT reporter activity in growing cells [57]. Electrophoretic mobility shift analysis of E box target probe/nuclear factor formed complexes, moreover, indicate that the gel retardation patterns clearly distinguish quiescent from cycling cells (**Fig. 4**) and, thereby, PAI-1 non-expressing from expressing cells, respectively (**Fig. 3**). While USF-1/E box binding activity was evident in both G_0 and proliferating cells, the complexes formed between the E box probe and nuclear extract protein had different mobilities with USF-1 present in both (**Fig. 4**). It is tempting to speculate, based on these findings, that changing dynamics between USF-1 and recruited (repressing vs. activating) regulatory proteins at the bound E box site determines the transcriptional status of the PAI-1 gene in quiescent and cycling cells.

5'-GGAAGCAGACCACGTGGTCTGTGCTTCC-3'




Figure 4. A double-stranded 28-mer E box (CACGTG) target probe (only 5'→3' sequence indicated) was end-labeled and incubated with nuclear extracts from G_0 or cycling cells for electrophoretic mobility shift analysis. Two major complexes with different relative migration patterns were resolved (complex I and complex II) that served to distinguish quiescent from proliferating cells. Addition of antibodies to USF-1 after incubation of nuclear factors with the target DNA produced a marked supershift for complex I and II indicating that USF-1 was present in both.

Similar to the TATA-proximal E box at nucleotides -160 to -165 in the rat PAI-1 gene [57], the CACGTG sequence within the growth-responsive -550 to -596 region of the human PAI-1 gene was originally identified as a USF-1 binding site [67]. This E box is 3' of three adjacent SMAD recognition motifs (AGAC); collectively, these sequences map to the PE2.1 segment of the PAI-1 gene (5'-CCTAGACAGACAAA CCTAGACAATCACGTGGCTGG-3') and have been implicated in transforming growth factor- β (TGF- β)-inducible expression [74]. Recent *in vitro* findings suggested that the CACGTG hexanucleotide and its adjoining AGAC sites are occupied by the HLH-Zip factor TFE3 and SMAD-3, respectively, under conditions of TGF- β stimulation [75]. USF-1 may also bind to this same E box [67] but, in this circumstance, the PAI-1 gene appears to be unregulated by TGF- β [74,75]. Such approaches to

promoter function are, at best, inferential. The use of deoxyoligonucleotide probes and isolated transcription factors or nuclear extracts to identify binding elements, while clearly advantageous for determining the sequence requirements for DNA recognition, can be influenced by the relative concentration of the individual proteins presented to the deoxyoligonucleotide and the binding/electrophoretic conditions used. Indeed, using such procedures, the human PAI-1 gene has been variously implicated as a target for several E box-resident HLH-Zip transcription factors including MYC/MAX, USF-1/2, HIF-1, and TFE3 [e.g., 49,66,74,75].

One technique that avoids some of the ambiguities associated with purely *in vitro* methods to the study of DNA-protein interactions is chromatin immunoprecipitation (ChIP). ChIP is a relatively new approach to define *in vivo* relationships between transcriptionally critical *cis* elements and specific *trans*-acting control factors. Living cells, cultured under particular growth conditions, are fixed with formaldehyde, a tight dipolar crosslinking agent that effectively produces both protein-protein and protein-nucleic acid crosslinks [76-78]. Isolated chromatin is sonicated to an appropriate size and fragments immunoprecipitated with antisera to specific chromatin-associated proteins. After reversal of the crosslinks, regions of DNA involved in protein binding are identified by PCR. The details of this procedure (**Fig. 5**) were the subject of a recent comprehensive review [79].




Figure 5. A summary flow chart describing the basic outline of a chromatin immunoprecipitation analysis of DNA-protein interactions.

ChIP assessment of the E box site in the PE2.1 region of the human PAI-1 gene suggested an unexpected dynamic occupancy by USF-1 as a function of growth state (**Fig. 6**). This motif was clearly a platform for USF-1 binding in quiescent cells (**Fig. 6**) consistent with E box target probe analysis by electrophoretic mobility shift assay (**Fig. 4**). In cells that were stimulated back into the cell cycle, however, USF-1 antibodies precipitated significantly less DNA (as indicated by a greatly reduced PCR signal) while analysis of DNA fragments obtained with antisera to acetylated histone 4 confirmed that the PAI-1 promoter underwent chromatin remodeling events associated with transcriptional activation. Such obvious cell cycle-dependent changes in the ChIP profile and the requirement for intact E box sites in PAI-1 expression [57,75] suggest that USF-1 may participate in multiple functions at the PAI-1 E box depending on particular protein partners and cellular growth state. Some anti-USF-1-precipitable DNA was, in fact, evident in G₀ chromatin raising the possibility that the critical epitopes may be masked by recruited co-activators during cell cycle progression. The potential existence of such higher order USF-1-containing chromatin complexes in proliferating cells is actually supported by resolution of the slowly migrating complex I in probe targeting studies (**Fig. 4**). While it may be tempting to speculate that USF-1 complexes are simply replaced on the PAI-1 E box during growth activation, the available data provides for alternative explanations. One relevant model proposes that USF-1 or the closely-related family member USF-2, when present as homodimers, may actually repress PAI-1 expression in G₀ cells (**Fig. 3**) and complex II (**Fig. 4**) could mediate this effect. Subsequent conversion of USF-1 to a *trans*-activator may occur alone or in cooperation with other regulatory elements (e.g., USF-2). Indeed, support for this hypothesis derives from the finding that both USF-1 and USF-2 homodimers repress rRNA transcription while USF-1/USF-2 heterodimeric complexes are effective *trans*-activators [73]. Dimer replacement at the critical E box motif likely occurs soon after, or coincident with, the G₀→G₁ transition, may require USF-1 phosphorylation by mitogen-




Figure 6. ChIP analysis of chromatin from G₀ and growth-activated (G₁) cells using antibodies to USF-1 and acetylated histone 4. Primer sets were designed to amplify PAI-1 promoter segments corresponding to the E box region in the PE2.1 site and a TATA-proximal (histone 4) sequence. USF-1 was a major PE2.1 E box-binding protein in G₀ but not G₁ cells (see text). The near-transcriptional start site of the PAI-1 gene bound significantly more acetylated histone 4 in G₁ as compared to G₀ cells consistent with chromatin remodeling associated with stimulated expression.

activated protein kinases during growth stimulation [49] and may be followed (in mid-to-late G₁) by binding of the unique PAI-1 repressor E2F1 to the adjoining 3' GC-rich region of the PAI-1 promoter [36,37].

The continuing analysis of cell culture systems particularly amenable to molecular dissection of growth state-dependent PAI-1 expression controls [15,23-26,49] will provide fresh insights into the transcriptional constraints on this important gene. Most notably, these approaches can potentially define critical *in vivo* regulatory factors that may ultimately prove to be novel "therapeutic targets" for the treatment of various diseases associated with PAI-1 dysregulation including cancer, vascular disorders and progressive fibrosis. Molecular targeting of PAI-1 transcripts has already shown promise as one means to regulate cellular invasive/motile traits [49]. Future studies are likely to extend the available targets to include elements of the PAI-1 transcriptional control network.

Acknowledgments

Supported by grants from the NIH (GM-57242) and the Department of the Army (DAMD17-00-1-0124).

References

1. Lanahan, A., Williams, J.B., Sanders, L.K., and Nathans, D. 1992, Mol. Cell. Biol. 12, 3939.
2. Williams, G.T., Abler, A.S., and Lau, L.F. 1992, Molecular and Cellular Approaches to the Control of Proliferation and Differentiation. Stein, G.S. and Lian, J.B., editors. Academic Press, San Diego, 114.
3. Vincent, S., Marty, L., LeGallic, L., Jeanteur, P., and Fort, P. 1993, Oncogene 8, 1603.
4. Wick, M., Burger, C., Brusselbach, S., Lucibello, F.C., and Muller, R. 1994, J. Cell Sci. 107, 227.
5. Almendral, J.M., Sommer, D., MacDonald-Bravo, H., Burckhardt, J., Perera, J., and Bravo, R. 1988, Mol. Cell. Biol. 8, 2140.
6. Ryseck, R.P., MacDonald-Bravo, H., Zerial, M., and Bravo, R. 1989, Exp. Cell Res. 180, 537.
7. Muller, R., Mumburg, D., and Lucibello, F.C. 1993, Biochim. Biophys. Acta 1155, 151.
8. Lau, L.F. and Nathans, D. 1985, EMBO J. 4, 3145.
9. Lau, L.F. and Nathans, D. 1987, Proc. Natl. Acad. Sci. USA 84, 1182.
10. Slack, J.K. and Higgins, P.J. 1996, Cell Motil. Cytoskel. 33, 83.
11. Ryan, M.P. and Higgins, P.J. 1994, Actin: Biophysics, Biochemistry and Cell Biology. Estes, J.E. and Higgins, P.J., editors. Plenum Press, NY, 215.
12. Grimaldi, G., DiFiore, P., Locatelli, E.K., Falco, J. and Blasi, F. 1986, EMBO J. 5, 855.
13. Bellas, R.E., Bendori, R., and Farmer, S.R. 1991, J. Biol. Chem. 266, 12008.
14. Gluck, U., Fernandez, J.L.R., Pankov, R., and Ben-Ze'ev, A. 1992, Exp. Cell Res. 202, 477.
15. Ryan, M.P. and Higgins, P.J. 1993, J. Cell. Physiol. 155, 376.
16. Folkman, J. and Moscona, A. 1978, Nature 273, 345.
17. Ingber, D.E. 1990, Proc. Natl. Acad. Sci. USA 87, 3579.
18. Huang, S., Chen, C.S., and Ingber, D.E. 1998, Mol. Biol. Cell 9, 3179.
19. Miranti, C.K. and Brugge, J.S. 2002, Nature Cell Biol. 4, 83.
20. Danen, E.H.J. and Yamada, K.M. 2001, J. Cell. Physiol. 189, 1.
21. Schwartz, M.A. and Assoian, R.K. 2001, J. Cell Sci. 114, 2553.
22. Pu, Q.Q. and Streuli, C.H. 2002, Bioessays 24, 17.
23. Ryan, M.P., Kutz, S.M., and Higgins, P.J. 1996, Biochem. J. 314, 1041.

24. Iyer, V.R., Eisen, M.B., Ross, D.T., Schuler, G., Moore, T., Lee, J.C., Trent, J.M., Staudt, L.M., Hudson, J., Boguski, M.S., Lashkari, D., Shalon, D., Botstein, D., and Brown, P.O. 1999, *Science* 283,83.
25. Mu, X.C., Staiano-Coico, L., and Higgins, P.J. 1998, *J. Cell. Physiol.* 174, 90.
26. Kutz, S.M., Nickey, S.A.T., White, L.A., and Higgins, P.J. 1997, *J. Cell. Physiol.* 178, 8.
27. Schneiderman, J., Sawdey, M., Craig, H., Thinnies, T., Bordin, G., and Loskutoff, D.J. 1993, *Am. J. Path.* 143, 753.
28. Thornton, A.J., Bruzdinski, C.J., Raper, S.E., and Gelehrter, T.D. 1994, *Cancer Res.* 54, 1337.
29. Andreasen, P.A., Egelund, R., and Peterson, H.H. 2000, *Cell Mol. Life Sci.* 57, 25.
30. Higgins, P.J., Chaudhari, P., and Ryan, M.P. 1991, *Biochem. J.* 273, 651.
31. Seiffert, D., Mimuro, J., Schleef, R.R., and Loskutoff, D.J. 1994, *Cell Differ. Dev.* 32, 287.
32. Lawrence, D.A., Palaniappan, S., Stefansson, S., Olson, S.T., Francis-Chmura, A.M., Shore, J.D., and Ginsburg, D. 1997, *J. Biol. Chem.* 272, 7676.
33. Loskutoff, D.J., Curriden, S.A., Hu, G., and Deng, G. 1999, *APMIS* 107, 54.
34. Czekay, R.P., Aertgeerts, K., Curriden, S.A., and Loskutoff, D.J. 2003, *J. Cell Biol.* 160, 781.
35. Ciambone, G.J. and McKeown-Longo, P.J. 1990, *J. Cell Biol.* 111, 2183.
36. Koziczak, M., Krek, W., and Nagamine, Y. 2000, *Mol. Cell. Biol.* 20, 2014.
37. Koziczak, M., Muller, H., Helin, K., and Nagamine, Y. 2001, *Eur. J. Biochem.* 268, 4969.
38. Al-Fakhri, N., Chavakis, T., Schmidt-Woll, T., Huang, B., Cherian, S.M., Bobryshev, Y.V., Lord, R.S., Katz, N., and Preissner, K.T. 2003, *Biol. Chem.* 384, 423.
39. Guadagno, T.M. and Assoian, R.K. 1991, *J. Cell Biol.* 115, 1419.
40. Guadagno, T.M., Ohtsubo, M., Roberts, J.M., and Assoian, R.K. 1993, *Science* 262, 1572.
41. Hawks, K. and Higgins, P.J. 1998, *J. Cell. Physiol.* 176, 293.
42. Samarakoon, R. and Higgins, P.J. 2002, *J. Cell Sci.* 115, 3093.
43. Samarakoon, R. and Higgins, P.J. 2003, *J. Cell. Physiol.* 195, 411.
44. Carmeliet, P. and Collen, D. 1995, *Thromb. Haemost.* 74, 429.
45. Carmeliet, P. and Collen, D. 1996, *Haemostasis* 26, 132.
46. Stefansson, S. and Lawrence, D.A. 1996, *Nature* 383, 441.
47. Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y., and Chapman, H.A. 1997, *J. Clin. Invest.* 100, 58.
48. Providence, K.M., Kutz, S.M., Staiano-Coico, L., and Higgins, P.J. 2000, *J. Cell. Physiol.* 182, 269.
49. Providence, K.M., White, L.A., Tang, J., Gonclaves, J., Staiano-Coico, L., and Higgins, P.J. 2002, *J. Cell Sci.* 115, 3736.
50. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Loskutoff, D.J. 1996, *J. Cell Biol.* 134, 1563.
51. Deng, G., Curriden, S.A., Hu, G., Czekay, R.P., and Loskutoff, D.J. 2001, *J. Cell. Physiol.* 189, 23.
52. Kjoller, L., Kanse, S.M., Kirkegaard, T., Rodenburg, K.W., Ronne, E., Goodman, S.L., Preissner, K.T., Ossowski, L., and Andreasen, P.A. 1997, *Exp. Cell Res.* 232, 420.
53. Mignatti, P. and Rifkin, D.B. 2000, *Adv. Cancer Res.* 78, 103.
54. Planus, E., Barlovatz-Meimon, G., Rogers, R.A., Bonavaud, S., and Ingber, D.E. 1997, *J. Cell Sci.* 110, 1091.
55. Lopez-Aleman, R., Redondo, J.M., Nagamine, Y., and Munoz-Canoves, P. 2003, *Eur. J. Biochem.* 270, 814.
56. Boehm, J.R., Kutz, S.M., Sage, E.H., Staiano-Coico, L., and Higgins, P.J. 1999, *J. Cell. Physiol.* 181, 96.
57. White, L.A., Bruzdinski, C., Kutz, S.M., Gelehrter, T.D., and Higgins, P.J. 2000, *Exp. Cell Res.* 260, 127.
58. Johnson, M., Bruzdinski, C., Winograd, S.S., and Gelehrter, T.D. 1992, *J. Biol. Chem.* 267, 12202.

59. Sawadogo, M. and Roeder, R.G. 1985, *Cell* 43, 165.
60. Lin, Q., Luo, X., and Sawadogo, M. 1994, *J. Biol. Chem.* 269, 23894.
61. Littlewood, T.D. and Evan, G.E. 1994, *Protein Profile Transcription Factors 2: Helix-Loop-Helix*, Vol. 1. Academic Press, NY, 639.
62. Workman, J.L., Roeder, R.G., and Kingston, R.E. 1990, *EMBO J.* 19, 1299.
63. Smale, S.T. and Baltimore, D. 1989, *Cell* 57, 103.
64. Du, H., Roy, A.L., and Roeder, R.G. 1993, *EMBO J.* 12, 501.
65. Roy, A.L., Carruthers, C., Gutjahr, T., and Roeder, R.G. 1993, *Nature* 365, 359.
66. Prendergast, G.C. and Cole, M.D. 1989, *Mol. Cell. Biol.* 9, 124.
67. Riccio, A., Pedone, P.V., Lund, L.R., Olsen, T., Olson, H.S., and Andreasen, P.A. 1992, *Mol. Cell. Biol.* 12, 1846.
68. Hopewell, R., Li, L., MacGregor, D., Nerlov, C., and Ziff, E.B. 1995, *J. Cell Sci.* 19, 85.
69. Lun, Y., Sawadogo, M., and Perry, M. 1997, *Cell Growth Diff.* 8, 275.
70. Carter, R.S., Ordentlich, P., and Kadesch, T. 1997, *Mol. Cell. Biol.* 17, 18.
71. Pognonec, P., Boulukos, K.E., Aperlo, C., Fujimoto, M., Ariga, H., Nomoto, A., and Kato, H. 1997, *Oncogene* 14, 2091.
72. Blanas, M. and Rutter, W. 1992, *Science* 256, 1014.
73. Ghosh, A.K., Data, P.K., and Jacob, S.T. 1997, *Oncogene* 14, 589.
74. Hua, X., Liu, X., Ansari, D.O., and Lodish, H.F. 1998, *Genes Dev.* 12, 3084.
75. Hua, X., Miller, Z.A., Wu, G., Shi, Y., and Lodish, H.F. 1999, *Proc. Natl. Acad. Sci. USA* 96, 13130.
76. McGhee, J.D. and von Hippel, P.H. 1975, *Biochem.* 14, 1281.
77. McGhee, J.D. and von Hippel, P.H. 1975, *Biochem.* 14, 1297.
78. Solomon, M.J. and Varshavsky, A. 1985, *Proc. Natl. Acad. Sci. USA* 82, 6470.
79. Orlando, V. 2000, *Trends Biochem. Sci.* 25, 99.

Author Proof

Upstream Stimulatory Factor Regulates E Box-Dependent PAI-1 Transcription in Human Epidermal Keratinocytes

ROSALIE R. ALLEN, LI QI, AND PAUL J. HIGGINS*

Center for Cell Biology & Cancer Research, Albany Medical College,
Albany, New York

Certain growth factors (e.g., TGF- β 1) initiate a "plastic" response in human keratinocytes (HaCaT cells) characterized by changes in gene expression and increased cell motility. While microarray analyses identified a number of involved genes, plasminogen activator inhibitor type 1 (PAI-1) is among the subset most highly responsive to TGF- β 1. Previous antisense attenuation of PAI-1 synthesis confirmed an essential role for this protease inhibitor in cell motility (Providence et al., 2002, *J Cell Sci* 115:3767–3777; Providence and Higgins, 2004, *J Cell Physiol* 200:297–308). It was important, therefore, to clarify molecular mechanisms underlying PAI-1 expression control in human keratinocytes. A consensus E box motif (5'-CACGTG-3') at nucleotides –566 to –561 in the PE2 region of the *PAI-1* gene was required for TGF- β 1-induced transcription of a PAI-1 promoter-driven luciferase reporter. Truncation of the PE2 E box or mutation of the CACGTG hexanucleotide to CAAITG inhibited growth factor-stimulated promoter function confirming the importance of this site in inducible expression. A similar mutation at the PE1 E box (nucleotides –682 to –677), in contrast, did not result in reduced luciferase activity. Competing CACGTG-containing DNAs, regardless of the presence or absence of PAI-1-specific flanking sequences or lacking accessory sequences (i.e., Smad-binding sites, AAT trinucleotide spacer), inhibited complex formation between HaCaT cell nuclear factors and a 45-mer PE2 region probe. A deoxyoligonucleotide that differed from the consensus E box by a CG \rightarrow AT substitution (the same base change incorporated into the PAI-1p806-luciferase reporter by site-directed mutagenesis) but with random (i.e., non-PAI-1) flanking sequences also failed to compete with the PE2 region probe for protein binding whereas the same construct with an intact CACGTG motif was an effective competitor. The major protein/DNA interactions in the PE2 segment, therefore, are E box-dependent. USF-1, a member of the upstream stimulatory factor family, bound the PE2 construct suggesting a role for USF proteins in E box residence and *PAI-1* gene expression. Chromatin immunoprecipitation, using primers designed to amplify a 300-bp PE2-associated promoter fragment and containing no other E box motifs except the target CACGTG at nucleotides –566 to –561, confirmed that this site was occupied by USF-1 or a USF-1-containing complex in both quiescent and TGF- β 1-stimulated cells. Transfection of a dominant-negative USF construct effectively attenuated serum- and TGF- β 1-induced PAI-1 synthesis as well as TGF- β 1-stimulated Matrigel barrier invasion. Dominant-negative USF-expressing keratinocytes, moreover, had a significantly reduced capacity for Matrigel barrier invasion. USF elements, therefore, are important regulators of growth factor-initiated PAI-1 transcription (as predicted from the identification of *PAI-1* as a direct USF target gene) and the associated epithelial migratory response. *J. Cell. Physiol.* 9999: 1–10, 2004. © 2004 Wiley-Liss, Inc.

Cells utilize several multicomponent proteolytic systems to migrate through stromal barriers with invasive ability frequently dependent on conversion of plasminogen to the broad-spectrum protease plasmin by urokinase plasminogen activator (uPA) (e.g., Lund et al., 1999). The catalytic properties of uPA are regulated, in turn, by the fast-acting type-1 serine protease inhibitor (SERPIN) plasminogen activator inhibitor type 1 (PAI-1) (Andreasen et al., 2000). This cascade is a major determinant of the overall pericellular proteolytic balance, effectively modulating the highly inter-related processes of extracellular matrix (ECM) remodeling and cell migration (Okedon et al., 1992; Jeffers et al., 1996; Mazzieri et al., 1997; Bajou et al., 1998; Farina et al., 1998; Lund et al., 1999; Providence et al., 2000; Reijerkerk et al., 2000; Zhou et al., 2000; Brooks et al., 2001; Legrand et al., 2001).

PAI-1 is most prominent among the subset of TGF- β 1-induced genes that accompany development of epithelial "plasticity" (Boehm et al., 1999; Akiyoshi et al., 2001; Zavadil et al., 2001), a phenotypic transition associated with enhanced expression of matrix-degrading proteases, cytoarchitectural restructuring, and increased cell motility (Gilles et al., 1997; Santibanez et al., 1999; Arias, 2001; Kutz et al., 2001; Thiery, 2002; Giusti et al., 2003). This protease inhibitor, moreover, is a major promigratory factor in invasive breast carcinoma cells (e.g., Chazaud et al., 2002; Palmieri et al., 2002) and

elevated tumor levels of PAI-1 correlate with a poor patient prognosis and reduced disease-free survival time (Dublin et al., 2000; Chappuis et al., 2001; Chazaud et al., 2002). PAI-1 appears to be a particularly critical element in the program of tissue invasion acting to limit plasmin generation, thus preserving an ECM "scaffold" permissive for stromal migration (Bajou et al., 1998, 2001). Although TGF- β 1-stimulated PAI-1 synthesis may regulate cell motility via fine control of uPA-dependent matrix barrier proteolysis (Mignatti and Rifkin, 2000; Providence et al., 2003 for reviews), this SERPIN also functions in a more general context to modulate integrin–ECM or uPA/uPA receptor (uPAR)–ECM

Contract grant sponsor: NIH; Contract grant numbers: GM57242, T32 HL07194; Contract grant sponsor: US Army Breast Cancer Program; Contract grant numbers: DAMD17-00-1-0124, DAMD17-02-1-0270.

*Correspondence to: Paul J. Higgins, Center for Cell Biology & Cancer Research, Albany Medical College, Mail Code 165, 47 New Scotland Avenue, Albany, NY 12208.
E-mail: higginp@mail.amc.edu

Received 14 July 2004; Accepted 27 July 2004

Published online in Wiley InterScience
(www.interscience.wiley.com.), 00 Month 2004.
DOI: 10.1002/jcp.20211

interactions affecting, thereby, cell-to-substrate adhesion (Deng et al., 1996, 2001; Kjoller et al., 1997; Loskutoff et al., 1999; Andreasen et al., 2000; Gutierrez et al., 2000; Koziczak et al., 2000; Mignatti and Rifkin, 2000; McMahon et al., 2001; Stefansson et al., 2001; Palmieri et al., 2002; Providence et al., 2002; Al-Fakhri et al., 2003; Czekay et al., 2003; Stefansson and Lawrence, 2003). Even minor changes in PAI-1 expression, therefore, would be expected to influence motile behavior by either or both mechanisms (e.g., Liu et al., 1995; Chapman, 1997; Loskutoff et al., 1999; Mignatti and Rifkin, 2000; Czekay et al., 2003; Providence and Higgins, 2004). Indeed, recent findings confirmed that antisense down-regulation of PAI-1 synthesis, or use of PAI-1 function-blocking antibodies, effectively inhibits basal as well as growth factor-stimulated cell migration (Brooks et al., 2001; Chazaud et al., 2002; Providence et al., 2002, 2003).

TGF- β 1 controls on specific "invasion-modulating" target genes (i.e., *PAI-1*) is largely transcriptional (e.g., Riccio et al., 1992; Petzelbauer et al., 1996; Kutz et al., 2001). Prominent TGF- β 1-activated sites include the hexanucleotide E box motif (5'-CACGTG-3') in the PE2 region of the PAI-1 promoter and related sequences that are recognized by a subgroup of basic helix-loop-helix/leucine zipper (bHLH-LZ) transcription factors (e.g., MYC, MAX, TFE3, USF-1, USF-2, and HIF-1 α) (Riccio et al., 1992; Dennler et al., 1998; Hua et al., 1998, 1999; White et al., 2000; Fink et al., 2002; Grinberg and Kerppola, 2003). The most TATAA-proximal consensus E box, situated at nucleotides -160 to -165 upstream of the transcription start site in the rat *PAI-1* gene, for example, binds USF-1 and is required for PAI-1 promoter-driven reporter expression in growing, TGF- β 1-stimulated and hypoxia-stressed cells (Kietzmann et al., 1999; White et al., 2000). This motif likely functions, therefore, as a "platform" for recruitment of positive and negative regulators of PAI-1 transcription (e.g., Samoylenko et al., 2001) which may vary depending on the stimulus and/or growth state (White et al., 2000; Qi and Higgins, 2003).

Recent chromatin immunoprecipitation analysis identified USF family members as *in vivo* DNA-binding proteins at the PE2 site of the *PAI-1* gene in proliferating human keratinocytes (Qi and Higgins, 2003). This study details the critical involvement of the PE2 region E box in TGF- β 1-stimulated PAI-1 transcription as well as the sequence requirements for USF-1/PAI-1 E box interactions. Data are also presented indicating that expression of a dominant-negative USF construct (USF-1A) decreased both PAI-1 levels and the invasive ability of immortalized keratinocytes, implicating the importance of USF target genes in migration through stromal barriers.

MATERIALS AND METHODS

Cell culture

HaCaT and RK epidermal keratinocytes were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) (Boehm et al., 1999; Providence et al., 2002). Confluent cultures were washed with HBSS and maintained in serum-free medium for 3 days to initiate a state of growth arrest before stimulation with serum (20%) or recombinant TGF- β 1 (1 ng/ml; R&D Systems, Minneapolis, MN). Pre-exposure to the p38 inhibitor III (380 nM; Calbiochem, San Diego, CA) or the MEK inhibitors PD98059 (50 μ M; BioSource, Camarillo, CA) and U0126 (10 μ M; Promega, Madison, WI) was for 30 min prior to growth factor addition. Inhibitor III (a potent, selective, ATP site-directed p38 MAPK inhibitor) was selected to target p38 since

the more commonly used compound SB203580 also attenuates TGF- β receptor signaling.

Northern blots

Cellular RNA was isolated with Purescript (Gentra, Minneapolis, MN), denatured at 55°C for 15 min in 1 \times MOPS, 50% formamide, and 6.5% formaldehyde prior to separation in agarose/formaldehyde gels (1.2% agarose, 1.1% formaldehyde, 1 \times MOPS), transferred to Nytran membranes in 10 \times SSC (3M NaCl, 0.3 M Na citrate, pH 7.0) and UV-crosslinked. Membranes were incubated for 2 h at 42°C in 50% formamide, 5 \times Denhardt's solution, 5 \times SSC, 1% SDS, 100 μ g/ml sheared/heat denatured salmon sperm DNA (ssDNA) then hybridized overnight with 32 P-labeled cDNA probes for human PAI-1 and GAPD at 42°C in 50% formamide, 2.5 \times Denhardt's solution, 1% SDS, 5 \times SSC, 100 μ g/ml ssDNA, and 10% dextran sulfate. Blots were washed three-times (for 15 min each) at 42°C followed by three additional washes at 55°C in 0.1 \times SSC/0.1% SDS before exposure to film.

Chromatin immunoprecipitation (ChIP)

Quiescent and TGF- β 1-treated HaCaT cells were fixed with 1% formaldehyde, chromatin isolated, sonicated (fragment range = 300–1,000 bp), precleared with protein A agarose beads coated with ssDNA, and incubated overnight at 4°C with 2 μ g IgG (see text⁹³). Immune complexes were collected with protein A agarose/ssDNA beads, washed, eluted, and cross-links reversed at 65°C for 5 h. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. A 300 bp region encompassing the PE2 E box of the human PAI-1 promoter was amplified by PCR.

Nuclear extracts

Cells were rinsed in ice-cold PBS, scrape-harvested, washed twice in Tris-buffered saline (0.14 M NaCl, 0.5 mM KCl, 1.4 mM Na₂HPO₄, 25 mM Tris, 1.4 mM CaCl₂, 0.5 mM MgCl₂), resuspended in 800 μ l 10 mM HEPES buffer, pH 7.9, containing 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and protease inhibitor cocktail (PIC; leupeptin, aprotinin, pepstatin A [each at 10 μ g/ml], 1 mM PMSF), incubated on ice for 15 min, and 50 μ l 10% NP-40 added prior to a 10 sec vortex lysis. Nuclei were collected by centrifugation, resuspended in 100 μ l cold extraction buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, PIC), rocked on ice for 15 min, and the soluble fraction recovered by centrifugation at 14,000 rpm for 5 min. Where indicated, incubation of nuclear extracts with potato acid phosphatase (PAP, 1 U/5 μ g nuclear protein; Sigma Chemical Co., St Louis, MO) was for 15 min at room temperature.

Electrophoretic mobility shift assay (EMSA)

Double-stranded deoxyoligonucleotides (5 pM) (Table 1) were end-labeled by incubation for 10 min at room temperature in 70 mM Tris-HCl buffer, pH 7.6, containing 10 mM MgCl₂, 5 mM DTT, γ - 32 P-dATP (3,000 Ci/mmol) and T4 polynucleotide kinase then purified by elution from 5 kDa cellulose spin columns (Millipore, Bedford, MA). Target probes (25–50,000 cpm) were incubated for 20 min at room temperature in a final reaction volume of 20 μ l with 2–10 μ g nuclear extract protein/ml in binding buffer (4% glycerol, 1 mM MgCl₂, 0.5 mM EDTA, 0.5 mM DDT, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1 μ g/ μ l poly dI:dC) in the absence or presence of the indicated antibody (2 μ g) or a 100-fold molar excess of unlabeled competing DNA (White et al., 2000). Gel loading buffer (25 mM Tris-HCl, pH 7.5, 0.02% bromophenol blue, 0.02% xylene cyanol, 4% glycerol) was added and reaction mixtures separated on 4% acrylamide Tris/Borate/EDTA gels. Gels were pre-run at 100 V for 30 min prior to sample separation at 125 V at room temperature for 3 h.

Oligonucleotide pulldown assay

Nuclear extract protein (50–100 μ g) was incubated with 100 pM biotinylated DNA (Table 1) for 18 h at 4°C in binding buffer (as above) but containing 0.5 μ g/ μ l poly dI:dC and PIC. Complexes were harvested with magnetic streptavidin-coated beads (Pierce, Madison, WI) for 30 min on ice prior to three

TABLE 1. Double-stranded deoxyoligonucleotides used for EMSA

Deoxyoligonucleotide description	Sequence
Human PAI-1 PE2 construct	5'-CAAGTCCTAGACAGACAAAACCTAGACAATCACGTGGCTGGCTGC-3'
Human PAI-1 PE2 CG → AT mutant	5'-CAAGTCCTAGACAGACAAAACCTAGACAATCAATTGGCTGGCTGC-3'
Human PAI-1 PE2 CA → TC mutant	5'-CAAGTCCTAGACAGACAAAACCTAGACAATCCGTGGCTGGCTGC-3'
Human PAI-1 PE1 construct	5'-GTCTGGACACGTGGGGGGAGTCAGCCGTGTATCATCGGAG-3'
PE2 Smad mutant (AGAC → CTTG)(SBE mutation)	5'-CAAGTCCTCTTGGCTTGAACCTCTTGAATCACGTGGCTGGCTGC-3'
PE2 distal SBE construct (SIS2)	5'-CAAGTCCTAGACAGACAAAAC-3'
PE2 AAT deletion (-AAT)	5'-CAAGTCCTAGACAGACAAAACCTAGACCACGTGGCTGGCTGC-3'
PE2 18-mer fragment with the AAT spacer and E box (PE2S)	5'-AATCACGTGGCTGGCTGC-3'
PE2 proximal SBE, AAT spacer and E box (PE2SBE)	5'-CTAGACAATCACGTGGCT-3'
Rat PAI-1 promoter proximal E box construct	5'-TACACACACGTGTCCAG-3'
Consensus E box (no PAI-1-flanking sequences)	5'-CACCCGGTCACGTGGCTACACC-3'
Mutant E box (no PAI-1-flanking sequences)	5'-CACCCGGTCAATTGGCTACACC-3'

washes with 2 M NaCl, boiled for 10 min in 2 × Laemmli sample buffer, separated on 9% SDS/PAGE gels and proteins transferred to nitrocellulose membranes for immunoblotting with USF-1 antibodies.

Luciferase reporter assay

Regions of the human PAI-1 promoter (nucleotides -806 to +72, -606 to +72, -506 to +72) were PCR-amplified using primers designed to add 5' SacI and 3' XhoI restrictions sites. PCR products were gel-purified, ligated into TOPO TA (Invitrogen, Carlsbad, CA), and cloned into the SacI/XhoI site of the pGL3 luciferase vector (Promega) to create the reporter PAI-1p806-Luc. The dinucleotide substitution (CACGTG → CAATTG) in the PE1 and PE2 region E boxes was created using the Quick-Change site-directed mutagenesis kit (Stratagene, San Diego, CA). HaCaT cells were transfected with the full-length luciferase reporter or derivatives thereof (see text^{Q3}) using Lipofectamine, serum-starved for 1 day, then stimulated with TGF-β1 for 8 h prior to extraction. Luciferase activity was normalized by co-transfection with an SV40 driven β-galactosidase-expressing plasmid and development of the respective signals using a luciferase/β-galactosidase assay kit (Promega).

USF-1 expression construct transfection and PAI-1 Western blotting

RK cells were transfected with a dominant-negative USF-1 construct (USF-1A) or wild-type (WT) USF-1 expression plasmid using Lipofectamine Plus (Invitrogen). Serum-starved (3 days) cells were stimulated with serum (20%) or TGF-β1 (1 ng/ml), extracted in 50 mM HEPES buffer (pH 7.0, containing 0.5% deoxycholate and 0.1% SDS), lysates clarified by centrifugation at 14,000 × g, 10–20 μg extract protein diluted in 2 × Laemmli sample buffer, separated on SDS/9% acrylamide gels and transferred to nitrocellulose. Membranes were blocked in 3% milk (in 0.05% Triton-X 100/PBS) prior to sequential incubations with rabbit antibodies to rat PAI-1 (#1062; American Diagnostica, Stamford, CT) and horseradish peroxidase-conjugated goat anti-rabbit IgG and reactive bands visualized using ECL/autoradiography. All blots were subsequently stripped and reprobed with antibodies to ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA) to assess protein loading levels.

Matrigel invasion assay

For assessment of invasive traits, quiescent (5×10^4) cells were added to Matrigel-coated chambers (8 μm pore size; BD Clontech, Palo Alto, CA). TGF-β1 (1 ng/ml) or solvent was added to the upper chamber while the lower chamber contained DMEM/10% FBS. After 24 h, membranes were fixed and cells stained with Hoechst dye. The number of keratinocytes that migrated to the bottom of the filter was determined by microscopy. To determine the fraction of HA-tagged construct-expressing keratinocytes, cells were fixed, permeabilized, and stained sequentially with anti-HA antibodies (Santa Cruz Biotechnology) and Alexa-Fluor 568-labeled secondary antibodies.

RESULTS

TGF-β1 activation of PAI-1 transcription requires an intact E Box within the PE2 region of the PAI-1 gene

Several TGF-β1 response elements, including three SMAD-binding sites (AGAC) (SBEs) and two E box motifs (CACGTG), map within the PE1 and PE2 regions of the human PAI-1 promoter (Fig. 1A, Table 1). While nucleotides -598 to -532 (upstream of the transcription start site) specifically appear to be involved in the response to TGF-β1, only the CACGTG motif (and a 5' 5 nucleotide flank as well as a 3' segment consisting of approximately 20 nucleotides) yielded a DNase I-protected footprint (Riccio et al., 1992). To topographically position TGF-β1 regulatory elements within the 5'-PE1-PE2-3' domains of the PAI-1 gene in the HaCaT cell system, luciferase reporter assays were designed to assess the consequences of specific truncations and nucleotide substitutions on PAI-1 promoter activity. Compared to the full-length PAI-1p806-Luc construct, PAI-1p606-Luc (in which 0.2 kb of 5' sequence was removed including the PE1 region E box) retained approximately 50% of the TGF-β1-inducible signal indicating that major (albeit not the only) TGF-β1-response sites reside within the proximal 606 bp of the PAI-1 promoter (Fig. 1B). Further elimination of nucleotides -606 to -506, removing the three SBEs and the PE2 region E box, reduced reporter expression by >7-fold. The dinucleotide substitution CACGTG to CAATTG in the PE2 region E box (-806 E2 mut), moreover, resulted in a significant attenuation in full-length PAI-1p806-driven transcriptional activity (Fig. 1B), highlighting the functional significance of this site in the reporter response to TGF-β1. The identical mutation at the PE1 E box (-806 E1 MUT) was without effect. Decreased expression as a consequence of the -806 to -606 truncation, therefore, likely eliminated sequences essential for full reporter activation other than just the PE1 region hexanucleotide E box.

Since an intact consensus PE2 region E box motif is required for the maximal transcriptional response of the PAI-1p806-Luc reporter to TGF-β1 (Fig. 1B), it was important to identify specific E box-binding nuclear proteins in human keratinocytes that may mediate gene control. A double-stranded 45-mer PE2 region deoxyoligonucleotide was designed (Fig. 2A; Table 1) (with eight and nine base pair extensions 5' of the last SBE and 3' of the E box, respectively), ³²P end-labeled and used in mobility shift assays. Factors capable of binding this DNA target were evident in nuclear extracts from quiescent as well as constitutively-growing and TGF-




Fig. 1. TGF- β 1-induced PAI-1 transcription is E box-dependent. Topography of the PAI-1p806-Luc reporter construct illustrating the relative positions of the two (PE1 and PE2 region) E box sequences, the three Smad binding elements and the two central E box nucleotides (CG) selected for mutation (A). Luciferase assays in HaCaT transfectants used the indicated promoter constructs and a relatively

short (i.e., 8 h) exposure to TGF- β 1 (B); ovals depict the wild-type (WT) E box motifs while X indicates the mutated (CG \rightarrow AT) PE1 and PE2 region E boxes. Luciferase signal was normalized by co-transfection with a SV40-driven β -galactosidase expression vector and expressed as fold-increase relative to non-TGF- β 1-stimulated cells. Data plotted is the mean \pm standard error of four independent experiments.

β 1-stimulated cells (Fig. 2B). This finding provided an opportunity to utilize the 45-mer PE2 construct to assess the relative contributions of the SBEs, E box flanking sequences, and the E box motif to nuclear protein binding. All unlabeled CACGTG hexanucleotide-containing DNAs, regardless of the presence or absence of PAI-1-specific 5' and 3' flanking sequences or SBEs (Table 1), significantly decreased probe complex formation (Fig. 2C). Most importantly, a deoxyoligonucleotide that differed from the consensus E box by a CG \rightarrow AT substitution (identical to the base change incorporated into the PAI-1p806-Luc by site-directed mutagenesis) and containing no PAI-1 flanking sequences failed to compete with the PE2 region probe for factor binding, whereas the same construct with an intact CACGTG motif was an effective competitor (Fig. 2C; Table 1). The major protein/DNA interactions in the PE2 segment, therefore, appear to be E box-dependent. Double-stranded E box containing deoxyoligonucleotides with all three SBEs mutated (AGAC \rightarrow CTTG) or lacking the AAT trinucleotide spacer sequence (Fig. 3A; Table 1) also successfully competed for protein binding with the labeled 45-mer PE2 DNA target (Fig. 3B), and formed nuclear protein/DNA complexes when presented as labeled probes (not shown⁴⁴), further minimizing the potential contribution of the PE2 region AAT spacer or SBEs to site occupancy. These data are consistent with the absence of DNase I protection at the PE2 segment SBEs (Riccio et al., 1992). Fragments containing the E box sequence and either three 5' or three 3' flanking base pairs, however, competed less effectively (Fig. 3B) or failed to bind protein to the same extent as the labeled

PE2 target (Fig. 3C), suggesting the necessity for more than three flanking nucleotides for efficient protein/DNA interactions.

The PE2 region E box binds bHLH-LZ proteins of the USF family

A proximal promoter E box in the rat PAI-1 gene is an important platform for protein binding in response to proliferative stimuli and mild hypoxia as well as to individual growth factors including TGF- β 1 (Kietzmann et al., 1999; White et al., 2000). Previous nuclear extract immunodepletion analysis and tethered deoxyoligonucleotide affinity chromatography identified USF-1 as one PAI-1 E box binding element (White et al., 2000; Providence et al., 2002). Inhibition of complex formation by USF-1 antibodies (Fig. 3B) and supershift approaches (Fig. 4A) confirmed that USF-1 similarly recognized the 45-mer PE2 construct. In accord with the sequence constraints for probe binding defined by EMSA (Figs. 2C, 3B), deoxyoligonucleotide pull-down assays additionally substantiated that an intact consensus CACGTG motif was required for optimal site recognition by USF-1 (Fig. 4B). It appears that USF proteins are primarily responsible for binding the PE2 PAI-1 promoter region construct as addition of antibodies capable of recognizing the bHLH-LZ factor TFE3 were unable to either supershift, or disrupt formation of, protein/DNA complexes (Fig. 4A). Phosphorylation of USF-1, moreover, is necessary for DNA binding (Cheung et al., 1999; Galibert et al., 2001) and, consistent with this requirement, the predominant form of USF-1 that eluted from PAI-1 deoxyoligonucleotide affinity columns co-migrat-



Fig. 2. PE2 probe-binding activity by HaCaT cell nuclear factors is growth state-independent and E box-specific. Nuclear extracts from quiescent, constitutively-growing and TGF- β 1-stimulated HaCaT cells were incubated with the double-stranded 45-mer ³²P-labeled PE2 region deoxyoligonucleotide (A; Table 1) (only one strand is shown) and the reaction products separated on non-denaturing 4% acrylamide gels (B). For competition assays, extracts were incubated

with a 100-fold molar excess of the indicated unlabeled double-stranded DNA constructs (as described in Table 1) prior to addition of ³²P-labeled PE2 target probe and electrophoretic separation of complexes (C). The apparent differences in band migration upon addition of cold competing sequences (C) is an electrophoretic artifact and not an actual change in complex mobility.

ed with the 45 kDa (phospho-USF-1) species (Providence et al., 2002). PE2 binding ability was TGF- β 1-independent but did, indeed, require phosphorylation as PAP treatment of nuclear extracts from quiescent or TGF- β 1-stimulated cells prior to addition of the 45-mer target sequence eliminated the characteristic band shift resolved by EMSA (Fig. 4A). Control experiments confirmed that USF-1 protein levels were not affected by PAP treatment (Fig. 4C). While the activity of USF proteins and other E box-binding transcription factors is modulated by phosphorylation, the involved enzymes (i.e., the mitogen-activated protein [MAP] kinases) may differ (e.g., Cheung et al., 1999; Galibert et al., 2001). A pharmacologic approach was designed to address this issue specifically with regard to *PAI-1* gene control. The MEK inhibitor PD98059 effectively reduced TGF- β 1-stimulated *PAI-1* transcripts by >75% (Fig. 5A). The p38 inhibitor effectively attenuated growth factor-induced HSP27 phosphorylation (not shown^{Q5}), attesting its functionality in the present experimental system, but failed to affect either *PAI-1* mRNA induction or protein/DNA complex formation (Fig. 5B,C).

USF regulates induced *PAI-1* protein expression and barrier invasion

Although both EMSA and pull-down approaches can yield important information regarding specific sequence requirements for probe recognition, it was necessary to establish that the PE2 region was, in fact, a platform for

USF/DNA interactions *in vivo*. Chromatin immunoprecipitation, using primers designed to amplify a 300-bp PE2-associated promoter fragment and containing no other E box motifs except the target CACGTG at nucleotides -566 to -561 (Fig. 1), confirmed that this site was occupied by USF-1 or a USF-1-containing complex in both quiescent and TGF- β 1-stimulated cells (Fig. 6A). This finding, moreover, provided the rationale to directly evaluate the role of USF proteins in the regulation of *PAI-1* transcription. RK cells were transiently transfected, therefore, with a dominant-negative USF-1 construct (USF-1A) or wild-type (WT) USF-1 expression vector. Substitution of the WT USF-1 basic DNA-binding region with an acidic domain confers increased homo- or hetero-dimer stability between USF-1A and endogenous USF-1 or USF-2, respectively (Sirito et al., 1998); such dimers, however, are unable to interact with their target DNA motif (Galibert et al., 2001). Thus, the overall effect of USF-1A introduction is to disrupt the formation of functional USF homo- or hetero-dimers. Cells were cultured under quiescent conditions, stimulated with serum or TGF- β 1 and *PAI-1* protein levels assessed by Western blotting. A significant decrease in *PAI-1* protein was evident in dominant-negative USF-1A transfectants upon stimulation with TGF- β 1 or FBS when compared with untransfected or WT USF-1 controls (Fig. 6B). Introduction of the WT USF-1 construct into RK cells did not alter levels of induced *PAI-1* expression relative to untransfected cultures, confirm-




Fig. 3. Sequence requirements for probe binding. Schematic of the PE2 PAI-1 promoter sequence illustrating the position of the SMAD binding elements (SBE), the trinucleotide (AAT) spacer, and the E box motif; truncated and mutated sequences are highlighted (A). Nuclear extracts from quiescent and TGF- β 1-treated cells were incubated with 32 P-labeled PE2 DNA (A) in the presence or absence of a 100-fold molar excess of the indicated unlabeled competing DNA (see also Table 1; B) or incubated with 32 P-labeled WT 45-mer PE2 DNA or truncated probe targets (C) and reaction products separated on non-

denaturing 4% acrylamide gels. The difference in the low-affinity complexes resolved with the S1S2 probe, as compared with the PE2S and PE2SBE fragments, may indicate SMAD recognition of the AGAC repeat element in the S1S2 construct (C). An antibody specific for USF-1 (USF-1 Ab) was used (B) in complex-blocking mode (White et al., 2000). This approach avoids resolution of supershifted complexes that might complicate the banding profile and identifies the topmost band as the major USF-1-binding species. Arrow indicates position of specific formed complexes.

ing its suitability as a plasmid control (see "Discussion"). Attenuation of the TGF- β 1-associated increase in PAI-1 synthesis, moreover, correlated with a complete inhibition in growth factor-stimulated keratinocyte invasion through basement membrane (Matrigel) barriers (Fig. 6C).

DISCUSSION

An E box motif in the PE2 region of the human *PAI-1* gene is required for the maximal response of the PAI-1p806-Luc reporter to TGF- β 1. Site occupancy and transcriptional activity, furthermore, require conservation of the PE2 core E box structure as the CACGTG → CACGGA and TCCGTG dinucleotide substitutions (in the rat gene) (White et al., 2000) and a CACGTG → CAATTG or TCCGTG replacement in the human gene, with retention of PAI-1 flanking sequences, resulted in loss of both competitive binding and TGF- β 1-dependent reporter activity. The dinucleotide PE2 domain CACGTG → CAATTG mutation (within the context of the full-length PAI-1p806-Luc plasmid), moreover, significantly attenuates TGF- β 1-stimulated transcriptional signal, confirming the importance of this site in inducible expression. The present data are also consistent with the known hexanucleotide preference (CACGTG or CACATG) of USF proteins (Littlewood and

Evan, 1995; Ismail et al., 1999; Samoylenko et al., 2001) and strongly suggest that USF family members with PAI-1 PE2 site E box-occupancy potential are constitutively present (and active) regardless of cellular growth state. Successful PAI-1 probe competition by a CACGTG "core" flanked by non-PAI-1 sequences and the failure of specific E box mutants to similarly compete (or to produce band shifts when used as targets) further indicate that an intact hexanucleotide E box motif is necessary and sufficient for USF-1 binding. This appears to contrast with the highly cooperative constraints for E box recognition by other bHLH-LZ proteins (e.g., TFE3) that utilize accessory factors (Grinberg and Kerppola, 2003). Depending on the relative abundance of E box-binding factors in individual cell types, the promoter context and specific flanking nucleotides (e.g., Szentirmay et al., 2003), proteins that dock at adjoining sites may also be required (e.g., Hua et al., 1998). The relative abundance of USF-1 in HaCaT cells (Providence et al., 2002) and low, virtually undetectable, levels of TFE3, moreover, are likely significant determinants in the final composition of specific E box-binding complexes.

ChIP analysis confirmed that USF-1 is a PE2 region E box resident factor in vivo and preliminary EMSA data additionally indicate that USF-2 can potentially recognize the same site (not shown⁶). Considering the




Fig. 5. Signaling requirements for TGF- β 1-induced PAI-1 expression. The typical response of the endogenous *PAI-1* gene to a 4-h exposure to serum (FBS) or TGF- β 1 is illustrated in the Northern blot in (A). The absence of PAI-1 mRNA in serum-deprived HaCaT cells (Q) is consistent with quiescence-associated PAI-1 repression (e.g., Ryan et al., 1996; Qi and Higgins, 2003). Treatment with the MEK inhibitor

PD98058 (50 μ M) for 30 min prior to addition of TGF- β 1 effectively attenuates (by >75%) induced-expression. The p38 inhibitor III, in contrast, did not affect either TGF- β 1-induced PAI-1 transcript levels (B) or nuclear protein/PE2 region DNA complex formation (C). Hybridization signals that represent the two PAI-1 transcripts (3.0- and 2.2-kb) and the normalization control GAPD are indicated in (A, B).




Fig. 6. Dominant-negative USF-1 (USF-1A) attenuates TGF- β 1-induced PAI-1 protein expression and barrier invasion. USF-1 was confirmed to be an endogenous PAI-1 promoter PE2 region DNA-binding factor by chromatin immunoprecipitation using antibodies to USF-1 (A). Controls included addition of sonicated cellular DNA but without immunoprecipitation (input DNA), addition of PAI-1p806-Luc DNA as a control template for PCR (template DNA) and PCR reaction mixtures with H₂O in place of DNA (-DNA). L = sizing ladder. To evaluate the effects of molecular genetic interference with USF function, RK cells were untransfected or transfected with CMV-driven WT USF-1 or CMV-driven dominant-negative USF-1A. Whole cell lysates from quiescent cultures or cells stimulated with 20% FBS or 1 ng/ml TGF- β 1 were collected, separated on 9% SDS-PAGE, proteins

transferred, and blots probed with anti-rat PAI-1 antibody (B). Transfers were reprobed with antibodies to ERK1/2 to assess protein loading. Invasion of RK cells expressing either WT (USF-1) or dominant-negative (USF-1A) expression constructs was compared \pm TGF- β 1 (C). Data in (C) specifically represent TGF- β 1-induced fold-invasion of Matrigel-coated barriers (i.e., TGF- β 1-associated invasion/untreated controls); histogram represents mean \pm standard error from eight migration evaluations. Approximately 60% of the RK cells used in invasion assays were anti-HA positive (i.e., 60% transfection efficiency; Providence et al., 2002). Only 5% of cells that invaded the Matrigel barrier, in contrast, stained positively with the HA antibody, indicating that the majority of USF-1A-expressing cells were non-invasive.

TGF- β 1. USF-1A transfection and subsequent PAI-1 down-regulation, in fact, completely ablated the TGF- β 1-associated increase in invasive potential of RK cells compared to WT USF-1-expressing controls. USF elements are clearly important regulators of both PAI-1 gene control (as predicted from the identification of PAI-1 as a direct USF target gene) and cellular migratory processes. Although it remains to be determined if USF regulates the expression of "migration modifier" genes other than PAI-1, these approaches may ultimately lead to the identification of novel molecular targets and subsequent design of transcription-focused "therapies" to manage specific *in vivo* consequences of PAI-1 over-expression (tumor progression, tissue fibrosis, vascular disease).

LITERATURE CITED

- Akiyoshi S, Ishii M, Nemoto N, Kawabata M, Aburatani H, Miyazano K. 2001. Targets of transcriptional regulation by transforming growth factor- β : Expression profile analysis using oligonucleotide arrays. *Jpn J Cancer Res* 92:252-268.
- Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT. 2003. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. *Biol Chem* 384:423-435.
- Andreasen PA, Egelund R, Peterson HH. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. *Cell Mol Life Sci* 57:25-40.
- Arias AM. 2001. Epithelial mesenchymal interactions in cancer and development. *Cell* 105:425-431.
- Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. *Nat Med* 4:923-928.
- Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff DJ, Collen D, Carmeliet P, Foidart JM, Noel A. 2001. The plasminogen activator inhibitor PAI-1 controls *in vivo* tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. *J Cell Biol* 152:777-784.
- Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. 2002. p38 mitogen-activated protein kinase is required for TGF β -mediated fibroblastic transdifferentiation and cell migration. *J Cell Sci* 115:3193-3206.
- Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. 2001. Transforming growth factor- β 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Mol Biol Cell* 12:27-36.
- Boehm JR, Kutz SM, Sage EH, Staiano-Coico L, Higgins PJ. 1999. Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor- β 1. *J Cell Physiol* 181:96-106.
- Brooks TD, Slomp J, Quax PHA, De Bart ACW, Spencer MT, Verheijen JH, Charlton PA. 2001. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells *in vivo*. *Clin Exp Metastasis* 18:445-453.
- Carter RS, Ordentlich P, Kadesch T. 1997. Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer. *Mol Cell Biol* 17:18-23.
- Chapman HA. 1997. Plasminogen activators, integrins, the coordinate regulation of cell adhesion and migration. *Curr Opin Cell Biol* 9:714-724.
- Chappuis PO, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, Sappino AP. 2001. Functional evaluation of plasmin formation in primary breast cancer. *J Clin Oncol* 19:2731-2738.
- Chazaud B, Ricour R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. 2002. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer populations. *Am J Pathol* 160:237-246.
- Cheung E, Mayr P, Coda-Zabetta F, Woodman PG, Boam DSW. 1999. DNA-binding activity of the transcription factor upstream stimulatory factor 1 (USF-1) is regulated by cyclin-dependent phosphorylation. *Biochem J* 344:145-152.
- Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. 2003. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. *J Cell Biol* 160:781-791.
- Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? *J Cell Biol* 134:1563-1571.
- Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. *J Cell Physiol* 189:23-33.
- Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. 1998. Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* 17:3091-3100.
- Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. 2000. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong association with tumor pathology. *Am J Pathol* 157:1219-1227.
- Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. 1998. Transforming growth factor- β 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. *Int J Cancer* 75:721-730.
- Fink AR, Kazlauskas A, Poellinger L, Ebbesen P, Zachar V. 2002. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. *Blood* 99:2077-2083.
- Galibert M-D, Carreira S, Goding CR. 2001. The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced Tyrosinase expression. *EMBO J* 20:5022-5031.
- Gilles C, Polette M, Birembaut P, Brunner N, Thompson EW. 1997. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. *Clin Exp Metastasis* 15:519-526.
- Giusti C, Desruisseau S, Ma L, Calvo F, Martin P-M, Berthois Y. 2003. Transforming growth factor β -1 and amphiregulin act in synergy to increase the production of urokinase-type plasminogen activator in transformed breast epithelial cells. *Int J Cancer* 105:769-778.
- Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. *Genes Dev* 14:1553-1577.
- Goueli BS, Janknecht R. 2003. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. *Oncogene* 22:8042-8047.
- Grinberg AV, Kerpola TK. 2003. Both Max and TFE3 cooperate with Smad proteins to bind the plasminogen activator inhibitor-1 promoter, but they have opposite effects on transcriptional activity. *J Biol Chem* 278:11227-11236.
- Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. 2000. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. *Cancer Res* 60:5839-5847.
- Hua X, Liu X, Ansari DO, Lodish HF. 1998. Synergistic cooperation of TFE3 and smad proteins in TGF β -induced transcription of the plasminogen activator inhibitor-1 gene. *Genes Dev* 12:3084-3095.
- Hua X, Miller ZA, Wu G, Shi Y, Lodish HF. 1999. Specificity in transforming growth factor β -induced transcription of the plasminogen activator inhibitor-1 gene: Interactions of promoter DNA, transcription factor μ E3, and Smad proteins. *Proc Natl Acad Sci USA* 96:13130-13135.
- Ismail PM, Lu T, Sawadogo M. 1999. Loss of USF transcriptional activity in breast cancer cell lines. *Oncogene* 18:5582-5591.
- Janknecht R. 2002. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. *Histol Histopathol* 17:657-668.
- Jeffers M, Rong S, Vande Woude GF. 1996. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. *Mol Cell Biol* 16:1115-1125.
- Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM. 2000. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. *J Cell Sci* 113:227-235.
- Kietzmann T, Roth U, Jungermann K. 1999. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. *Blood* 94:4177-4185.
- Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. *Exp Cell Res* 232:420-421.
- Koziczak M, Krek W, Nagamine Y. 2000. Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. *Mol Cell Biol* 20:2014-2022.
- Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. 2001. TGF- β 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. *J Cell Sci* 114:3905-3914.
- Lawrence⁹⁷ DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D. 1997. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. *J Biol Chem* 272:7676-7680.
- Lefrançois-Martinez AM, Martinez A, Antoine B, Raymondjean M, Kahn A. 1995. Upstream stimulatory factor proteins are major components of the glucose response complex of the L-type pyruvate kinase gene promoter. *J Biol Chem* 270:2640-2643.
- Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P. 2001. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial cell migration. *Exp Cell Res* 264:326-333.
- Littlewood TD, Evan GL. 1995. Helix-loop-helix proteins. *Protein Profiles* 2:612-703.
- Liu G, Shuman MA, Cohen RL. 1995. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. *Int J Cancer* 60:501-506.
- Loskutoff DJ, Curriden SA, Hu G, Deng G. 1999. Regulation of cell adhesion by PAI-1. *APMIS* 107:54-61.
- Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Dano K. 1999. Functional overlap between two classes of matrix-degrading proteases in wound healing. *EMBO J* 18:4645-4656.
- Luo X, Sawadogo M. 1996. Functional domains of the transcription factor USF2: Atypical nuclear localization signals and context-dependent transcriptional activation domains. *Mol Cell Biol* 16:1367-1375.
- Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. *EMBO J* 16:2319-2332.
- McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. 2001. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. *J Biol Chem* 276:33964-33968.
- Meier JL, Luo X, Sawadogo M, Straus SE. 1994. The cellular transcription factor USF cooperates with varicella-zoster virus immediate-early protein 62 to symmetrically activate a bi-directional viral promoter. *Mol Cell Biol* 14:6896-6906.
- Mignatti P, Rifkin DB. 2000. Nonenzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology. *Adv Cancer Res* 78:103-157.
- Okeadon⁹⁸ LE, Sato Y, Rifkin DB. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial migration independent of its proteolytic activity. *J Cell Physiol* 150:258-263.

- Palmieri D, Lee JW, Juliano RL, Church FC. 2002. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-231 breast cancer cells. *J Biol Chem* 277:40950–40957.
- Petzelbauer E, Springhorn JP, Tucker AM, Madri JA. 1996. Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF- β 1. *Am J Pathol* 149:923–931.
- Providence KM, Higgins PJ. 2004. PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. *J Cell Physiol* 200:297–308.
- Providence KM, Kutz SM, Staiano-Coico L, Higgins PJ. 2000. PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. *J Cell Physiol* 182:269–280.
- Providence KM, White LA, Tang J, Goncalves J, Staiano-Coico L, Higgins PJ. 2002. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. *J Cell Sci* 115:3767–3777.
- Providence KM, Staiano-Coico L, Higgins PJ. 2003. A quantifiable in vitro model to assess effects of PAI-1 gene targeting on epithelial motility. *Methods Mol Med* 78:293–303.
- Qi L, Higgins PJ. 2003. Use of chromatin immunoprecipitation to identify E box-binding transcription factors in the promoter of the growth state-regulated human PAI-1 gene. *Recent Res Devel Mol Biol* 1:1–12.
- Qyang Y, Luo X, Lu T, Ismail PM, Krylov D, Vinson C, Sawadogo M. 1999. Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation. *Mol Cell Biol* 19:1508–1517.
- Reijerkerk A, Voest EE, Gebbink MF. 2000. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. *Eur J Cancer* 36:1695–1705.
- Riccio A, Pedone PV, Lund LR, Olsen T, Olsen HS, Andreasen PA. 1992. Transforming growth factor β 1-responsive element: Closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor 1 in the type-1 plasminogen activator inhibitor gene. *Mol Cell Biol* 12:1846–1855.
- Ryan MP, Kutz SM, Higgins PJ. 1996. Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. *Biochem J* 314:1041–1046.
- Samoylenko A, Roth U, Jungermann K, Kietzmann T. 2001. The upstream stimulatory factor-2a inhibits plasminogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hypoxia-inducible factor-1 binding site. *Blood* 97:2657–2666.
- Santibanez JF, Frontelo P, Iglesias M, Martinez J, Quintanilla M. 1999. Urokinase expression and binding activity associated with the transforming growth factor β 1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. *J Cell Biochem* 74:61–73.
- Sirito M, Lin Q, Deng JM, Behringer RR, Sawadogo M. 1998. Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. *Proc Natl Acad Sci USA* 95:3758–3763.
- Stefansson S, Lawrence DA. 2003. Old dogs and new tricks: Proteases, inhibitors, and cell migration. *Sci STKE* 189:pe24.
- Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. *J Biol Chem* 276:8135–8141.
- Szentirmay MN, Yang HX, Pawar SA, Vinson C, Sawadogo M. 2003. The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells. *J Biol Chem* 278:37231–37240.
- Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* 2:442–454.
- Viollet B, Lefrancois-Martinez AM, Henrion A, Kahn A, Raymondjean M, Martinez A. 1996. Immunochemical characterization and transacting properties of upstream stimulatory factor isoforms. *J Biol Chem* 271:1405–1415.
- Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE. 2001. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. *Mol Cell* 8:749–758.
- White LA, Bruzdinski C, Kutz SM, Gelehrter TD, Higgins PJ. 2000. Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. *Exp Cell Res* 260:127–135.
- Xing W, Danilovich N, Sairam MR. 2002. Orphan receptor chicken ovalbumin upstream promoter transcription factors inhibit steroid factor-1, upstream stimulatory factor, and activator protein-1 activation of ovine follicle-stimulating hormone receptor expression via composite cis-elements. *Biol Reprod* 66:1656–1666.
- Yu L, Herbert MC, Zhang YE. 2002. TGF- β receptor-activated p38 MAP kinase mediates Smad-independent TGF- β responses. *EMBO J* 21:3749–3759.
- Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, Bottinger EP. 2001. Genetic programs of epithelial cell plasticity directed by transforming growth factor- β . *Proc Natl Acad Sci USA* 98:6686–6691.
- Zhou HM, Nichols A, Meda P, Vassalli JD. 2000. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. *EMBO J* 19:4817–4826.

Q1: AU: please check the short title.

Q2: AU: please check, which text is being referred to here.

Q3: AU: please check, which text is being referred to here.

Q4: AU: please update.

Q5: AU: please update.

Q6: AU: please update.

Q7: AU: please provide citation.

Q8: AU: please provide citation.

Transworld Research Network
37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India



Recent Res. Devel. Cell Sci., 1(2004): 1-10 ISBN: 81-7895-112-6

Plasminogen activator inhibitor type-I expression targeting: New therapeutic approaches to regulate tumor growth and angiogenesis

Stacie M. Kutz and Paul J. Higgins

Center for Cell Biology & Cancer Research, Albany Medical College, Albany
New York 12208, USA

Abstract

Angiogenesis is a complex physiological and, in certain settings, pathophysiologic process involving the formation of new blood vessels from the existent vasculature or by recruited precursor cells. An efficient angiogenic response is highly dependent on focalized stromal remodeling by cooperating, often interdependent, proteolytic cascades and involves generation of the broad-spectrum protease plasmin from plasminogen through the catalytic action of urokinase plasminogen activator (uPA). uPA localizes to the sprouting endothelium while its major, fast-acting, type-I inhibitor (PAI-1) is expressed either by the uPA-synthesizing endothelial cohort or by stromal cells (i.e., fibroblasts) closely juxtaposed to the developing neovessels. The spatial restriction of critical elements in the plasmin cascade likely facilitates vessel outgrowth by maintaining a matrix

Correspondence/Reprint request: Dr. Paul J. Higgins, Center for Cell Biology & Cancer Research, Albany Medical College
Mail Code 165, 47 New Scotland Avenue, Albany, New York 12208, USA. E-mail: higginp@mail.amc.edu

"scaffold" permissive for cell migration. This review discusses the potential role of PAI-1 in tumor angiogenesis and the complex, concentration-dependent, effects of this protease inhibitor on cell migration and the angiogenic process. Evidence is presented that genetic ablation of PAI-1 expression in intact animals as well as in cultured cells has defined phenotypic outcomes. Collectively, these findings support development of PAI-1 antagonists, mutant PAI-1 molecules or reagents that target the PAI-1 expression network as potential anti-angiogenic chemotherapeutics.

Introduction

Angiogenesis is essential for embryonic development, menstrual cycling and wound healing as well as a major underlying contributor to the pathogenesis of psoriasis, rheumatoid arthritis, diabetic retinopathy and tumor growth. Endothelial cell "activation" by angiogenic factors is closely followed by degradation of the parent vessel basement membrane, stromal invasion and matrix remodeling as part of the outgrowth process. Following loss of basement membrane integrity, endothelial cells extend processes in the direction of the angiogenic stimulus and begin to migrate into the surrounding stroma forming a capillary sprout. A lumen gradually develops and reconstitution of the basement membrane signals sprout maturation [1,2]. Proliferation occurs in a cohort of cells just behind the migrating front and is likely required for continued maintenance of vessel growth. Stimulated endothelial cell locomotion within the angiogenic "field", furthermore, requires cycles of extracellular matrix (ECM) adhesion/detachment and precise control of the pericellular proteolytic environment [2-4]. These events are regulated (temporally and spatially) by members of the matrix metalloproteinase (MMP) family and by uPA-mediated conversion of plasminogen to plasmin [5-11]. The plasmin-generating cascade directly influences the overall pericellular proteolytic balance and is a critical determinant in directed cell movement, matrix remodeling and tissue invasion [12-24]. PAI-1 functions in this process to limit plasmin generation by inhibiting the catalytic activity of uPA [5,6], restricting downstream MMP activation and affecting, thereby, uPA-dependent ECM degradation and *in vivo* cell motility [6,25,26]. Targeted knockout/reconstitution studies, moreover, identified PAI-1 as essential for, and an efficient modulator of, the neovascularization process. Recent findings, in fact, support a multifunctional role for PAI-1 in angiogenesis (e.g., this uPA inhibitor regulates stromal barrier proteolysis, facilitates endothelial cell migration by focalized exposure of cryptic matrix-binding sites, stabilizes nascent vessel structure and controls cell-to-matrix adhesion/de-adhesion). Indeed, analyses of systems that model specific stages in angiogenesis have disclosed that PAI-1 can exert potent pro- and anti-angiogenic effects depending on the context and the concentration (as well as specific activity) of this SERPIN (serine protease inhibitor) in the tissue microenvironment.

PAI-1 in the angiogenic response

Endothelial cell migration and capillary sprouting requires proteolysis [2,27]. Studies in mice deficient in elements in the plasmin activation cascade confirmed the importance of uPA, PAI-1 and plasmin in cell migration [28]. Excessive protease activity as typically evident in chronic wounds, however, prevents the coordinated assembly of endothelial cells into capillary structures highlighting the requirement for an appropriate proteolytic "balance" in tubular network formation [29,30]. Genetic studies *in vivo*,

moreover, have implicated PAI-1 as an important regulator of this balance [31,32]. Indeed, PAI-1 is expressed specifically in angiogenic "cords" and migrating endothelial cells (**Figure 1**) as well as in stromal cells in direct contact with the sprouting neovessels but not in the quiescent endothelium [33-38]. PAI-1^{-/-} mice, moreover, are incapable of mounting an efficient angiogenic response to transplanted tumors or implants of potent angiogenic growth factors (e.g., bFGF) [33,35,37] although this deficiency could be corrected by injection of PAI-1-expressing adenovirus. PAI-1 appears to promote angiogenesis by inhibition of plasmin activity, thus preserving an appropriate matrix scaffold for capillary network formation or providing required neovessel stability [32]. Exogenous PAI-1, under specific circumstances, can also significantly limit vessel construction (at least in the chick chorioallantoic membrane model; CAM) [38]. These findings [i.e., 32,38] in all probability reflect the context and complexity of different angiogenic processes which, in turn, depend on the level of expression of participating elements, the nature of the ECM involved, the system studied and the growth factor environment. PAI-1 deficit (as in the PAI-1^{-/-} mouse) would likely result in loss of ECM integrity (due to excessive protease activity) and compromise endothelial cell-ECM adhesion, each required for a successful angiogenic response (**Figure 2**). Relatively high PAI-1 concentrations in the local environment, on the other hand, may also be detrimental to angiogenesis by inhibiting the required proteolytic activity necessary for focalized dissection of the ECM by activated endothelial cells. Indeed, expression of a long half-life PAI-1 mutant protein inhibited sprout formation by human endothelial




Figure 1. Identification of PAI-1-expressing endothelial cells in outgrowth culture. Human saphenous vein endothelial cells migrate into a fibrin gel within 2 weeks after placement of vein "rings" into a fibrin matrix (left panel). The original ring is at the upper right. Cells that migrate out of the vein segment express PAI-1 (upper right panel). Substitution of pre-immune rabbit serum in place of PAI-1 antibodies resulted in loss of immunoreactivity (Control, lower right panel). Unlike the obvious expression of PAI-1 by endothelial elements locomoting through the fibrin gel, the residual endothelium in the explant was PAI-1-negative.




Figure 2. Targeted down-regulation of PAI-1 synthesis inhibits *in vitro* tubulogenesis. Construction of Rc/CMV plasmid vectors that drive expression of a full-length PAI-1 cDNA insert, cloned in sense (PAI) and antisense (IAP) orientations, under control of a CMV promoter (left panel). The black fill-in region corresponds to the PAI-1 cDNA insert. EC-1 parental cells were transfected with the Rc/CMVIAP vector and stable clones derived. To assess the success of Rc/CMVIAP driven down-regulation of PAI-1 synthesis and matrix accumulation, saponin-extracts of 35 S-methionine-labeled cells were separated by gel electrophoresis and proteins visualized by fluorography (middle panel). One derivative (4HH) did not express detectable PAI-1 protein nor accumulate PAI-1 in the matrix (middle panel). Cells transfected with Rc/CMV vector without insert expressed levels of PAI-1 similar to that of EC-1 controls. Wild-type T2 cells (top right panel) formed highly-branched and anastomosing capillary networks when suspended in a complex support matrix consisting of a 3:1 mixture of Vitrogen-Matrigel. Many of these tubular processes had clearly evident lumens. Extensive sprout formation was evident at the tips of T2 branches, moreover, indicative of both invasive and differentiated compartments. PAI-1^{-/-} 4HH cells (bottom right panel), in contrast, failed to construct stable tubular structures and extensively degraded the gel matrix.

cells in fibrin gels, blocked angiogenesis in the CAM assay and inhibited prostate tumor growth in SCID mice [39]. Recent findings [40], using the Matrigel implant model of *in vivo* angiogenesis, have confirmed that PAI-1 is essential for efficient neovessel formation and implant invasion but that the PAI-1 "tissue" content critically influences the angiogenic outcome. This SERPIN is a potent stimulator of angiogenesis at low or physiologic levels but significantly impairs or completely inhibits vessel formation, lumen development and implant invasion at high concentrations [40]. This last point is highly relevant therapeutically and supported by recent findings highlighting the role of PAI-1 as an inhibitor of capillary dissolution. Indeed, uPA-mediated plasmin generation activates MMP 1 and 9 causing endothelial cell collagen gel contraction and capillary tube regression (with associated apoptosis); both events are inhibited by PAI-1 [41]. Moreover, attenuation of PAI-1 activity with neutralizing antibodies accelerates tube regression supporting the contention that endogenous PAI-1 is the major negative regulator of this process [42]. These results suggest that continued PAI-1 expression by formed capillary structures is required to maintain their stability and, in fact, to prevent vessel loss.

PAI-1 and cell motility

Cell migration within a complex tissue structure involves several interactive protease systems [e.g., 10,18,20,43-46] and is often dependent on plasmin generation by uPA [47-50]. PAI-1 synthesis and matrix accumulation closely accompany acquisition of the motile phenotype [21,51,52]. Recently, a unique vector that encodes a PAI-1-GFP chimeric protein driven by PAI-1 promoter sequences was developed in this laboratory (**Figure 3**) [22]. This construct provides for the direct visualization of induced PAI-1 deposition into cellular migration trails during the real time of stimulated motility. Secreted PAI-1 most likely accumulates in the cellular undersurface region in a complex with the matrix protein vitronectin [53,54]. *In vitro* studies suggest that PAI-1 occupancy of its docking site on vitronectin may dissociate uPA receptor (uPAR)-vitronectin interactions, resulting in the detachment of cells that utilize uPAR as a vitronectin anchor [55-57]. Alternatively, PAI-1 may directly inhibit αv integrin-mediated attachment to vitronectin by blocking accessibility to the RGD sequence located proximal to the uPAR binding site [57-59] (**Figure 4**). uPAR-associated uPA/PAI-1 complexes, furthermore, are internalized by endocytosis promoting uPA receptor recycling [8] and, thereby,




Figure 3. Visualization of PAI-1-GFP chimera deposition into cellular migration tracks. Schematic of a pEGFP-1-based vector in which a fusion transcript consisting of 1.3 kb of PAI-1 coding sequences and GFP is expressed under the control of a 0.8 kb PAI-1 "promoter" (top panel). Seeding of PAI-1 promoter-PAI-1 coding-GFP transfectant RK cells at low density provides for the clear visualization of the PAI-1-GFP fusion protein in cellular migration trails (bottom panel). The small bright image at the extreme right end of the trail is the cell body.

transfectants) was associated with a significant impairment in cellular migratory ability [20,22]. Most importantly, targeted down-regulation of PAI-1 transcripts impairs cell motility *in vitro* [21] and inhibits endothelial capillary formation on basement membrane (Matrigel) coated culture surfaces (**Figure 5**), a rapid process dependent on cell migration.




Figure 5. Capillary formation on Matrigel requires migration. T2 cells were stably transfected with the "empty" Rc/CMV vector (V) or vector bearing a full-length PAI-1 cDNA insert in antisense configuration (IAP) (as in Figure 2). Northern analysis indicated that control T2 cells or T2/V cells expressed abundant PAI-1 transcripts (left panel) and formed well-developed highly-branched tubular structures with luminal spaces within 48 hours after plating onto hydrated Matrigel-coated surfaces (middle panel). T2/IAP transfectants, in contrast, had significantly reduced PAI-1 mRNA levels (left panel) and failed to migrate and coalesce into a defined capillary network. T2/IAP cells remained either as single cells (without any evidence of an associated migratory track) or formed small multicellular aggregates (right panel).

Several recent studies, using dominant-negative constructs and pharmacologic inhibitors, confirmed that cellular motile responses, *in vitro* angiogenesis and associated PAI-1 induction are dependent on ERK signaling [20,68]. These findings, coupled with the success of the genetic-based approach to modulate PAI-1 expression directly at the mRNA transcript level [20,22] or indirectly, by disruption of the involved transduction pathway [69], support the contention that PAI-1 expression modulation can be utilized to manipulate specific aspects of the angiogenic process. PAI-1-specific antagonists, mutant PAI-1 molecules or reagents to target the PAI-1 signaling or transcriptional networks are currently under development [38]. The potential of this approach was highlighted by the ability of a non-uPA-inhibitory PAI-1 mutant protein to attenuate angiogenesis *in vivo* most likely by interference with cellular attachment to vitronectin in the provisional ECM [38]. Although in many cases the mechanism of action of such PAI-1-focused therapeutics remains to be determined, initial results indicate this strategy may lead to novel, clinically-relevant, options for cancer treatment.

Acknowledgements

This work was supported by grants from the NIH (GM57242) and the Department of the Army Breast Cancer Program (DAMD17-98-1-8015, DAMD17-00-1-0124, DAMD17-02-1-0270).

References

1. Tonnesen, M.G., Feng, X., and Clark, R.A. 2000, *J. Invest. Dermatol. Symp. Proc.* 5, 40-46.
2. Iwasaka, C., Tanaka, K., Abe, M., and Sato, Y. 1996, *J. Cell. Physiol.* 169, 522-531.
3. Madri, J.A., Sankar, S., and Romanic, A.M. 1996, *The Molecular and Cellular Biology of Wound Repair*, R.A.F. Clark (Ed.), Plenum Press, New York, 355.
4. Greenwood, J.A., and Murphy-Ullrich, J.E. 1998, *Microsc. Res. Tech.* 43, 420-432.
5. Mignatti, P., Rifkin, D.B., Welgus, H.G., and Parks, W.C. 1996, *The Molecular and Cellular Biology of Wound Repair*, R.A.F. Clark (Ed.), Plenum Press, New York, 427.
6. Pollanen, J., Ross, W., and Vaeheri, A. 1991, *Adv. Cancer Res.* 57, 273-328.
7. Hiraoka, N., Allen, E., Apel, I.J., Gyetteo, M.R., and Weiss, S.J. 1998, *Cell* 95, 365-377.
8. Andreasen, P.A., Kjoller, L., Christensen, L., and Duffy, M.J. 1997, *Int. J. Cancer* 72, 1-22.
9. Farina, A.R., Coppa, A., Tiberio, A., Tacconelli, A., Turco, A., Colletta, G., Gulino, A., and Mackay, A.R. 1998, *Int. J. Cancer* 75, 721-730.
10. Zhou, H.M., Nichols, A., Meda, P., and Vassalli, J.D. 2000, *EMBO J.* 19, 4817-4826.
11. Legrand, C., Polette, M., Tournier, J.M., de Bentzmann, S., Huet, E., Monteau, M., and Birembaut, P. 2001, *Exp. Cell Res.* 264, 326-333.
12. Pepper, M.S., Vassalli, J.D., Montesano, R., and Orci, L. 1987, *J. Cell Biol.* 105, 2535-2541.
13. Pepper, M.S., Sappino, A.P., Montesano, R., Orci, L., and Vassalli, J.D. 1992, *J. Cell. Physiol.* 153, 129-139.
14. Cajot, J.F., Schleuning, W.D., Medcalf, R.L., Bamat, J., Testuz, J., Liebermann, L., and Sordat, B. 1989, *J. Cell Biol.* 109, 915-925.
15. Okedon, L.E., Sato, Y., and Rifkin, D.B. 1992, *J. Cell. Physiol.* 150, 258-263.
16. Liu, G., Shuman, M.A., and Cohen, R.L. 1995, *Int. J. Cancer* 60, 501-506.
17. Jeffers, M., Rong, S., and Vande Woude, G.F. 1996, *Mol. Cell. Biol.* 16, 1115-1125.
18. Mazziere, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S., and Mignatti, P. 1997, *EMBO J.* 16, 2319-2332.
19. Wysocki, A.B., Kusakabe, A.O., Chang, S., and Tuan, T.L. 1999, *Wound Repair Regen.* 7, 154-165.
20. Providence, K.M., and Higgins, P.J. 2004, *J. Cell. Physiol.* (in press).
21. Providence, K.M., Kutz, S.M., Staiano-Coico, L., and Higgins, P.J. 2000, *J. Cell. Physiol.* 182, 269-280.
22. Providence, K.M., White, L.A., Tang, J., Gonclaves, J., Staiano-Coico, L., and Higgins, P.J. 2002, *J. Cell Sci.* 115, 3767-3777.
23. Reijkerkerk, A., Voest, E.E., and Gebbink, M.F. 2000, *Eur. J. Cancer* 36, 1695-1705.
24. Brooks, T.D., Slomp, J., Quax, P.H.A., De Bart, A.C.W., Spencer, M.T., Verheijen, J.H., and Charlton, P.A. 2001, *Clin. Exp. Metastasis* 18, 445-453.
25. Cajot, J.F., Bamat, J., Bergonzelli, G.E., Kruitof, E.K., Medcalf, R.L., Testuz, J., and Sordat, B. 1990, *Proc. Natl. Acad. Sci. USA* 87, 6939-6943.
26. Mignatti, P., and Rifkin, D.B. 2000, *Adv. Cancer Res.* 78, 103-157.
27. Mandriota, S.J., and Pepper, M.S. 1997, *J. Cell Sci.* 110, 2293-2302.
28. Carmeliet, P., and Collen, D. 1998, *FASEB J.* 9, 934-938.
29. Montesano, R., Pepper, M.S., Vassalli, J.D., and Orci, L. 1987, *J. Cell. Physiol.* 132, 509-516.
30. Pepper, M.S., Belin, D., Montesano, R., Orci, L., and Vassalli, J.D. 1990, *J. Cell Biol.* 111, 743-755.
31. Lambert, V., Munaut, C., Noel, A., Frankenke, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M.P., Foidart, J.M., and Rakic, J.M. 2001, *FASEB J.* 15, 1021-1027.
32. Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V., Praus, M., Lund, L.R., Frandsen, T.C., Brunner, N., Dano, K., Fusenig, N.E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.M., and Noel, A. 2001, *J. Cell Biol.* 152, 777-784.
33. Mazar, A.P., Henkin, J., and Goldfarb, R.H. 1999, *Angiogenesis* 3, 15-32.
34. Bacharach, E., Itin, A., and Keshet, E. 1998, *Blood* 92, 939-945.

35. Bajou, K., Noel, A., Gerard, R.D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N.E., Carmeliet, P., Collen, D., and Foidart, J.M. 1998, *Nature Med.* 4, 923-928.
36. Lane, T.F., Iruela-Arispe, M.L., and Sage, E.H. 1992, *J. Biol. Chem.* 267, 16736-16745.
37. Gutierrez, I.S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V.A., and Castellino, F.J. 2000, *Cancer Res.* 60, 5839-5847.
38. Stefansson, S., Petitclerc, E., Wong, M.K.K., McMahon, G.A., Brooks, P.C., and Lawrence, D.A. 2001, *J. Biol. Chem.* 276, 8135-8141.
39. Swiercz, R., Keck, R.W., Skrzypczak-Jankun, E., Selman, S.H., and Jankun, J. 2001, *Oncol. Reports* 8, 463-470.
40. McMahon, G.A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M.K.K., Westerick, R.J., Ginsburg, D., Brooks, P.C., and Lawrence, D.A. 2001, *J. Biol. Chem.* 276, 33964-33968.
41. Davis, G.E., Allen, K.A.P., Salazar, R., and Maxwell, S.A. 2001, *J. Cell Sci.* 114, 917-930.
42. Davis, G.E., Bayless, K.J., and Mavila, A. 2002, *Anat. Rec.* 268, 252-275.
43. Lund, L.R., Romer, J., Bugge, T.H., Nielsen, B.S., Frandsen, T.L., Degen, J.L., Stephens, R.W., and Dano, K. 1999, *EMBO J.* 18, 4645-4656.
44. Murphy, G., and Gavrilovic, J. 1999, *Curr. Opin. Cell Biol.* 11, 614-621.
45. Friedl, P., and Bocker, E.B. 2000, *Cell. Mol. Life Sci.* 57, 41-64.
46. Ridley, A.J. 2001, *J. Cell Sci.* 114, 2713-2722.
47. Bugge, T.H., Flick, M.J., Danton, M.J., Daugherty, C.C., Romer, J., Dano, K., Carmeliet, P., Collen, D., and Degen, J.L. 1996, *Proc. Natl. Acad. Sci. USA* 93, 5899-5904.
48. Romer, J., Lund, L.R., Kriksen, J., Ralkiaer, E., Zeheb, R., Gelehrter, T.D., Dano, K., and Kristensen, P. 1991, *J. Invest. Dermatol.* 97, 803-811.
49. Carmeliet, P., Moons, L., Lijnen, R., Janssens, S., Lupu, F., Collen, D., and Gerard, R.D. 1997, *Circulation* 96, 3180-3191.
50. Creemers, E., Cleutjens, J., Smits, J., Heymans, S., Moons, L., Collen, D., Daemen, M., and Carmeliet, P. 2000, *Am. J. Path.* 156, 1865-1873.
51. Seebacher, T., Manske, M., Zoller, J., Crabb, J., and Bade, E.G. 1992, *Exp. Cell Res.* 203, 504-507.
52. Kutz, S.M., Providence, K.M., and Higgins, P.J. 2001, *Cell Motil. Cytoskeleton* 48, 163-174.
53. Seiffert, D., Mimuro, J., Schleef, R.R., and Loskutoff, D.J. 1994, *Cell Differ. Devel.* 32, 287-292.
54. Lawrence, D.A., Palaniappan, S., Stefansson, S., Olson, S.T., Francis-Chmura, A.M., Shore, J.D., and Ginsburg, D. 1997, *J. Biol. Chem.* 272, 7676-7680.
55. Kjoller, L., Kanse, S.M., Kirkegaard, T., Rodenburg, K.W., Ronne, E., Goodman, S.L., Preissner, K.T., Ossawski, L., and Andreasen, P.A. 1997, *Exp. Cell Res.* 232, 420-429.
56. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Loskutoff, D.J. 1996, *J. Cell Biol.* 134, 1563-1571.
57. Loskutoff, D.J., Curriden, S.A., Hu, G., and Deng, G. 1999, *APMIS* 107, 54-61.
58. Stefansson, S., and Lawrence, D.A. 1996, *Nature* 383, 441-443.
59. Germer, M., Kanse, S.M., Kirkegaard, T., Kjoller, L., Felding-Habermann, B., Goodman, S., and Preissner, K.T. 1998, *Eur. J. Biochem.* 253, 669-674.
60. Chapman, H.A. 1997, *Curr. Opin. Cell Biol.* 9, 714-724.
61. Ciambrone, G.J., and McKeown-Longo, P.J. 1990, *J. Cell Biol.* 111, 2183-2195.
62. Isogai, C., Laug, W.E., Shimada, H., DeClerck, P.J., Stins, M.F., Durden, D.L., Erdreich-Epstein, A., and DeClerck, Y.A. 2001, *Cancer Res.* 61, 5587-5594.
63. Li, F., Goncalves, J., Faughnan, K., Steiner, M.G., Pagan-Charry, I., Eposito, D., Chin, B., Providence, K.M., Higgins, P.J., and Staiano-Coico, L. 2000, *Exp. Cell Res.* 258, 245-253.
64. Chazaud, B., Ricoux, R., Christov, C., Plonquet, A., Gherardi, R.K., and Barlovatz-Meimon, G. 2002, *Am. J. Path.* 160, 237-246.
65. Deng, G., Curriden, S.A., Hu, G., Czekay, R.P., and Loskutoff, D.J. 2001, *J. Cell. Physiol.* 189, 23-33.

66. Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y., and Chapman, H.A. 1997, *J. Clin. Invest.* 100, 58-67.
67. Czekay, R.P., Aertgeerts, K., Curriden, S.A., Loskutoff, D.J. 2003, *J. Cell Biol.* 160, 781-791.
68. Kutz, S.M., Nickey, S., White, L.A., and Higgins, P.J. 1997, *J. Cell. Physiol.* 170, 8-18.
69. Kutz, S.M., Hordines, J., McKeown-Longo, P.J., and Higgins, P.J. 2001, *J. Cell Sci.* 114, 3905-3914.